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Abstract
Microbial pathogens in food cause an estimated 6.5-33 million cases of human
illness and up to 9,000 deaths in the United States each year.  Over 40 different
foodborne microbial pathogens, including fungi, viruses, parasites, and bacteria,
are believed to cause human illnesses.  For six bacterial pathogens, the costs of
human illness are estimated to be $9.3-$12.9 billion annually.  Of these costs,
$2.9-$6.7 billion are attributed to foodborne bacteria.  These estimates were
developed to provide analytical support for USDA’s Hazard Analysis and
Critical Control Point (HACCP) systems rule for meat and poultry. (Note that
the parasite Toxoplasma gondii is not included in this report.)  To estimate med-
ical costs and productivity losses, ERS uses four severity categories for acute
illnesses: those who did not visit a physician, visited a physician, were hospital-
ized, or died prematurely.  The lifetime consequences of chronic disease are
included in the cost estimates for E. coli O157:H7 and fetal listeriosis.  
Keywords: cost-of-illness, foodborne pathogens, lost productivity, medical
costs.
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Summary
Foodborne illnesses from six bacterial pathogens are estimated to account
for $2.9-$6.7 billion in human illness costs in the United States each year.
This report provides the first comprehensive, detailed cost-of-illness analy-
ses for the six bacteria in one document, and it puts all cost figures in 1993
dollars.  These estimates were developed to provide analytical support for
USDA’s Hazard Analysis Critical Control Point (HACCP) systems rule for
meat and poultry.  (The parasite Toxoplasma gondii is not included in this
report.) 
Microbial pathogens in food cause an estimated 6.5 million to 33 million cases
of human illness and up to 9,000 deaths annually, according to the Council for
Agricultural Science and Technology.  Foods most likely to cause human ill-
ness are animal products such as red meat, poultry and eggs, seafood, and dairy
products.
The six bacterial pathogens studied in this report—all found in animal prod-
ucts—are Salmonella, Campylobacter jejuni, Escherichia coli O157:H7,
Listeria monocytogenes, Staphylococcus aureus, and Clostridium perfringens.
The U.S. Centers for Disease Control and Prevention (CDC) is the source of
most epidemiological information on numbers of foodborne illnesses and deaths
used in this report.
The cost of human illness caused by the six bacterial pathogens is between $9.3
billion and $12.9 billion annually in the United States.  Between $2.9 billion
and $6.7 billion of these costs are attributed to foodborne causes. 
To estimate medical costs and productivity losses, ERS uses four severity cate-
gories for acute illnesses—those who: did not visit a physician, visited a physi-
cian, were hospitalized, or died prematurely.  The lifetime consequences of
chronic disease are included in the cost estimates for E. coli O157:H7 and fetal
listeriosis.  The cost estimates can be used to evaluate the economic impact of
foodborne diseases, to target pathogen reduction efforts, and to compare bene-
fits and costs of control efforts in order to determine the most cost-effective
measures.
Bacteria are one type of microorganism that cause diseases.  Others are fungi,
parasites, and viruses.  More than 40 different foodborne pathogens, including
some bacteria, are believed to cause human illnesses.  Our estimates of the
annual costs to society of foodborne illness would increase considerably if all
foodborne pathogens were included in the analysis, all chronic illnesses that are
triggered by foodborne disease were considered, and less conservative estimates
were used to value premature death.
Some pathogens that cause human illness are carried by animals but do not
cause disease in the animals. E. coli O157:H7 lives harmlessly in the intestinal
tracts of some cattle, but humans who eat undercooked meat from infected ani-
mals can develop illness that in some cases leads to kidney failure.Economic Research Service/USDA                       Bacterial Foodborne Disease:  Medical Costs and Productivity Losses / AER-741     v
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Abbreviations
AIDS Acquired immunodeficiency syndrome
AV Artificial ventilation
BLS Bureau of Labor Statistics
CAPD Continuous ambulatory peritoneal disease
CCPD Continuous cyclic peritoneal disease
CDC Centers for Disease Control and Prevention
CFR  Case fatality rate
COI Cost-of-illness
CPI Consumer Price Index
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ESRD End-stage renal disease
FSIS Food Safety and Inspection Service
GAO Government Accounting Office
GBS Guillain-Barré syndrome
GPO Government Printing Office
HC Hemorrhagic colitis
HCFA Health Care Finance Administration
HUS Hemolytic Uremic Syndrome
ICD International Classification of Diseases
ICU Intensive care unit
IOM Institute of Medicine
IVIG Immunoglobulin treatments
LS Landefeld and Seskin
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PE Plasma exchange
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USDA United States Department of Agriculture
VOSL Value of a statistical life
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Medical and Economic Terms
The definitions below clarify terms used in this report.
Bacteria.  One-celled microorganisms that are either free-living or parasitic,
some of which may be pathogenic.
Bacteremia.  Presence of viable bacteria in the bloodstream.
Case.  An individual who is ill following ingestion of food.  Outbreak cases
reported by CDC are determined to be contaminated on the basis of laboratory
analysis and/or epidemiological evidence.  Not all outbreak cases need be con-
firmed by laboratory analysis if there is sufficient epidemiological evidence
linking them to the outbreak.  
Campylobacteriosis.  An illness in humans caused by Campylobacter jejuni or
C. coli.  Symptoms range from general malaise and diarrhea lasting for a day, to
severe abdominal pain and bloody diarrhea, which may last several weeks. 
Cholecystitis.  Inflammation of the gall bladder.
Colonization.  “Implantation and growth of a microorganism on a host”
(Dorland’s Dictionary 1994).
Colony forming unit (CFU). Unit of measurement for viable bacteria numbers.
Consumer price index (CPI). A measure of the average change in prices over
time in a fixed “market basket” of goods and services purchased either by urban
wage earners and clerical workers or by all urban consumers.
Contingent valuation method.  The use of surveys of individuals to elicit their
preferences, measured in monetary terms (willingness to pay, WTP), for a speci-
fied improvement in their health outcomes.  It circumvents the absence of mar-
kets for health outcomes by presenting survey respondents with hypothetical
markets in which they are asked their WTP for the improvement in question.
Cost of illness (COI) method.  An approach that is used to estimate the societal
costs of a particular illness or injury in a given time frame (typically a 1-year peri-
od).  The approach typically focuses on two main types of societal costs associat-
ed with the particular illness or injury:  direct medical and non-medical costs and
indirect costs of lost productivity due to morbidity or premature mortality.
Diarrhea.  Three or more unusually frequent evacuations of loose stools within
a 24-hour period.  Diarrhea may be caused by microbial, parasitic, or viral
infections, or other factors.
Direct costs.  Costs associated with resources expended for healthcare (compare
with indirect costs).*  Does not include lost wages—see productivity loss and
indirect costs.
Direct medical costs.  The costs of resources for medical treatment (e.g., the
cost of a physician visit).*Economic Research Service/USDA                       Bacterial Foodborne Disease:  Medical Costs and Productivity Losses / AER-741     vii
Direct non-medical costs.  Costs incurred in connection with a health inter-
vention or illness, but which are not expended for medical care itself (e.g., the
transportation costs associated with a physician visit).* 
Discounting.  A method for adjusting the value of future costs and benefits to
an equivalent value today to account for time preference and opportunity cost,
i.e., a dollar today is worth more than a dollar a year from now (even if inflation
is not considered).*
Discount rate.  A rate used in determining a present value equivalent of a
future stream of dollars.  The lower the discount rate, the higher the present
value of a future stream of dollars.
Endocarditis.  Infection of the heart.
Gastroenteritis.  Inflammation of the intestine and stomach.
Guillain-Barré Syndrome (GBS).  An autoimmune reaction of the body that
affects the peripheral nerves and causes weakness, paralysis, and occasionally
death.
Hedonic wage studies.  Statistical analyses that estimate the effect of intrinsic
job characteristics, such as health risks, fringe benefits, or autonomy, on pay.
Hemodialysis.  Separation of large and small molecules of the blood by use of
selective diffusion through a semipermeable membrane.  A medical treatment
used to treat kidney failure.
Hemolytic Uremic Syndrome (HUS).  A disease characterized by kidney
failure and neurological failure.  HUS especially strikes children under 5 years
of age and the immunocompromised elderly.
Hemorrhagic Colitis.  A clinical syndrome manifested by bloody inflammation
of the colon.  This syndrome can be the result of several diseases including E.
coli O157:H7 disease.
Hospital discharge.  The completion of an inpatient’s continuous period of stay
in a hospital where the stay lasts one night or more.
Human capital approach.  A method for estimating the impact of an individ-
ual’s illness or premature death on society by measuring the discounted value of
his/her productivity loss (labor earnings) due to morbidity or premature mortality.
Immunocompromised.  Individuals with a weakened immune system, making
them susceptible to additional infections.
Incidence.  A measure of the magnitude of a disease, usually expressed as the
number of new cases of a disease per 100,000 individuals in the U.S. population
in a 1-year period.viii     Bacterial Foodborne Disease:  Medical Costs and Productivity Losses / AER-741                      Economic Research Service/USDA
Incidence-based costs.  The total lifetime costs of new cases of a disease or
injury that occur during a certain period of time.*
Indirect costs.  The resources forgone either to participate in an intervention or
as the result of a health condition (e.g., earnings forgone because of loss of time
from work).*
Infection.  An illness or carrier state arising from colonization of foodborne
microbial pathogens in the human gastrointestinal tract or other parts of the
human body.  Human antibodies that resist these pathogens may cause chronic
complications.
Infectious Dose.  The number of organisms that make individuals ill or carriers.
In reality, there is a probability distribution associated with different pathogen
exposure levels.
Isolation rate.  In microbiology, the rate at which an organism is identified in a
culture.
Labor force participation rate.  The percentage of average civilian noninstitu-
tional population in the civilian labor force in a year.  The civilian labor force
comprises all employed and unemployed civilians in the noninstitutional popu-
lation 16 years and over.
Life expectancy.  The average remaining lifetime in years for an individual of a
particular age, given sex-specific and age-specific death rates.
Listeriosis.  A gastrointestinal illness in humans caused by Listeria.  Illness
caused by the bacterium, Listeria monocytogenes, may be either mild or severe.
Milder cases are characterized by a sudden onset of fever, severe headache,
vomiting, and other influenza-type symptoms.  Severe cases can result in
meningitis, chronic illness, and death.  Listeriosis may appear mild in healthy
adults and more severe in fetuses, the elderly, and the immunocompromised.
Pregnant women with Listeria infections may have spontaneous abortions and
offspring with visual, mental, or other problems.  Outbreak data show that the
incubation period ranges from 3 to 70 days.
Meningitis.  Infection of the brain or spinal tissues.
Neonate.  A newborn child.
Net present value (NPV).  The sum that results when the discounted value of
the costs of a prevention strategy is deducted from the discounted value of the
benefits of the strategy.*
Opportunity costs.  The monetary value of the resources used in providing a
specific set of health-care services valued in terms of forgone alternative uses.*
Outbreak data.  CDC data on foodborne disease outbreaks define an outbreak
as an incident in which two or more persons experienced a similar illness after
ingestion of a common food, and epidemiologic analysis implicated a food as Economic Research Service/USDA                       Bacterial Foodborne Disease:  Medical Costs and Productivity Losses / AER-741     ix
the source of the illness.  There are two exceptions, botulism and chemical poi-
soning, in which one case constitutes an outbreak.
Pathogen.  A disease-causing agent such as a certain bacterium, parasite, virus,
or fungus.
Pneumonia.  Acute or chronic disease characterized by inflammation of the
lungs.  The disease is typically caused by bacteria, viruses, or other agents.
Premature mortality.  a) Any preventable death.  b) Deaths that occur
before a specified age, often age 65, or the average life expectancy of a cer-
tain population.*
Prevalence.  The total number of cases of a given disease at a particular point
in time, includes new (i.e., incidence) as well as chronic cases.
Productivity loss.  The monetary value of output that would have been pro-
duced in the absence of an illness, disability, injury, morbidity, or premature
mortality.
Reiter syndrome.  Inflammation of the joints and sometimes the eyes and uri-
nary tract.  Reiter syndrome (a form of reactive arthritis) typically lasts for 6
weeks and can go on to develop other rheumatoid syndromes, such as rheuma-
toid arthritis.  Reactive arthritis is seen equally in females and males, and some-
times in children.  Almost all sexually acquired Reiter syndrome cases are seen
in males aged 20-40 years.
Recurrent.  “1. Running back, or toward the source, 2. returning after remis-
sions” (Dorland’s Dictionary 1994).
Reservoir of infection. “1. Any person, animal, arthropod, plant, soil, or sub-
stance, or a combination of these, in which an infectious agent normally lives
and multiplies, on which it depends primarily for survival, and where it repro-
duces itself in such a manner that it can be transmitted to a susceptible host.  2.
The natural habitat of the infectious agent” (Dict. of Epid. 1995, p. 146).
Resistance.  “The natural ability of an organism to resist microorganisms or
toxins produced in disease” (Dorland’s Dictionary 1994).
Risk premium.  The increased wage needed to attract workers to riskier jobs.
Salmonellosis.  An illness in humans caused by Salmonella.  The disease
induces fever, nausea, abdominal cramps, diarrhea, and sometimes vomiting.
Severity ranges from mild diarrhea to bacteremia and death.
Sepsis.  “Presence of disease-causing organisms or their toxins in the blood or
tissues” (Webster’s Dictionary 1984).  Sepsis is a syndrome of decreased blood
pressure and capillary leakage.
Septicemia.  “Systemic disease caused by pathogenic organisms and their tox-
ins in the bloodstream” (Webster’s Dictionary 1984).x     Bacterial Foodborne Disease:  Medical Costs and Productivity Losses / AER-741                      Economic Research Service/USDA
Sequelae.  Abnormal conditions that arise following the acute phase of a dis-
ease.  For example, kidney failure may follow acute E. coli O157:H7 disease.
Serotypes.  “A group of related microorganisms distinguished by its composi-
tion of antigens” (Webster’s Dictionary 1984).  Serotype is sometimes called
serovar.
Societal perspective.  The perspective of society as a whole.  Economic analy-
ses typically take a societal perspective to include all benefits of a program
regardless of who receives them and all costs regardless of who pays them.*
Surveillance data.  Data on individual cases of foodborne illness that were cul-
tured in a laboratory and reported to the CDC surveillance system.
Virulence.  The pathogenic or poisonous potential of bacteria, fungi, or other
agents.
Willingness-to-pay (WTP).  A measure of the value an individual would place
on reducing risk of death or illness.  It is the maximum dollar amount the indi-
vidual would be willing to give up in a given hypothetical risk-reducing situa-
tion.
* These terms are from Haddix, A. C., S. M. Teutsch, P. A. Shaffer, and D. O.
Duñet (eds.).  Prevention Effectiveness: A Guide to Decision Analysis and
Economic Evaluation. New York: Oxford University Press, 1996 (definitions
may have been adapted for this report).Economic Research Service/USDA                       Bacterial Foodborne Disease:  Medical Costs and Productivity Losses / AER-741     xi
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Introduction
Foodborne diseases in the United States cost billions
of dollars each year.  The Council for Agriculture and
Science Technology (CAST) concludes that microbial
pathogens in food cause 6.5-33 million cases of human
illnesses in the United States and up to 9,000 deaths
each year (1994).  Pathogens are microorganisms that
cause diseases and include bacteria, fungi, parasites,
and viruses.  Researchers at the Economic Research
Service (ERS) of the U.S. Department of Agriculture
(USDA) estimate that the annual cost of human ill-
nesses for seven of these foodborne pathogens (six
bacteria and one parasite) from all food sources is
$5.6-$9.4 billion (Federal Register Feb. 3, 1995).  Of
these estimated costs, meat and poultry sources
account for $4.5-$7.5 billion (Federal Register Feb. 3,
1995).  These estimates undervalue the true costs of
foodborne illnesses to society, because there are over
40 different foodborne pathogens believed to cause
human illnesses (CAST 1994, pp. 11-15).  
This report documents ERS analyses for the six bacte-
ria mentioned above, providing a comprehensive,
detailed accounting of how the cost-of-illness (COI)
estimates were calculated and updated to 1993
dollars.1 Previously, documentation for COI studies
on these bacteria were spread out over diverse sources
as each individual COI analysis was completed.  This
report is the first to comprehensively document the
ERS COI analyses in terms of a given base year (in
this case, 1993 dollars).  The intended audience for 
this report is all researchers and policymakers interest-
ed in the societal costs of food safety. 
Specifically, this report presents previously estimated
costs of salmonellosis (Roberts 1988), listeriosis
(Roberts and Pinner 1990), E. coli O157:H7 disease
(Roberts and Marks 1995), campylobacteriosis (Lin et
al. 1993), Staphylococcus aureus illness (Roberts
1989), and Clostridium perfringens illness (Roberts
1989), after updating to 1993 dollars and with more
recent estimates of annual cases and deaths.  These
six bacteria from all food sources cost the United
States an estimated $2.9-$6.7 billion annually (in
1993 U.S. dollars), with $1.8-$4.8 billion attributable
to meat and poultry (Federal Register Feb. 3, 1995). 
The COI estimates reported here can be used in three
main ways.  First, they can be used to evaluate the eco-
nomic impact of foodborne diseases on the United
States.  Second, they can be used to target pathogen
reduction efforts toward the most costly diseases.
Third, they can be used to compare benefits and costs
of control efforts to determine the most cost-effective
interventions. 
Bacteria
Of the four pathogen types (i.e., bacteria, fungi, para-
sites, and viruses),  Bean et al. (1990) found that over
90 percent of confirmed foodborne human illness
cases and deaths reported to the Centers for Disease
Control and Prevention (CDC) are attributed to bacte-
ria.2 Bacteria are commonly found in soil, water,
Bacterial Foodborne Disease





1The parasite, Toxoplasma gondii, was not included in this docu-
ment because we wanted to focus on bacterial pathogens as a
group and because the cost-of-illness analysis for T. gondii was well
documented by Roberts and Frenkel (1990).
2Note that bacteria are more easily cultured than viruses and there-
fore the percentage attributed to bacteria may be biased upward.
Also note that roughly half of the foodborne outbreaks cannot be
attributed to a specific bacterial, viral, parasitic, or fungal pathogen.2 Bacterial Foodborne Disease:  Medical Costs and Productivity Losses / AER-741                      Economic Research Service/USDA
plants, and animals (including humans).  Most bacte-
ria do not cause human illnesses and society relies on
some bacteria to make bread, alcohol, vitamins, and
antibiotics.  Bacteria in the human body outnumber
human cells (CAST 1994, p. 24).  Over 400 species of
bacteria live harmlessly in the gastrointestinal tracts of
humans and some live on human skin (CAST 1994, p.
24).  For example, Staphylococcus aureus lives harm-
lessly on human skin and in nasal cavities of up to 50
percent of all people in the United States; present in
food, however, it can produce toxins that cause human
illness (Labbe 1989, p. 498).  
Food sources account for most human illness cases
caused by the six bacteria discussed here except for
Staphylococcus aureus.  People can also be exposed
to some bacteria through inhalation, contaminated
drinking water, and contact with infected pets, farm
animals, and humans.  Here, “food sources” is broadly
defined to include all sources of exposure to
pathogens in the food chain, between exposure at the
farm or production level to exposure at the food con-
sumption level.  Here, food sources also include sec-
ondary sources of exposure to foodborne illnesses,
such as transmission of a foodborne illness from an ill
person to other family members or other children in a
day care center.  Therefore, “foodborne illnesses” or
“foodborne diseases” can originate at any of these
stages.
Table 1 lists seven pathways through which people
can be exposed to pathogens found in animals.
Illnesses from exposure to pathogens through any of
those seven pathways are included in estimates of
foodborne diseases.  Illnesses in farm families or
slaughterhouse workers that arise from either direct or
indirect contact with live animals are categorized here
as illnesses from food sources, because these illnesses
would not have occurred had these people not been
exposed to this occupational hazard.  
Although table 1 focuses on pathogens found in meat,
an abbreviated list could be developed for pathways
of human exposure to pathogens found in non-animal
food sources, such as on fruits and vegetables.  Also,
the seven pathways in table 1 do not have an equal
likelihood of causing human illnesses.  Most food-
borne illnesses occur from consumption of food con-
taminated with pathogens.  Less common is the inclu-
sion of kitchen/processing plant workers who become
Table 1—Potential pathways of human exposure to pathogens found in animals
I. Direct contact with live food animal.
°  Food animal bite.
°  Contact with the skin, fur, tail, etc., and microorganisms found there.
II. Indirect contact with the live food animal.
°  Aerosol contamination of the barn and air system.
°  Contamination of the walls, floor, gates, etc.
°  Animal waste.
°  Bites by flies or fleas that had become disease vectors from previous contact with infected animals.
III. Direct contamination by the carcass.
°  Penetration of the skin of the personnel handling meat by microorganisms.
°  Entry of organisms through cuts and nicks on the hand of slaughterhouse or processing plant workers.
IV. Indirect contamination by the carcass.
°  Aerosol contamination through pathogens released when the carcass is cut up and/or slapped onto the counter.
°  Contact with knives, wiping clothes, sinks, etc., where pathogens have been deposited.
V. Cross contamination of other edible products from the environment, other foods, or pests.
°  In the slaughterhouse, spreading from one contaminated carcass to others.
°  Meat products in the processing plant.
°  Other raw or cooked foods in the kitchen of a private home or commercial feeding establishment.
VI. Consumption of meat, poultry, and dairy products.
VII. Person-to-person transmission.
Source: Economic Research Service, USDA, adapted from Roberts, T. “A Retrospective Assessment of Human Health Protection Benefits from
Removal of Tuberculous Beef,” Journal of Food Protection 49,4(April 1986):293-8.Economic Research Service/USDA                      Bacterial Foodborne Disease:  Medical Costs and Productivity Losses / AER-741     3
ill by handling contaminated food.  For example, bru-
cellosis, psittacosis, and tuberculosis are occupational
hazards among slaughterhouse workers.  
Some pathogens that cause human illnesses are car-
ried by animals but do not cause animal diseases.
Escherichia coli O157:H7 seems to live innocuously
in the intestinal tracts of some cattle, though people
who eat rare hamburgers from infected animals can
develop bloody diarrhea and kidney failure.  
Farm livestock and poultry infected with bacterial
pathogens may spread infection among the herd or
flock through their excrement.  Nonetheless, contami-
nation of meat and poultry flesh does not usually
occur until slaughter.  For example, Martz (1994-95)
quotes Stephen Knabel, a food scientist at
Pennsylvania State University, as stating that “only 5
percent of live poultry are contaminated with
Salmonella, but after processing, nearly half of the
carcasses contain Salmonella.”  Defeathering, slaugh-
tering, chilling, and processing stages all provide
opportunities for cross-contamination.  Accidental
puncturing of the intestinal tract during slaughter can
lead to widespread contamination of the packing line.  
Animal products such as milk and eggs also require
proper handling.  For example, if pasteurization of raw
milk is not done properly, some Listeria may survive,
though injured, and recover sufficiently to grow in
refrigerated milk.  Proper sanitation on the farm, in
fishing vessels, and in slaughter and processing plants
can reduce the pathogen level in food that goes to
retail.
For each of the six bacterial pathogens discussed here,
table 2 provides estimates of the number of annual
U.S. cases and deaths from all sources and from food-
borne sources.  The estimates are subject to revision as
new data become available or alternative databases are
used.
Table 3 presents major and minor food sources for
these pathogens.  Foods most likely to cause out-
breaks of human illness in the United States are ani-
mal foods and their products such as meat, poultry,
seafood, dairy products, and eggs (CAST 1994, p.
32).  Table 3 also lists acute symptoms and chronic
complications associated with infections from each of
these foodborne pathogens.
Human illnesses caused by microbial pathogens are
generally classified in three categories:  foodborne
infections, foodborne toxicoinfections, and foodborne
intoxications (CAST 1994, pp. 17-20).  Figure 1
shows the classification of foodborne disease causes.  
• Foodborne infections occur when pathogens are
eaten and are then established in the body.  The
pathogens usually multiply inside human intestinal
tracts, irritate the lining of the intestines, and cause
human illnesses.  Sometimes, the pathogens invade
other tissues causing additional infections.  Of the six
pathogens investigated here, Listeria, Salmonella,
and Campylobacter cause foodborne infections.
• Foodborne toxicoinfections occur when the
pathogens produce harmful or deadly toxins while
multiplying in human intestinal tracts.  It is these
toxic byproducts and not the pathogens themselves
that cause human illnesses.  In this report, two
pathogens that cause foodborne intoxication are
examined: Clostridium perfringens and E. coli
O157:H7.  
• Foodborne intoxications are caused by consuming
food that contains either toxins released during the
growth stages of specific bacteria (e.g., enterotox-
ins produced by Staphylococcus aureus, a pathogen
included here) or mycotoxins produced by molds.
Illnesses from foodborne intoxications tend to
occur quickly after consumption, because they do
not involve any establishment or growth stage in
the human body.
The CAST report (1994, p. 27) identifies four main
categories of factors that increase the risk or severity
of a foodborne illness:  microbial factors such as the
type, strain, and quantity of pathogens or toxins
ingested; host factors such as age, stress, health of
the individual’s immune system, and personal
hygiene; diet-related factors such as consumption of
antacids and nutritional deficiencies; and other fac-
tors such as geographical location.  
Most cases of foodborne illnesses are classified as
acute, because they have a rapid onset and are self-
limiting.  Acute foodborne illnesses can be mild or
severe and may result in premature death.  Common
acute symptoms of foodborne illnesses are gastroin-
testinal problems and vomiting.  Table 2—Estimated annual U.S. cases, deaths, and percentage foodborne for selected bacterial pathogens, 1993
Total Total Percent Foodborne Foodborne
Pathogen cases deaths foodborne cases deaths
- - - - - - - -Number- - - - - - - - Percent - - - - - - - -Number- - - - - - - -
Campylobacter jejuni or coli 2,500,000f 200-730f 55-70h 1,375,000 - 1,750,000 110-511
Clostridium perfringens 10,000b 100b 100b 10,000 100
Escherichia coli O157:H7 10,000-20,000a 200-500a 80a 8,000 - 16,000 160-400
Listeria monocytogenes 1,795-1,860d 445-510d 85-95e 1,526-1,767 378-485
Salmonella (non-typhoid) 800,000-4,000,000bc 800-4,000bc 87-96bg 696,000 - 3,840,000 696-3,840
Staphylococcus aureus 8,900,000b 7,120b 17b 1,513,000 1,210
Total 12,221,795-15,431,860 8,865-12,960 N/A 3,603,526 - 7,130,767 2,654-6,546
N/A = Not applicable.
Sources: USDA, Economic Research Service, based on:
a Personal communication with researchers at the U.S. Centers for Disease Control and Prevention, and from the article: American Gastroenterological Association, “Consensus Conference
Statement on E. coli O157:H7 Infections, An Emerging National Health Crisis.” July 11-13, 1994. Gastroenterology 108(1995):1923-1934.
bBennett, J.V., S.D. Holmberg, M.F. Rogers, and S.L. Solomon. “Infectious and Parasitic Diseases.” R.W. Amler and H.B. Dull (eds.), Closing the Gap: The Burden of Unnecessary Illness.N e w
York: Oxford University Press, 1987.
cHelmick, C.G., P.M. Griffin, D.G. Addiss, R.V.Tauxe, and D.D. Juranek. “Infectious Diarrheas.” Chapter 3 in Everhart, J.E. (ed.), Digestive Diseases in the United States: Epidemiology and
Impact. U.S. Dept. Health and Human Serv., NIH, NIDDKD, NIH Pub. No. 94-1447, 1994, pp. 85-123.
dRoberts, T., and R. Pinner. “Economic Impact of Disease Caused by Listeria monocytogenes.” In Miller, A.J., J.L. Smith, and G.A. Somkuti (eds.), Foodborne Listeriosis. Amsterdam, The
Netherlands: Elsevier Science Publishing Co., Inc. 1990, pp. 137-149.
eSchuchat, Anne. CDC, personal communication with T. Roberts at the FDA Science Forum on Regulatory Sciences, Washington, DC, Sept. 29, 1994.
fTauxe, R.V. “Epidemiology of Campylobacter jejuni Infections in the United States and other Industrialized Nations.” Chapter 2 in Nachamkin, Blaser, and Tompkins (eds.), Campylobacter jejuni:
Current Status and Future Trends, Washington, DC: American Assoc. of Microbiology, 1992, pages 9-19.
gTauxe, R.V. and P.A. Blake. 1992. “Salmonellosis.” Chapter 12 in Last, J.M., R.B. Wallace, and E. Barrett-Conner (eds.), Public Health & Preventive Medicine, 13th ed., Norwalk, Connecticut:
Appleton & Lange, pp. 266-268.






































































































































ATable 3—Pathogen food reservoirs/transmission and possible acute symptoms and chronic complications
Pathogen Food sources Acute symptoms and chronic complications1
Campylobacter jejuni Major: poultry Acute: abdominal pain, diarrhea (sometimes bloody), fever, malaise, vomiting.
or coli Minor: milk, mushrooms, clams, Chronic: appendicitis, arthritis, carditis, cholecystitis, colitis, endocarditis, erythema nodosum, Guillain-
hamburger, water, cheese, pork Barré syndrome, hemolytic-uremic syndrome, meningitis, pancreatitis, Reiter syndrome, septicemia,
shellfish, eggs, cake icing. urinary tract infection.
Clostridium perfringens Major: meat, meat stews, meat pies, Acute: diarrhea, nausea
and beef, turkey and chicken gravies. Chronic: gas gangrene, necrotizing enteritis.
Minor: beans, seafood.
Escherichia coli Major: beef particularly ground beef. Acute: abdominal pain, diarrhea, fever, malaise.
O157:H7 Minor: poultry, apple cider, raw milk, Chronic: erythema nodosum, hemolytic uremic syndrome, chronic kidney disease, thrombotic
vegetables, cantaloupe, hot dogs, thrombocytopenic purpura, seronegative arthropathy.
mayonnaise, salad bar items.
Listeria monocytogenes Major: soft cheese, pâté, ground meat. Acute: fever, severe headache, vomiting, sometimes delirium or coma.
Minor: poultry, dairy products, hot Chronic: chronic neurological complications, endocarditis, granulomatous lesions in organs, internal 
dogs, potato salad, chicken, seafood, or external abscesses, meningitis, sepsis, septicemia.
vegetables.
Salmonella Major: poultry, meat, eggs, milk, and Acute: abdominal pain, bloody stools, cold chills, dehydration, diarrhea, exhaustion, fever, headache,
(non-typhoid)  their products. and sometimes vomiting.
Minor: vegetables, fruits, chocolate, Chronic: abscesses, aortitis, arthritis, cholecystitis, colitis, endocarditis, epididymo-orchitis, meningitis,
peanuts, shellfish. myocarditis, pericarditis, pneumonia, proderma or pyelonephritis, rheumatoid syndromes, septicemia, 
reactive arthritis, Reiter syndrome, splenic abscesses, thyroiditis.
Staphylococcus aureus Major: workers handling foods: meat  Acute: severe nausea, cramps, vomiting, prostration, often with diarrhea.
(especially sliced meat) poultry, fish, Chronic: none identified to date.
canned mushrooms.
Minor: dairy products, prepared salad
dressing, ham, salami, bakery items,
custards, cheese.
1USDA, Economic Research Service, adapted from:
Bean, N. H., P. M. Griffin, J. S. Goulding, and C. B. Ivey. “Foodborne Disease Outbreaks, 5 Year Summary, 1983-1987,” CDC Surveill. Summ. Morb. Mort. Weekly Rep. (MMWR) 39, 
SS-1(March 1990):15-59 and J. Food Prot. 53(1990):711-728.
Benenson, Abram S. Ed., Control of Communicable Diseases in Man. Amer. Public Health Assoc., 15th edition, 1990.





































































































































56 Bacterial Foodborne Disease:  Medical Costs and Productivity Losses / AER-741                      Economic Research Service/USDA
Archer and Kvenberg (1985) estimate that 2-3 percent
of these acute cases develop secondary long-term ill-
nesses or chronic sequelae.  Chronic sequelae of food-
borne illnesses can occur in any part of the body and
include rheumatoid, cardiac, and neurological syn-
dromes (table 3).  These chronic illnesses may afflict
the patients for the remainder of their lives or cause
premature death.  For example, reactive arthritis and
Guillain-Barré syndrome (a major cause of non-trau-
ma neuromuscular paralysis in the United States) may
follow Campylobacter infections.  
Traditionally, only acute cases of some foodborne dis-
eases have been recorded.  Improved collection and
documentation of data on foodborne illnesses may
increase our understanding of the magnitude of chronic
sequelae and show that the longrun effects of chronic
illnesses are often greater than the initial acute
illnesses.
Regulation
Food safety regulations reduce human illnesses through
preventing and controlling the presence and amount of
foodborne pathogens and other disease-causing ele-
ments (e.g., pesticides) in food.  In making food safe-
ty policy decisions, the Federal Government relies, in
part, on economic information of foodborne illnesses
and alternative regulatory programs that reduce food-
borne health risks (i.e., increase food safety).  A com-
parison of societal benefits and costs among programs
aimed at reducing different pathogens can facilitate
setting priorities as to which pathogens should be tar-
geted first.  Estimates and comparisons of the benefits
and costs of competing programs can also help the
Federal Government efficiently allocate tax dollars.  
A case in point is the Pathogen Reduction Program
proposed in 1994 by the Food Safety and Inspection
Service (FSIS) of the USDA.  As part of this program,
FSIS promulgated a Hazard Analysis Critical Control
Point (HACCP) system to improve the current meat
and poultry inspection.  A portion of the COI esti-
mates from this document plus the estimated annual
costs of illness caused by Toxoplasma gondii, a para-
site, provide the foundation of the estimated benefits
of HACCP (Federal Register Feb. 3, 1995).
Preliminary results indicate that the benefits of imple-
menting HACCP outweigh the costs.
Source: CAST report, Figure 2.1, 1994 (adapted from Bryan, 1982).
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Table 4 outlines societal costs of foodborne illness-
es.  The three cost categories are costs incurred by
individuals/households, industry, and the regulatory
and public health sector.  Note that traditional COI
analyses often include only individual’s/household’s
medical costs and cost of lost productivity.  Other
costs are usually omitted due to lack of suitable
measures.
The costs of food safety regulation include expendi-
tures associated with design and implementation of,
and compliance with, such programs.  In fiscal year
1994, the Federal Government budgeted $1.2 billion
on food safety regulatory activities, such as inspection
and laboratory testing (GAO March 1996).  The food
industry also incurs millions of dollars of expense to
comply with food safety rules and regulations.  If new
regulations are added to the current system, industry
compliance costs will be higher.
Societal benefits of food safety regulation arise from
improvement of individuals’ health status.  From an
economic perspective, these benefits include, at least,
savings in disease prevention and mitigation expendi-
tures, increases in worker productivity, reduction in
pain and suffering, and reduction in anxiety about
foodborne health risk.  
ERS COI estimates represent the maximum benefits
that could be obtained if the microbial infections or
intoxications were eliminated or reduced.  However,
eradication of these illnesses is neither technically nor
economically feasible at present.  The information
contained in this report can help Federal agencies
identify the most cost-beneficial risk-reduction strate-
gies for bacterial pathogens.
Overview of the Willingness-to-Pay
and Cost-of-Illness Methods
Three principles guide economic analysis of regula-
tions aimed at improving health and safety.  The first
is that benefits from the regulation need to be mea-
sured and compared with costs, because regulatory
costs are opportunity costs.  That is, the resources
used could have been applied elsewhere, with poten-
tially greater health benefits.  For example, an expen-
diture of $100 million that is expected to prevent 4
deaths may not be very sensible if that $100 million
could have prevented 50 deaths by being spent in
another application.
The second principle asserts that health and safety reg-
ulations typically do not aim to save the lives of spe-
cific people who would otherwise die, but rather aim
at reducing the level of risk of illness and death faced
by large populations.  That view intertwines with the
third principle, that the benefits of a regulation do not
represent the value of keeping a specific person alive,
but rather the value of reducing those risks.  To this
end, the most theoretically appropriate way to value a
risk reduction is to ask what affected individuals are
willing to pay for it.  However, as we shall see here,
estimating the costs of an illness by summing estimat-
ed medical costs and costs of lost earnings is useful for
studying specific policy questions.
Taken together, the principles recognize that regula-
tors act on behalf of society to reduce societal risk by
spending taxpayers’ money and by setting and enforc-
ing regulations.  In other contexts, people spend their
own money to reduce health risks (e.g., through regu-
lar physician visits, or through diet control, or when
choosing among different brands of durable goods
like cars, household appliances, or power equipment).
Once it is recognized that regulation delivers an out-
come (small risk reductions) that people also purchase
in other public and private venues, one can ask
whether publicly delivered risk reductions appear to
be worth it to the relevant populations, based on what
they are willing to expend to achieve risk reductions
in other contexts.
Economic theory provides a precise framework that
associates the benefits of risk reduction with the
amount that people are willing to pay to achieve the
reduction, and suggests methods of measuring those
benefits (Just et al. 1982).  As is often the case, some 
key theoretical constructs cannot be observed; as a result,
practical applications of the theory aim at approxima-
tions of the theoretically appropriate measures.  The
practical applications for human illnesses can be grouped
into two primary methods of benefit estimation, the cost-
of-illness (COI) method and the willingness-to-pay
(WTP) method.  The WTP method aims, as the name
implies, to estimate the value that individuals place on
reductions in risk to identify the value to society of pub-
licly provided risk reduction.8 Bacterial Foodborne Disease:  Medical Costs and Productivity Losses / AER-741                      Economic Research Service/USDA






Hospitalization or nursing home
Drugs and other medications
Ambulance or other travel costs
Income or productivity loss for—
Ill person or person dying
Caregiver for ill person
Other illness costs—








Pain and other psychological suffering
Risk aversion
Averting behavior costs—
Extra cleaning/cooking time costs
Extra cost of refrigerator, freezer, etc.
Flavor changes from traditional recipes (especially meat, milk, egg dishes)
Increased food cost when more expensive but safer foods are purchased
Altruism (willingness to pay for others to avoid illness)
Industry costs2
Costs of animal production:
Morbidity and mortality of animals on farms
Reduced growth rate/feed efficiency and increased time to market
Costs of disposal of contaminated animals on farm and at slaughterhouse
Increased trimming or reworking at slaughterhouse and processing plant
Illness among workers because of handling contaminated animals or products
Increased meat product spoilage due to pathogen contamination
Control costs for pathogens at all links in the food chain:
New farm practices (age-segregated housing, sterilized feed, etc.)
Altered animal transport and marketing patterns (animal identification, feeding/watering)
New slaughterhouse procedures (hide wash, knife sterilization, carcass sterilizing)
New processing procedures (pathogen tests, contract purchasing requirements)
Altered product transport (increased use of time/temperature indicators)
New wholesale/retail practices (pathogen tests, employee training, procedures)
Risk assessment modeling by industry for all links in the food chain
Price incentives for pathogen-reduced product at each link in the food chain
Outbreak costs:
Herd slaughter/product recall
Plant closings and cleanup
Regulatory fines
Product liability suits from consumers and other firms
Reduced product demand because of outbreak:
Generic animal product - all firms affected
Reduction for specific firm at wholesale or retail level
Increased advertising or consumer assurances following outbreak
See footnotes at end of table. --ContinuedEconomic Research Service/USDA                      Bacterial Foodborne Disease:  Medical Costs and Productivity Losses / AER-741     9
Table 4—Societal costs of foodborne illness--Continued
Regulatory and public health sector costs for foodborne pathogens
Disease surveillance costs to:
Monitor incidence/severity of human disease by foodborne pathogens
Monitor pathogen incidence in the food chain
Develop integrated database from farm to table for foodborne pathogens
Research to:
Identify new foodborne pathogens for acute and chronic human illnesses
Establish high-risk products and production and consumption practices
Identify which consumers are at high-risk for which pathogens
Develop cheaper and faster pathogen tests
Risk assessment modeling for all links in the food chain
Outbreak costs:
Costs of investigating outbreak
Testing to contain an outbreak (for example, serum testing and administration of immunoglobulin in persons exposed to
Hepatitis A)
Costs of cleanup
Legal suits to enforce regulations that may have been violated3
Other considerations:
Distributional effects in different regions, industries, etc.
Equity considerations, such as special concern for children 
1 Willingness-to-pay estimates for reducing risks of foodborne disease is a comprehensive estimate of all these categories (assuming that the
individuals have included employer-funded sick leave and medical programs in their estimates). The estimate is comprehensive and covers
reduced risks for everyone—those who will become ill as well as those who will not.
2 Some industry costs may fall with better pathogen control, such as reduced product spoilage, possible increases in product shelf-life, and
extended shelf-life permitting shipment to more distant markets or lowering shipment costs to nearby markets.
3 In adding up costs, care must be taken to assure that product liability costs to firms are not already counted in the estimated pain and suffer-
ing cost to individuals. However, the legal and court expenses incurred by all parties are societal costs.
Source: USDA, Economic Research Service, based on Roberts, Tanya, and Ewen Todd. “Approaches to Estimating the Cost of Foodborne
Disease,” WHO Consultation on the Economic Implications of Animal Production Food Safety. Washington, DC, June 8-10, 1995.
The COI approach can be thought of as measuring the
costs of an illness to the measured economy, via
effects on current and future Gross Domestic Product.
In brief, COI measures the sum of medical expenses,
forgone earnings of affected individuals, and produc-
tivity losses to employers of affected individuals on
paid sick leave.  The important advantage of a COI
measure is that it employs readily available and reli-
able data.  Also, these relevant data are precise enough
to allow for sensitivity analyses of the response of the
measure to changes in medical costs, productivity
losses, and disease severity categories of affected indi-
viduals.  Because they are so tractable, COI measures
have been widely used for several decades. 
For some human illnesses, patients die prematurely or
are unable ever to return to work.  In a COI analysis,
the lost productivity for these patients can be repre-
sented either by human capital estimates of forgone
earnings or by WTP estimates of the value of a statisti-
cal life.  Therefore, the COI method can partially
incorporate the WTP measure for these categories of
patients.
In general, COI methods aim at calculating the costs of
illness to the measured economy.  That is not the same
thing as calculating the valuation that people place on
reductions in risk, because forgone earnings are not nec-
essarily a good indicator of that valuation.  Some
authors (Harrington and Portney 1987) argue that COI
can serve as a lower bound estimate for willingness to
pay.
Taken literally, human capital estimates of forgone
earnings suggest that the method places little value on
reducing risk of the elderly, because they have low
future earnings to forgo.  Similarly, the method typi-
cally attaches rather low values to risk reduction for
children, because future earnings are discounted to
present values.  Depending on the discount rate 10 Bacterial Foodborne Disease:  Medical Costs and Productivity Losses / AER-741                      Economic Research Service/USDA
used, the present value of children’s future earnings
can be quite small.  Common observation suggests
that assigning low values for reducing risks to chil-
dren and the elderly is not a good approach, since
we can observe people spending substantial
amounts on risk avoidance for those groups, espe-
cially children.  
More generally, the COI approach seems to be crude-
ly “economic” in the sense that it values lost income
and the associated consumption expenditures; but in
fact the approach does not conform with economic
theory because it fails to recognize the value that
individuals may place on (and pay for) feeling
healthy, avoiding pain, or using their free time.
Because the COI approach explicitly ignores these
valuable aspects of health, the method is generally
thought to understate the true societal benefits from
risk reduction.
While there are several methods that attempt to isolate
willingness to pay, recent attention in estimating the
value of a statistical life has focused on one, hedonic
wage estimation.3 Hedonic wage studies derive the
value of risk reduction by statistically estimating the
effect of occupational mortality and injury risks on
wages.  Typically, employers must offer workers high-
er wages to induce them to take a job with some
injury risks, as opposed to a similar job with no such
risks.  Conversely, workers accept jobs with lower
wages, given that those jobs offer minimal risks.  The
“risk premium” is then the increased wage needed to
attract workers to riskier jobs.  Economists began to
use statistical methods to estimate typical risk premi-
ums in the 1970’s, in analyses that could control for
other factors that influenced wages, such as education,
experience, and location.
Economists are partial to the hedonic wage method,
because it uses actual choices made in response to dif-
fering risk environments.  However, early applications
of the method were controversial for reporting widely
varying values for risk premiums.  With the develop-
ment of more precise risk measures, better under-
standing of the affected populations in the studies, and
better control variables, analysts have been able to 
generate a narrower range of values, leading to
greater acceptance of hedonic wage models in recent
years.
The typical hedonic wage study uses a measure of
mortality risk, and measures the effects of a change in
mortality risk on wages; a typical study might find
that an increase in mortality risk of 1 in 10,000 (one
extra death in a year for every 10,000 workers in the
relevant population) would be associated with a wage
increase of $300.  In an industry with 10,000 workers,
then, we could expect one additional worker to die
each year on average, and as a result total wage pay-
ments would be $3 million higher ($300 times 10,000
workers).  In that case we would say that the value of
a statistical life was estimated to be $3 million,
because industry had to pay that amount to induce
workers to take on a risk that would likely leave one
dead (alternatively, one could in this analysis say that
workers would in the aggregate be willing to pay $3
million, through wage reductions, to purchase a reduc-
tion in risk). 
Note the emphasis above on our second principle, that
what we purchase in these cases are small reductions
in health risks.  Analysts often carelessly refer to the
“value of a life” derived from these studies, which is
easily confused with the crude idea that economic
analyses associate the value of a life with lifetime
earnings.  But that is not what economic theory
describes as the appropriate measure, nor is it what
willingness-to-pay studies seek to uncover.  They seek
to measure the value that individuals place on small
reductions in risk, a value likely to be only loosely
related to income.
Does method matter?  Apparently so.  Cost-of-illness
studies, as shown in more detail below, estimate sep-
arate values of forgone earnings for illnesses and for
deaths.  COI aggregate estimates are usually domi-
nated by the forgone earnings associated with prema-
ture deaths; typical values of forgone earnings vary
between methods.  The Landefeld and Seskin value
of statistical life varies, depending on age, from
$11,867 to $1,584,605 in 1993 dollars.  However,
hedonic wage studies suggest that employed people
would be willing to pay between $3 million and $7
million (1990 dollars) to reduce the risks generating
each additional death (Viscusi 1993).  As a result,
the COI method is likely to give extremely conserva-
tive benefit estimates for publicly provided risk
reduction.
3Fisher et al. (1989, p. 89) divide the WTP approach into three
categories of studies: (1) contingent market studies, (2) consumer
market studies, and (3) wage-risk studies.Economic Research Service/USDA                      Bacterial Foodborne Disease:  Medical Costs and Productivity Losses / AER-741     11
Our example shows how hedonic wage studies use the
wage response to mortality risks to generate estimates
for the value of a statistical life.  The exercise points
out one current weakness of hedonic wage studies;
these studies have much better data, and more useable
estimates, for mortality risks than they do for morbidi-
ty risks (i.e., risk of temporary or chronic illness).
Even where morbidity risks are incorporated, it is
questionable how closely risk aversion to the job-
related illnesses resembles risk aversion to illnesses
associated with foodborne pathogens.  If we base esti-
mated values of risk reduction on hedonic wage stud-
ies only, we may make the error of understating the
value of the risk reduction because these studies focus
on mortality risks and often implicitly ignore morbidi-
ty risks.
Cost-of-Illness (COI) Method
This section outlines the basic framework behind the
six COI analyses presented here.  Due to differences
in available data and differences in chronic sequelae
examined for each bacterial pathogen, these six analy-
ses vary in depth, though all basically look at both
medical costs and the costs of lost productivity from
the illnesses.
Incidence
The first step in any COI analysis is to determine the
incidence of a specific illness.  Incidence rates are
often expressed as the number of new cases of a dis-
ease per 100,000 individuals in the U.S. population in
a 1-year period.4 The quantification of foodborne dis-
ease incidence is a matter of great controversy
because of uncertainties over the true state of the
world (CAST 1994; Roberts and Foegeding 1991).
The enumeration of a case of a foodborne disease
depends on whether:  (1) the affected individual rec-
ognizes food as the cause of the illness, (2) a physi-
cian is consulted, (3) a hospital is sought for treat-
ment, (4) the physician recognizes the illness as food-
borne, (5) the laboratory identifies a foodborne
pathogen, and (6) the case is reported to the CDC.
Because the nature and reporting of foodborne dis-
eases result in vast under-counting of the actual inci-
dence of illnesses, incidence rates are often estimated
by expert opinion.  
There are five main data sources for incidence of
acute foodborne illnesses:  (1) national surveys or
databases such as those conducted and published by
the National Center for Health Statistics (NCHS), (2)
CDC data ranging from reports of foodborne disease
to active surveillance studies, (3) risk models based
on pathogens’ prevalence in foods, and on infectious
doses, (4) medical data on individual cases, often pub-
lished in the literature as a case history, and (5)
extrapolations by experts to obtain estimates of the
total number of cases and the disease severity distrib-
utions (CAST 1994, p. 40).5 Extrapolations are
upward adjustments made to account for those cases
that go undiagnosed or unreported.  Estimates from
these data sources form the basis for some of the COI
studies of foodborne diseases.  Where data were avail-
able to suggest a range of cases and/or deaths, ranges
were used.
Costs
Given the incidence of an illness, we computed annu-
al medical costs and costs of lost productivity.
Where possible, we considered both acute and chron-
ic illnesses.
In general, medical costs include physician and hospi-
tal services, supplies, medications, and special proce-
dures required for a specific foodborne illness.
Hospitalization accounts for a large proportion of
these costs.  Estimates of medical costs come from
nationwide databases such as the published Medicare
reimbursement rates and per capita expenditures on
physician services from the Health Care Financing
Administration (HCFA), the American Hospital
Association’s Hospital Statistics, and the National
Center for Health Statistics’ National Hospital
Discharge Survey (NHDS) and National Mortality
Follow-back Survey.
In general, productivity loss measures the decline in
production (output) because workers were ill and
either missed work, performed poorly at work, were
unable ever to return to work, or died prematurely.
4To facilitate comparison of the relative occurrence of different
pathogens, incidence rates are used rather than prevalence rates.
The incidence of a disease signifies the number of new cases
occurring during a year in the United States. Prevalence measures
the number of people sick, regardless of when the disease began,
at a given point of time or over a period of time which may vary by
pathogen. For decisionmaking with respect to preventative pro-
grams (such as food safety regulations), incidence rates are the
appropriate statistics (Hartunian et al. 1980, p. 1249).
5Bennett et al. (1987) estimated the proportion of infections, for
known categories, acquired through food.12 Bacterial Foodborne Disease:  Medical Costs and Productivity Losses / AER-741                      Economic Research Service/USDA
Productivity losses for those who died or were unable
to return to work were calculated differently from
those who missed some work but later resumed work. 
For those cases in which work is interrupted tem-
porarily, the productivity loss is the product of time
lost from work multiplied by the corresponding wage
rate.  The daily wage of an individual is frequently
used in economic studies as a proxy for the value of
output produced in a day’s work.  When data are not
available on time lost from work due to illness, this
lost time is estimated by assuming a typical ratio of
time spent in the hospital to time lost from work.
Time spent by parents, as well as payments to paid
caretakers, caring for sick children may also be
included as forgone productivity.  
In this report, estimated productivity losses for those
who die or were unable to return to work were based
on Landefeld and Seskin’s (LS) (1982) human capi-
tal/WTP measure.  We used the LS estimates directly
in the first four COI analyses (salmonellosis, listerio-
sis, E. coli O157:H7 disease, campylobacteriosis).  In
the remaining two COI analyses (Staphylococcus
aureus intoxications and Clostridium perfringens
intoxications), we extrapolated COI estimates from
other analyses that used LS estimates directly.6
The LS method combines elements of both the human
capital and WTP methods to generate the present
value of expected lifetime after-tax income and house-
keeping services.  The LS method generates the pre-
sent value of expected lifetime after-tax income and
housekeeping services at a 3-percent real rate of
return, adjusted for an annual 1-percent increase in
labor productivity and a risk aversion factor of 1.6.
The risk aversion factor is based on the ratio of life
insurance premium payments to life insurance loss
payments.  In most cases, life insurance premiums
represent “household WTP for potential losses associ-
ated with the death of an income-earning household
member” (Landefeld and Seskin 1982, p. 562).  The
LS value of a statistical life lost is:
(1)
where T = remaining lifetime, t = a particular year, Yt
= after-tax income including labor and nonlabor
income, r = household’s opportunity cost of investing
in risk-reducing activities, and a = risk aversion fac-
tor.  Table 5 provides estimates of the value of statisti-
cal life using LS estimates, after averaging across
gender, interpolating between the LS’s 4-year age
groups, and updating to 1993 dollars.
General Framework for the Six COI Analyses
The general framework for the first two COI analyses
presented here (salmonellosis and campylobacteriosis)
used the following classification system: all cases
were first divided into four severity categories for
acute illness, and costs were then applied to each of
the categories.  The four severity categories were
those who: did not visit a physician, visited a physi-
cian, were hospitalized, or died prematurely.  Costs
were summed over the four categories to calculate
total costs.  Medical costs and costs of lost productivi-
ty were not calculated separately.7 The COI analyses
for salmonellosis and campylobacteriosis did not con-
sider chronic complications.  
The general framework for the third and fourth COI
analyses presented here (E. coli O157:H7 disease and
listeriosis) was more inclusive than the COI analyses
for salmonellosis and campylobacteriosis, because
some chronic complications were considered.  In the
E. coli O157:H7 disease and listeriosis COI analyses,
we first calculated medical costs and then calculated
lost productivity costs.  For each of these cost cate-
gories, acute and chronic cases were considered sepa-
rately.  We used the four severity subcategories for
acute illness from the previous two analyses (i.e.,
those who:  did not visit a physician, visited a physi-
cian, were hospitalized, or died).  After costs in each
subcategory were estimated, total costs were calculat-
ed.  For chronic cases, the lifetime course of disease
and associated costs were estimated.
The remaining two COI analyses (Staphylococcus
aureus intoxications and Clostridium perfringens
intoxications) were more simplistic in that estimates
6As previously mentioned, this study updates the annual COI of
Staphylococcus aureus and Clostridium perfringens intoxications
from Roberts (1989) to 1993 dollars and uses more recent esti-
mates of the numbers of cases and deaths. Roberts (1989) used
the LS estimates in this fashion and we continue the practice.
7These COI analyses rely heavily on data from Cohen et al.
(1978). Their data for the four disease severity categories did not
distinguish between medical costs and costs of lost productivity but
instead made vague comments such as “could mainly be attributed
to medical care.” Rather than impose assumptions about what per-
centage of total costs were attributed to medical costs and costs of
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Table 5 — Estimates of the value of a statistical life
Individual  Annual  Individual  Annual  Individual  Annual
age  interpolated value  age  interpolated value  age  interpolated value
0 $1,097,792 28 $1,506,486 58  $401,484
0.5 $1,112,617 29 $1,447,742 59  $365,960
1 $1,127,442 30 $1,448,998 60  $330,436
2 $1,157,093 31 $1,420,254 61  $294,911
2.5 $1,171,918 32 $1,391,510 62  $259,387
3 $1,184,108 33 $1,361,425 63  $237,002
4 $1,208,488 34 $1,331,340 64  $214,617
5 $1,232,869 35 $1,301,255 65  $192,232
6 $1,257,249 36 $1,271,170 66  $169,847
7 $1,281,630 37 $1,241,085 67  $147,462
8 $1,308,213 38 $1,205,340 68  $136,672
9 $1,334,796 39 $1,169,594 69  $125,881
10 $1,361,379 40 $1,133,849 70  $115,090
11 $1,387,962 41 $1,098,104 71  $104,300
12 $1,414,546 42 $1,062,358 72  $93,509
13 $1,438,530 43 $1,018,773 73  $86,870
14 $1,462,514 44 $975,188 74  $80,231
15 $1,486,497 45 $931,602 75  $73,592
16 $1,510,481 46 $888,017 76  $66,953
17 $1,534,465 47 $844,431 77  $60,314
18 $1,544,493 48 $803,427 78  $56,302
19 $1,554,521 49 $762,423 79  $52,290
20 $1,564,549 50 $721,418 80  $48,278
21 $1,574,577 51 $680,414 81  $44,265
22 $1,584,605 52 $639,410 82  $40,253
23 $1,574,730 53 $598,929 83  $34,576
24 $1,564,855 54 $558,449 84  $28,899
25 $1,554,980 55 $517,969 85  $23,221
26 $1,545,105 56 $447,489 86  $17,544
27 $1,535,229 57 $437,009 87  $11,867
Source: Compiled by USDA’s Economic Research Service, based on Landefeld and Seskin (LS) estimates. LS are divided by gender and
use four-year age groups. Here, these 1977 estimates are updated to 1993 dollars, averaged across gender, and interpolated within age
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of the annual number of cases were multiplied by esti-
mates of the average annual costs provided by Roberts
(1989) and updated to 1993 prices.  Roberts (1989)
did not report medical costs and costs of lost produc-
tivity separately (or acute and chronic cases separate-
ly), and therefore they are not reported separately
here.
COI Estimates of Salmonellosis
Salmonella is the main cause of documented food-
borne human illnesses in most developed countries
(CAST 1994, pp. 16, 32).  Although there are over
2,000 Salmonella serotypes,8 only around 200
serotypes are detected in the United States annually
(Benenson 1990, p. 382). Most strains of Salmonella
are from the S. enteritidis species and these strains are
traditionally classified by their serotype designation
and not by their species name (Helmick et al. 1994, p.
104).  For example, the serotype typhimurium is found
among the S. enteritidis species, yet is referred to as
S. typhimurium (Helmick et al. 1994, p. 104).  The 10
most common serotypes are responsible for over 70
percent of the U.S. human illnesses (Helmick et al.
1994, p. 104).  Human illness due to Salmonella
infections is most commonly caused by S. typhimuri-
um, S. enteritidis, or S. heidelberg serotypes in the
United States (Merck 1992).9
Typically, Salmonella-caused human disease is limited
to salmonellosis, an acute gastroenteritis.  After eating
contaminated food, salmonellosis generally appears in
6 to 74 hours with an average incubation period of 12
to 36 hours (Benenson 1990, p. 383).  Salmonellosis
may cause only mild abdominal discomfort, with diar-
rhea lasting less than a day.  Most people who become
ill in salmonellosis outbreaks believe they have the
stomach flu, not salmonellosis (Tauxe, 1987, personal
communication with Roberts).  Other symptoms may
include dehydration, fever, headache, nausea, stom-
achache, and sometimes vomiting (Benenson 1990).
In rare cases, blood may be present in the stools.  
Salmonella infections, like many other bacterial and
parasitic infections, can cause secondary-disease syn-
dromes, some of which may be chronic illnesses
(Archer 1984 and 1985; Mossel 1988) (table 3).  Most
Salmonella serotypes can penetrate the intestinal lin-
ing in humans without advancing deep into other tis-
sues (CAST 1994, p. 17).  Infrequently, the organism
may invade the bloodstream causing bacteremia or
septicemia, with potentially deadly results.  Some
complications of septicemia include endocarditis
(infection of the heart), meningitis (infection of the
brain or spinal tissues), and pneumonia (Merck 1992).
Deaths are uncommon.  
Most human salmonellosis comes from eating conta-
minated food (Helmick et al. 1994, p. 107), especial-
ly food from animal origin (Tauxe 1991, p. 565).
Tauxe and Blake (1992, p. 267) found that 87 percent
of all salmonellosis cases were foodborne (100 per-
cent minus 10 percent person-to-person and 3 percent
pets).  Bennett et al. (1987, p. 109) estimated that,
due to improvements in sanitation, nearly all (96 per-
cent) salmonellosis infections are foodborne (3 per-
cent waterborne and 1 percent from day care).  We
assume that 87 to 96 percent of all salmonellosis
cases are foodborne.
Salmonella contamination occurs in a wide range of
animal and plant products (table 3).  Poultry products
and eggs are frequently contaminated with S. enteri-
tidis, while beef products are commonly contaminated
with S. typhimurium (Merck 1992).10 Other food
sources of Salmonella may include raw milk or other
dairy products and pork.  Salmonella outbreaks also
have been traced to contaminated vegetables, fruits,
and marijuana (Helmick et al. 1994, p. 107). Tauxe
reports that Salmonella-associated bacteremia is com-
mon in AIDS patients, some of whom consume raw
milk, raw eggs, or raw beef under the mistaken belief
that these products will improve their health (Tauxe
1991, p. 566). 
Individuals vary greatly in their susceptibility to sal-
monellosis, depending partly on the virulence of the
8Webster’s dictionary (1988) defines serotypes as “a group of
related microorganisms distinguished by its composition of anti-
gens.”
9S. typhi, the cause of typhoid fever in the United States between
the late 1800’s and 1949, used to be the chief serotype affecting
humans in the United States (Tauxe 1991). Typhoid fever has been
virtually eliminated in the United States through public health mea-
sures such as improved drinking water treatment and sewage dis-
posal (Tauxe 1991). Therefore, this report covers non-typhoid
Salmonella cases.
10S. enteritidis serotype enteritidis has emerged as a major food
safety problem with shell eggs during the past decade because of
genetic or other changes that permit the organism to get inside the
egg. Infected hens transmit S. enteritidis to the egg as the egg is
produced (Tauxe 1991, p. 567). This has resulted in an epidemic of
S. enteritidis infections and a corresponding shift in the overall rank-
ing of serotypes. Salmonella outbreak investigations have shown
that the most common source of infections are grade A shell eggs
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serotype and partly on the individual’s immune system,
along with other factors such as the quantity of
Salmonella ingested.  The infectious dose may be as low
as one colony forming unit (CFU) for some Salmonella
serotypes (CAST 1994, p. 13; Archer and Young 1988,
p. 380).  Usually, ingestion of at least 102-3 organisms are
required for infection (Benenson 1990, p. 382).
Those most vulnerable to Salmonella infection and
secondary complications are infants, the elderly, and
the immunocompromised (e.g., those with cancer,
sickle cell anemia, and AIDS) (Helmick et al. 1994, p.
104).  People who take oral antibiotics may have
decreased colonization resistance to S. typhimurium
(CAST 1994, p. 25).  Riley et al. (1984, p. 878) sug-
gest that those Salmonella serotypes that are resistant
to antimicrobial agents depend more heavily on the
characteristics of the host to cause human illness than
do those serotypes sensitive to antimicrobial agents.
Arthritis complications provoked by Salmonella infec-
tion are more likely to be found among those who are
genetically predisposed (Helmick et al. 1994, p. 107). 
Ryan et al. (1987, p. 3271) found that children under
10 years of age were more likely to contract salmonel-
losis than people 10 years old or older.11 They also
found that those most severely affected out of a sam-
ple of culture-confirmed salmonellosis cases were
children 1 to 4 years old (Ryan et al. 1987, p. 3271).
Salmonellosis patients who are immunocompromised,
very old, or very young face a higher risk of death
(Benenson 1990, p. 381).  Figure 2 shows Salmonella
isolation rates by age and sex.
Estimates of Cases
Three basic sources of data can be used to estimate
the number of annual salmonellosis cases: surveil-
lance data, outbreak data, and extrapolations from sur-
11This result is based on a sample of persons with a salmonel-
losis-like illness after drinking contaminated milk. The data are
from a survey of persons in two Illinois counties (April 14-25, 1985).
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veillance and outbreak data.12 Since 1943, CDC’s
National Notifiable Diseases Surveillance System has
recommended that States report salmonellosis cases
(Helmick et al. 1994, p. 104).  This means that, in
participating States, physicians report salmonellosis
cases to local health departments, local health depart-
ments report these cases to State health departments,
and State health departments report total annual cases
to CDC (Tauxe 1991, p. 564).  Local health depart-
ments also investigate to determine if the cases are
foodborne.  This reporting results in a better estimate
of the incidence of salmonellosis than for most other
bacterial diseases.  A second surveillance reporting
system, introduced in 1963 where State public health
laboratories report Salmonella isolates to CDC
(Helmick et al. 1994, p. 104), has an even higher rate
of salmonellosis positive tests. 
Both surveillance data and outbreak are clearly under-
estimates.  As previously mentioned, infection may
not be suspected, cultured, diagnosed, or reported for
a variety of reasons.  Therefore, estimates of the
“true” incidence of salmonellosis are generally extrap-
olated from these two types of data.
Chalker and Blaser (1988, p. 120) investigated various
methods to calculate the annual number of Salmonella
infections not reported.  They estimated that each
year, only 1-5 percent of all Salmonella infections are
reported to CDC.  Tauxe (1991, p. 564) found that in
the late 1980’s, the National Salmonella Surveillance
System reported 40,000 to 45,000 Salmonella isolates
each year.  Using the low estimate of isolates (40,000)
and Chalker and Blaser’s multipliers,13 the CDC’s
best estimate of human Salmonella infections annual-
ly in the United States is 800,000 to 4 million cases
(Helmick et al. 1994, p. 104) (table 6).
This report uses a range of 800,000 to 4 million annu-
al cases of salmonellosis to update Roberts’ (1988)
COI estimates for salmonellosis.  As with each of the
six foodborne illnesses discussed here, salmonellosis
cases are divided into four severity categories, those
who:  do not seek medical attention, visit a physician,
are hospitalized, and die prematurely.  Both a low and
a high cost estimate were calculated for each severity
category.  Table 6 presents the estimated U.S. salmo-
nellosis cases by severity category.  Figure 3 presents
the distribution of estimated annual U.S. cases of sal-
monellosis and disease outcomes.
A 1984-85 survey found a 1.3-percent death rate for
reported cases of salmonellosis (CDC memo from the
Foodborne and Diarrheal Disease Branch, Oct. 31,
1994).14  After adjusting for unreported cases, it is
assumed that there is a 0.1 percent death rate for all
salmonellosis cases.  Applying this ratio to the esti-
mated range of 800,000 to 4 million salmonellosis
cases results in a range of 800 to 4,000 deaths occur-
ring annually.  This range of annual salmonellosis
deaths was used in this report.
12In the United States, most Salmonella infections are believed to
be sporadic cases as opposed to being associated with outbreaks
(Feldman and Blaser 1980, p. 436).
13That is, the actual number of infections is 20 to 100 times larger
than the 40,000 reported cases of salmonellosis.
Table 6—Estimated U.S. salmonellosis cases, 1993
Severity Estimated cases
of illness Low High
Number
No physician visit1 746,880 3,734,400




1 Cases in this category were calculated as a residual.
2 Assuming 5.04% of all cases visit a physician (Ryan 1987).
3 This category is for those who were hospitalized and survived.
Assuming 1.5% of all cases are hospitalized (Ryan et al. 1987).
4 Deaths are calculated using a case fatality rate of 1/1,000.
Those who die are assumed to be hospitalized prior to their deaths.
Therefore, the total number of salmonellosis patients hospitalized
each year is 12,800 in the low estimate and 64,000 in the high esti-
mate.
5 The low estimate of 800,000 cases was calculated by multiplying
CDC’s estimate of 40,000 Salmonella isolates (Tauxe 1991) by
Chalker and Blaser’s (1988) low estimate of the number (20) of
unreported cases to each reported case. The high estimate of 4
million cases was calculated by multiplying CDC’s estimate of
40,000 Salmonella isolates (Tauxe 1991) by Chalker and Blaser’s
(1988) high estimate of the number (100) of unreported cases to
each reported case.
14Death certificate data (Vital Statistics) reported to CDC show an
average of 79 deaths per year due to salmonellosis between 1979
and 1984 (Public Health Service, U.S. Dept. of Health and Human
Services, 1979-84). Death certificate information is very inaccurate
for two reasons. First, death certificates are filled out within hours
of death and are not updated with laboratory tests showing the
causative organism. Second, autopsy data are not subsequently
entered on the death certificate. However, these death data were
useful here in providing an age distribution of deaths attributed to
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The largest U.S. outbreak of salmonellosis occurred in
Chicago in 1985.  It was linked to two antimicrobial-
resistant strains of S. typhimurium in pasteurized milk
from one dairy plant (Ryan et al. 1987).15 Two sur-
veys of randomly selected households in two Chicago
area counties provided data on the extent of this out-
break.  For each of these surveys, Ryan et al. (1987)
estimated the average number of salmonellosis cases
based on the amount of illness in the survey samples
and the distribution of implicated milk.  The average
of these two incidence estimates is roughly 185,000
cases.  A third survey found that at least 2,777 of the
culture-confirmed cases were hospitalized (Ryan et al.
1987, pp. 3270 and 3272).16 These figures were used
to conservatively calculate that approximately 1.5 per-
cent (2,777/185,000) were hospitalized and survived.  
Applying this rate to the estimated 800,000 to 4 mil-
lion annual cases of salmonellosis provides an esti-
mate of the range of cases that were hospitalized for
salmonellosis (12,000 to 60,000).  To this range, the
800 to 4,000 estimated annual deaths were added
because those who died were likely to incur medical
costs associated with hospitalization prior to death.
Therefore, including deaths, the estimated number of
annual hospitalizations for salmonellosis ranges from
12,800 to 64,000.
Data from the 1985 Chicago milk outbreak were also
used to obtain estimates of the annual number of U.S.
salmonellosis patients who visited a physician.  A
sample of 600 cases was randomly drawn from the
culture-confirmed cases.  Of this sample, 63 percent
of the respondents reported that they visited a physi-
cian either in the emergency room or in a private
office (Ryan 1987, personal communication with
Roberts).  It was assumed that 63 percent of the
roughly 16,000 culture confirmed cases saw a physi-
cian and that none of the remaining 200,000 cases 
(184,000) saw a physician.17 The rate of doctor visits
15Ryan et al. (1987) suggest that the original source of the resis-
tant strains was the use of antimicrobials on dairy cattle. A cross-
connection between pasteurized and raw milk lines may have
been responsible for the outbreak (D’Aoust 1989, p. 360).
16Questionnaires were given to 15,459 (93 percent) of the
16,659 culture-confirmed cases. Of the 12,624 respondents,
2,777 (or 22 percent) were hospitalized (Ryan et al. 1987, pp.
3270 and 3272).
17Note that these estimates are slightly different than those used
for the calculations on hospitalizations. These estimates are from
preliminary data and are used to calculate a conservative estimate
of the percentage of salmonellosis cases who visited a physician.
The assumptions used here were suggested by Ryan (1987), CDC,
to offset the higher-than-average rate of people seeking medical
attention because of the publicity and the possibility of class action
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then is 5.04 percent for the whole Chicago outbreak
((63%)(16,000)/200,000).18 Multiplying 5.04 percent
times the estimated range of 800,000 to 4 million
annual salmonellosis cases results in an estimated
40,320 to 201,600 doctor visits for salmonellosis
annually.
The estimated number of salmonellosis cases where
no medical care was sought was computed as a resid-
ual (total cases minus all hospitalizations, including
deaths and physician visits).  Estimated cases for this
category range between 746,880 and 3,734,400 cases
annually.
Costs of Salmonellosis from All Sources 
Cohen et al. (1978) surveyed 234 people who had cul-
ture-confirmed cases of salmonellosis during the 1976
outbreak caused by eating S. heidelberg-contaminated
cheddar cheese in Colorado.  For the current analysis,
cost estimates for the different severity categories were
taken from Cohen et al. and updated to 1993 using
average weekly earnings or consumer price indexes
(CPI), where appropriate.  These costs are the only
estimates available in the literature.  Although Cohen
et al. state that 26 percent of the total cost of this out-
break is for lost income or productivity, 68 percent is
for medical costs, and 5 percent is for miscellaneous
costs, they do not separate medical costs from lost pro-
ductivity for each disease severity category.19
Therefore, table 7 presents the costs summary for
annual cases of salmonellosis, broken down by disease
severity category but not by type of cost.  
• No physician visit.  For this category, Cohen et al.
(1978) estimated that the costs per case were $125
in 1976 dollars.20 Per case costs increased from
$125 to $371 after adding 39 percent to account
for fringe benefits (U.S. Dept. Comm., Bureau of
the Census 1993, table 677) and updating to 1993
dollars.  Costs were updated to 1993 dollars with
Bureau of Labor Statistics’ (BLS) average weekly
earnings for all production or nonsupervisory
workers in private nonagricultural industries in
1993 (GPO: Economic Indicators, July 1994).
Estimated costs for the 746,880-3,734,400 cases
each year who did not seek physician care for sal-
monellosis totaled $276.8 million to $1,384.1
million.
• Physician visit only.  Cohen et al. (1978) estimat-
ed that salmonellosis patients who saw a physician
but were not hospitalized incurred an average cost
of $222 per case (1976 dollars) and stated that
these costs “could mainly be attributed to medical
care.”21 We updated Cohen et al.’s (1978) esti-
mate of $222 per case to $794 using BLS’s CPI
for the physician services component (U.S. Dept.
Comm., Bureau of the Census 1993, tables 151
and 163).  This amount is all inclusive (e.g., costs
of doctors’ fees, laboratory charges, and medica-
tion).22 For the 40,320-201,600 cases in the cate-
gory, we estimated total costs to run $32-$160
million annually.
• Hospitalized.  Cohen et al. (1978) also estimated that
salmonellosis patients who were hospitalized (and
survived) incurred an average cost of $1,750 per case
(1976 dollars) and stated that these costs “could
mainly be attributed to medical care or hospitaliza-
tion.”  We updated the $1,750 cost per case to 1993
dollars ($9,087) using BLS’s CPI for hospital rooms
(U.S. Dept. Comm., Bureau of the Census 1993,
table 163).  This estimate includes the costs of emer-
gency plus regular room charges, hospital doctors’
fees, medication, and operations.  Estimated medical
costs for the 12,000-60,000 hospitalized cases who
survived total $109.0-$545.2 million annually.  
• Deaths.  Roberts (1988 and 1989) extended Cohen
et al.’s estimates to include the value of lives lost
annually to salmonellosis.  This report updates
Robert (1988 and 1989) COI estimates for salmo-
nellosis to 1993 dollars.
18Note that this percentage is strikingly similar to that found in two
studies of salmonellosis surveillance cases in 1979-80 and 1984-85
where 2,200 of the 40,000 cases involved a visit to a doctor (or 5.5
percent) (Cohen and Tauxe 1986).
19Over all disease severity levels, Cohen et al. (1978) estimated
that those employed lost, on average, 12 days from work.
Moreover, family members missed an average of 3 days from work
to care for the sick relative (Cohen et al. 1978).
20Although Cohen et al. (1978) stated that these “costs were pri-
marily accountable to loss of salary or output,” they did not specify
what proportion is for lost productivity and what proportion is for
medical costs. Therefore, costs were not broken down between
these two cost sub-categories.
21Note that whereas physician expenses and laboratory tests
were the key costs cited by Cohen et al. (1978), productivity loss is
also included in their estimate.
22Adults over 50 years of age and infants incurred higher than
average costs due to more frequent or longer hospitalization (stay-
ing a median of 10 days versus 6 days for other age groups)
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We assumed that each of the 800-4,000 salmonel-
losis cases who die prematurely because of their ill-
ness incurred the same amount of medical costs as
a salmonellosis patient who was hospitalized and
survived ($9,087).  We estimated medical costs for
those who die from salmonellosis to range between
$7.3 million and $36.3 million annually.23
Assuming the reported age distribution is represen-
tative of all estimated salmonellosis deaths, it can
be used with Landefeld and Seskin’s (1982) value
of a statistical life (VOSL) numbers to estimate the
benefits of reducing premature death from salmo-
nellosis.  Updated to 1993 values using the
Consumer Price Index for all goods (U.S. Dept.
Comm, Bur. Lab. Stats. 1994), the average value for
the stream of productivity lost for each premature
salmonellosis death is $376,268.24 Multiplied by
the 800-4,000 estimated salmonellosis deaths, the
productivity loss estimates range from $301.0-
$1,505.1 million annually.  Combining this estimat-
ed productivity loss with the estimated $7.3-$36.3
million in medical costs sums to an annual total of
$308.3-$1,541.4 million for those who die from
salmonellosis.
• Total.  In summary, the annual human illness costs
of salmonellosis are substantial.  Our estimate of
the total costs of non-typhoid salmonellosis from
Table 7—Cost summary for U.S. salmonellosis cases, 19931
Cost per case  Estimated cases and total costs
Severity  Cohen This Low High
of illness et al. analysis Cases Costs Cases Costs
1976$ 1993$ Number Mil. Dollars Number Mil. Dollars
No physician visit2 125 371 746,880 276.8 3,734,400 1,384.1
Physician visit3 222 794 40,320 32.0 201,600 160.0
Hospitalized4 1,750 9,087 12,000 109.0 60,000 545.2
Deaths5 N/A 385,355 800 308.3 4,000 1,541.4
Total6 N/A N/A      800,000 726.1 4,000,000 3,630.8
If 87-96% are foodborne, foodborne costs are $0.6-3.5 billion annually.7
1Some numbers have been rounded for this table.
2Cases in this category were calculated as a residual. We use Cohen et al.’s estimate that the costs per case are $125 (1976 dollars), after we
increase this value by 39% to account for fringe benefits and update to 1993 dollars using average weekly earnings for non-agricultural workers
from the U.S. Dept. of Comm., Bureau of Labor Statistics (BLS).
3Assuming 5.04% of all cases visit a physician (Ryan, personal communication, 1987). Cost per case is from Cohen et al.’s (1978) estimate of
$222 (1976 dollars), updated to 1993 dollars using BLS’s CPI for physician services (U.S. Dept. of Comm., Bur. of the Census).
4This category is for those who were hospitalized and survived. Assuming 1.5% of all cases are hospitalized (Ryan et al. 1987). Cost per case
is from Cohen et al.’s (1978) estimate of $1,750 (1976 dollars), updated to 1993 dollars using BLS’s CPI for hospital rooms (U.S. Bur. of the
Census).
5Deaths are calculated using a case fatality rate of 1/1,000. Those who die are assumed to be hospitalized prior to their deaths and incur the
same costs as those who are hospitalized and survive. Therefore, the total number of salmonellosis patients hospitalized each year is 12,800
for the low estimate and 64,000 for the high estimate. Costs for those who die are the sum of the cost per hospitalized case ($9,087) and
Landefeld and Seskin’s (1982) average value of a statistical life for the age distribution ($376,268 after averaging across gender and updating to
1993 values using the average weekly earnings.)
6The low estimate of 800,000 cases was calculated by multiplying CDC’s estimate of 40,000 Salmonella isolates (Tauxe 1991) by Chalker and
Blaser’s (1988) low estimate of the number (20) of unreported cases to each reported case. The high estimate of 4 million cases was calculat-
ed by multiplying CDC’s estimate of 40,000 Salmonella isolates (Tauxe 1991) by Chalker and Blaser’s (1988) high estimate of the number (100)
of unreported cases to each reported case.
7The 87% foodborne estimate is from Tauxe and Blake (1992) and the 96% foodborne estimate is from Bennett et al. (1987).
24Therefore, the total cost of a death is $385,355 (table 7), the
sum of medical costs ($9,087) from Cohen et al. (1987) and pro-
ductivity losses ($376,268) from Landefeld and Seskin.
23Total medical costs for all hospitalized cases (those who survive
plus those who die) are estimated at $116.3 million to $581.6 mil-
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all sources ranges from $726.1 million to $3,630.8
million annually.  The difference between the low
and the high costs estimates is completely due to
the difference in the two estimates of the incidence
of salmonellosis.
Costs of Foodborne Salmonellosis
Adjusting for foodborne causes (87-96 percent), an
estimated 696,000 to 3,840,000 salmonellosis cases
stem from food sources each year (see page 70 of
text).  Of these cases, 649,786 to 3,585,024 do not
visit a physician for their illness and 35,078 to
193,536 visit a physician.  When adjusted for food-
borne causes, the range of all hospitalized cases
becomes 11,136 to 61,440 which includes a range of
696 to 3,840 deaths annually.25
The total costs of non-typhoid foodborne salmonel-
losis were estimated in the same manner as above.
Total costs range from $0.6 billion to $3.5 billion
annually.  
Remarks
Salmonellosis currently ranks as the most costly bac-
terial foodborne disease estimated to date, partly due
to the large number of cases and partly due to its viru-
lence among specific population subgroups:  the
elderly, infants, and, increasingly, the immunocompro-
mised.
The per person costs for the three non-death severity
categories rely exclusively on Cohen et al. (1978).  Of
particular concern is the cost estimate for those who
did not seek medical care, because it is based on such
a small sample.  These cases are a large contributor to
total costs because the vast majority of salmonellosis
cases are of mild severity.  Because Cohen et al.
(1978) did not explicitly state the medical costs and
productivity loss by severity level, estimates could be
improved with this information.  To the extent the
outbreak investigated in Cohen et al. (1978) may dif-
fer from a “typical” salmonellosis outbreak, several
sources of bias are possible; the disease severity may
be higher or lower than average depending on the
Salmonella serotype, the number of Salmonella
ingested, and the age and sex composition of the
group of people affected.  
These COI estimates do not include the costs of
chronic medical conditions, which may be significant.
The likelihood of such occurrences and associated
costs are unknown.  Archer (1984, 1985) estimated
that 2 percent of salmonellosis patients will end up
with reactive arthritis, an inflammation of the joints
that lasts from a few days to 6 months.  A fraction of
these cases develop rheumatoid arthritis, a life-long
inflammation of the joints.26 With better data on inci-
dence and associated costs of chronic illnesses caused
by salmonellosis, total costs of these chronic illnesses
could be computed and added to estimated costs asso-
ciated with acute salmonellosis.
Other costs to individuals are ignored.  For example, a
Canadian economist, Leo Curtin (1984) estimated that
the loss of leisure time was greater than the loss of
work time due to salmonellosis.  Estimates using his
methodology of valuing leisure time at the prevailing
wage rate would more than double the cost of salmo-
nellosis estimates presented here.
Since reporting of Salmonella began in 1943, the
reported incidence in the United States has increased
considerably (Tauxe 1991, p. 563).  For the past 30
years, this increase has been progressive and signifi-
cantly greater than the population increase (Chalker
and Blaser 1988, p. 113).  During the 1970’s, roughly
30-40 outbreaks and 20,000-25,000 isolates of salmo-
nellosis were reported to CDC versus 60-80 outbreaks
and 40,000-45,000 isolates in the late 1980’s
(Helmick et al. 1994, p. 104).27 Massive outbreaks of
salmonellosis such as the Chicago milk outbreak have
increased the annual average number of infections
reported to CDC.
The proportion of Salmonella infections due to S.
enteritidis has increased to the extent that this
serotype is now the most common cause of salmonel-
losis in some regions of the country (Tauxe 1991, p.
566).  As previously mentioned, S. enteritidis infec-
tions have been increasingly attributed to consump-
tion of lightly cooked or raw shell eggs.
25Some of these deaths are AIDS patients.
26As an aside, one survey found that rheumatoid arthritis sufferers
were willing to pay 22 percent of their household income to be rid
of arthritis (Thompson 1986, p. 394).
27In contrast, Shigella infections have remained constant over the
past 30 years, even though they are reported by identical mecha-
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Some evidence (e.g., 1985 outbreak traced to milk)
exists to support the theory that widespread use of
antimicrobials (i.e., tetracycline) for both human ill-
nesses and animal husbandry has led to an increase in
resistance and infection with specific strains of
Salmonella (MacDonald et al. 1987).  Tauxe et al.
(1991, p. 566) state that “treatment with antimicrobial
agents can actually promote Salmonella infections in
both humans and animals, particularly if the infecting
strain is resistant to the agents being used.”
AIDS patients are among the sub-groups most at risk
of salmonellosis.  Jackson et al. (1991, p. 32) discuss
AIDS patients with salmonellosis and cite Celum et
al. (1987) as saying that AIDS patients are 19.2 times
more likely to contract salmonellosis than people who
do not have AIDS.  Recurrent bacteremia caused by
Salmonella was included as an indicator of AIDS in
1987 (Tauxe 1991, p. 566).
Ryan et al. (1987, p. 3274) caution that the trend in
food production toward a relatively small number of
large producers make catastrophic consequences from
Salmonella contamination possible.  A case in point is
the 1994 Schwan Salmonella outbreak, associated
with consumption of ice cream, which led to around
100,000 cases in 25 States, including 102 hospitaliza-
tions (Food Chemical News Feb. 13, 1995, p. 53).
The Food and Drug Administration (FDA) has impli-
cated milk tanker trucks that previously carried raw
egg products as the source of this outbreak.
In addition, large and dispersed outbreaks have been
shown to cross State and national boundaries.  For
example, in 1984, a large international airline served
Salmonella-contaminated food on 29 flights from
London to the United States over a 3-day period,
affecting an estimated 2,737 passengers (Tauxe et al.
1987, p. 150).28 Incidents such as this have the poten-
tial to spread infections among people of many coun-
tries, especially where the infection can be spread per-
son-to-person.  A S. Chester outbreak in 1990 in the
United States was linked to cantaloupe from Central
America and Mexico (Ries et al. 1990).  These con-
cerns suggest a need for a global strategy for handling
food safety issues such as Salmonella infections in
humans.  
COI Estimates of Campylobacteriosis
There are nine named or proposed Campylobacter
species that are pathogenic or are believed to be
potentially pathogenic to humans (Tauxe et al. 1988,
p. 1).29 Of these, Campylobacter jejuni and C. coli
(two closely related species) organisms are the species
most frequently associated with campylobacteriosis in
humans.30 In the United States, most C. jejuni infec-
tions are associated with consumption of poultry and
most C. coli infections are associated with consump-
tion of pork.  Worldwide, Campylobacter is estimated
to cause 5 to 14 percent of all human diarrheal illness-
es (Benenson 1990, p. 69).  
Campylobacteriosis symptoms can range from diar-
rhea and lethargy that lasts a day to severe diarrhea
and abdominal pain (and occasionally fever) that lasts
for several weeks (Park et al. 1991, p. 995).  Diarrhea
and abdominal pain are the most common symptoms
and the vast majority of cases are mild.  Skirrow and
Blaser (1992, p. 3) report that abdominal pain from
campylobacteriosis can be so strong that it has been
misdiagnosed as originating from appendicitis and has
led to unnecessary appendectomy.  The incubation
period is 1 to 10 days, with most cases occurring 3 to
5 days after exposure (Benenson 1990, p. 70).
Although most cases of campylobacteriosis are self-
limiting, up to 20 percent have a prolonged illness
(longer than 1 week) or a relapse (Blaser et al. 1979),
and 2 to 10 percent may be followed by chronic
sequelae (CAST 1994, p. 11).  Complications that
may follow Campylobacter infections include menin-
gitis, cholecystitis (inflammation of the gall bladder),
urinary tract infection, appendicitis, septicemia, and
Reiter syndrome (urethritis, arthritis, and conjunctivi-
tis) (Mossel 1988) (table 3).  Mishu and Blaser (1993)
estimate that 20-40 percent of all Guillain-Barré
Syndrome (GBS) cases are caused by Campylobacter
infections.  GBS is the major cause of non-trauma-
related paralysis in the United States.  Although paral-
ysis from GBS is generally reversible over time, some
patients die prematurely because of the illness while
others are bedridden for life.
29In 1913, Campylobacter was discovered as a pathogen and was
called Vibrio fetus because it was associated with abortion and
infertility in cattle and sheep (Stern and Kazmi 1989, p. 72). The
link with human illness occurred in the 1950’s when Campylobacter
was isolated from human blood (Tauxe et al. 1988, p. 1).
30For the remainder of this report, C. jejuni will be used to refer to
both C. jejuni and C. coli.
28Passengers to the United States were not the only ones affect-
ed. The airline potentially exposed 23,576 passengers of 125 over-
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Poultry is the predominant source of sporadic cases of
Campylobacter (Tauxe 1992, p. 12).  In the United
States, an epidemiological study by Harris et al.
(1986a, p. 410) found that in approximately half of all
Campylobacter jejuni/coli enteritis cases, ingestion of
contaminated chicken was the primary source of
infection.  The intestine of birds and warm-blooded
animals is a natural habitat for Campylobacter (Park
et al. 1991, p. 101S) and studies have concluded that
chicken slaughter and processing leads to heavy sur-
face contamination (Park et al. 1991; Skirrow and
Blaser 1992, p. 6; Sjögren and Kaiser 1988, p. 3).  Up
to 80 percent of poultry at retail are contaminated
with Campylobacter (Skirrow and Blaser 1992, p. 4)
and contamination appears to peak during the summer
(July through October)(Tauxe et al. 1988; Harris et al.
1986b, p. 404).31 This seasonal pattern of contamina-
tion in raw poultry is reflected in the reported number
of Campylobacter isolates, by month and year, in the
United States between 1982 and 1989 (fig. 4).  To a
lesser extent, turkey, raw milk, cake icing, raw clams,
raw hamburger, water, and contact with pets have
been epidemiologically linked with human diseases in
the United States (Blaser et al. 1983a, p. 163; Stern
1992, p. 50; Tauxe et al. 1988; CAST 1994, p. 11).  
Campylobacteriosis outbreaks are relatively uncom-
mon, perhaps because Campylobacter jejuni does not
multiply in food; most outbreaks can be traced to
drinking untreated stream or river water or to drinking
raw milk (Helmick et al. 1994, p. 110).32
Campylobacter in unchlorinated water is a major
cause of travelers’ diarrhea (Benenson 1990, p. 69).  
31Note that reported isolates, which are primarily from sporadic
cases, peak in the summer (July-Aug.) whereas the distribution of
outbreaks is bimodal with peaks in May and October (Tauxe 1992,
p. 13). This difference may be largely due to the difference in
reservoirs, that is poultry for sporadic cases and raw milk and
contaminated water for outbreak cases (Tauxe 1992, p. 12).
32Bean and Griffin (1990, p. 806) provide estimates of the number
of foodborne disease outbreaks, by pathogen. Between 1973
and 1987, there were 53 Campylobacter, 190 Clostridium perfrin-
gens, 367 Staphylococcus aureus, and 790 Salmonella out-
breaks. They did not mention Listeria outbreaks and estimated E.
coli O157:H7 outbreaks are not relevant for this time period,
because E. coli O157:H7 was not identified as a cause of human
illness until 1982.
0
Source:  Tauxe, R. V., “Epidemiology of Infection in the United States and Other
Industrialized Nations.”  Chapter 2 in Nachamkin, Irving, Martin J. Blaser, and Lucy S. Tompkins, eds.
Washington, DC:  American Association of
Microbiology, 1992, p. 10.
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There is little evidence to suggest that significant per-
son-to-person transmission of Campylobacter takes
place (Tauxe 1992, p. 11).  However, there have been
a few documented cases of pregnant women with bac-
teremia that have been associated with severe fetal
infections (Blaser et al. 1983a, p. 165).
There is uncertainty as to the percentage of
Campylobacter cases that are foodborne.  In a Seattle-
King County Department of Public Health surveil-
lance study (1984, p. 153), roughly 55 percent of all
Campylobacter cases were attributed to food origins:
drinking raw milk (5.2 percent) and eating poultry
(48.2 percent).33 Deming et al. (1987) summarized in
Tauxe [1992, p. 15] found that 70 percent of campy-
lobacteriosis cases in students at a Georgia college
were attributed to eating chicken (the remaining 30
percent were attributed to contact with cats).  We 
assumed that 55-70 percent of all U.S. campylobacte-
riosis cases are foodborne.
The human infective dose is relatively small.
Robinson (1981) describes his personal experience
where 500 Campylobacter cells caused disease.  Yet,
there is great variation in individual susceptibility and
illness severity.  Benenson claims that in developing
countries, most individuals develop immunity to
Campylobacter in their first year of life (1990, p. 70).
This may also be true in developed countries.  In
developed countries such as the United States, infants
have the highest reported incidence of campylobacte-
riosis, with young adults in the second highest risk
category (Tauxe et al. 1988, p. 11).  In developing
countries, children under 2 years of age are the most
likely to have Campylobacter infections (Blaser et al.
1983a) and illnesses (Benenson 1990, p. 69).  Up to
age 45, males have higher isolation rates for
Campylobacter than do females, but this difference
has not been adequately explained (Tauxe 1992, p.
10).  Figure 5 shows the reported Campylobacter iso-
lates by age and sex between 1982 and 1986. 
33Of the remaining Campylobacter jejuni infections, 6.3 percent
were from pets, 9 percent from foreign travel (which could also be
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Estimates of Cases
The discovery of the extent of infections with
Campylobacter was made possible in the late 1970’s
by the development of an isolation technique that
requires incubator conditions and a specific medium
(Tauxe 1992, p. 9; Helmick et al. 1994, p. 109).
Helmick et al. (1994, p. 109) report that in laboratories
that test for foodborne pathogens including
Campylobacter, Campylobacter is the most commonly
isolated bacterial pathogen from persons with diarrhea
in the United States, and C. jejuni is the most com-
monly isolated Campylobacter species.34 In 5-year
CDC surveillance, 91 percent of the isolates reported
the species and 99 percent of these specified C. jejuni
as the reported species (Tauxe et al. 1988, p. 9). 
Although there has been a national surveillance for
campylobacteriosis since 1982, participation is volun-
tary, and there is tremendous variation in internal
reporting requirements between States (Tauxe 1992, p.
9).  Unlike Salmonella, isolates of Campylobacter are
not routinely referred for confirmation or serotyping
except when an unusual isolate is found or in outbreak
situations (Tauxe 1992, p. 9).  But even during out-
breaks, not all physicians routinely order diagnostic
laboratory testing for patients sick with diarrheal ill-
nesses.  With better surveillance, Campylobacter
infections would likely outnumber Salmonella infec-
tions (Tauxe 1992, p. 9).35
The limitations of Campylobacter surveillance are
especially critical because the vast majority of cases
are sporadic and not the result of outbreaks (Tauxe
1992, p. 11).  Individuals sick with campylobacteriosis
may be more likely to seek medical care (and have
diagnostic testing) during outbreaks than when cases
are sporadic, especially when there is widespread pub-
licity and the possibility of legal action.
In 1980, a Collaborative Diarrheal Disease Study
Group (conducted by CDC) studied the relative fre-
quency with which Campylobacter, Shigella, and
Salmonella were isolated from stool cultures at eight
hospitals over a 15-month period (Blaser et al.
1983b).  They found that, for all age groups,
Campylobacter species were isolated 4.6 times more
frequently than Shigella species and twice as often as
Salmonella species (Blaser et al. 1983b, p. 360).36
This supports the hypothesis that if both
Campylobacter and Salmonella infections had equal
surveillance efforts, Campylobacter isolates would be
more common (Tauxe 1992, p. 12).  If Campylobacter
were analyzed in the same fashion as Shigella or
Salmonella, then the estimated isolation rate would be
36-40 per 100,000 (Tauxe 1992, p. 12).37
Rosenberg et al. (1977, p. 459) used national surveil-
lance data to estimate that as few as 33 percent of
physician visits for patients sick with shigellosis
resulted in a stool culture.  This low proportion that
has diagnostic testing further documents the extent of
potential underreporting of foodborne illnesses.
Following Tauxe (1992, p. 12), we conservatively
assumed that 67 percent of patients who visit physi-
cians with complaints of diarrheal illnesses have stool
cultures ordered.  This raises the estimated isolation
rate for Campylobacter from 36-40 per 100,000 to 54-
60 per 100,000 (Tauxe 1992, p. 12).  
Sacks et al. (1986) report results from an investigation
of a campylobacteriosis outbreak associated with a
contaminated community water supply in Florida.
They found that of 865 cases, roughly 5.4 percent (or
47) visited a physician for acute gastroenteritis (p.
425).  Tauxe (1992, p. 12) uses this percentage com-
bined with his estimated isolation rate for
Campylobacter (54-60 per 100,000) to estimate the
rate of C. jejuni infection of roughly 1 percent of the
U.S. population annually (not including asymptomatic
cases).  Given a 1993 residential U.S. population of
257,908,000 (U.S. Dept. Comm., Bureau of the
Census 1993), there were over 2.5 million estimated
cases of campylobacteriosis in 1993.  Helmick et al.
(1994, p. 109) state that the true number of annual
cases of Campylobacter infections each year in the
34C. jejuni is the main reported isolate in stool cultures but this
may be because the stool culture media is more appropriate for C.
jejuni than for other Campylobacter species (Tauxe et al. 1988). In
general, isolation methods and methods used to identify species
other than C. jejuni are expensive and cumbersome, which means
less is known about the extent and severity of human illness
caused by these species.
35Underreporting occurs for a host of other reasons previously
described (e.g., many ill people do not seek medical care). Another
reporting problem for Campylobacter is that it has only recently
been assigned a code in the International Classification of Disease
(ICD) system, which means that many otherwise useful medical
databases (e.g., the National Hospital Discharge Survey) cannot
provide information on incidence.
36Note that Tauxe (1992, p. 12) says that Campylobacter was iso-
lated 4.5 times more often than Shigella.
37The reported isolation rate of Shigella species is 8/100,000 and
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United States is likely 2 million to 10 million cases.
We (conservatively) assume 2.5 million cases of
campylobacteriosis each year in the United States in
our update of Lin et al.’s (1993) COI estimate for
campylobacteriosis (table 2).
Table 8 presents the estimated U.S. campylobacterio-
sis cases, broken down by the four disease severity
categories used throughout this report.  Figure 6 pre-
sents the distribution of estimated annual cases of
campylobacteriosis and disease outcomes.
While the distribution of disease severity is similar to
that of salmonellosis, campylobacteriosis is generally
less deadly than salmonellosis, leading to an estimated
200 to 730 deaths annually versus an estimated 800 to
4,000 deaths for salmonellosis.  Tauxe (1992) reports
that Smith and Blaser (1985) used surveillance data to
estimate a death rate of 24 per 10,000 culture-con-
firmed cases of Campylobacter infections.  Tauxe
(1992, p. 14) applied this death rate to the estimated
annual number of culture-confirmed Campylobacter
infections to calculate an estimated 200 deaths from
campylobacteriosis each year.  Tauxe also used data
from a series of Campylobacter outbreaks to estimate
an upper bound on the number of premature deaths due
Table 8—Estimated U.S. campylobacteriosis
cases, 1993
Severity Estimated cases
of illness Low High
Number
No physician visit1 2,352,300 2,351,770




1 Cases in this category were calculated as a residual.
2 Assuming 5.4% of all cases visit a physician (Sacks et al. 1986).
3 This category is for those who were hospitalized and survived.
Assuming 0.5% of all cases are hospitalized (Sacks et al. 1986).
4 The low estimate of 200 deaths was calculated in Tauxe (1992)
using Smith and Blaser’s (1985) case fatality rate of 24/10,000 cul-
ture-confirmed cases. The high estimate of 730 deaths was calcu-
lated in Tauxe (1992) using his case fatality rate of 3/10,000 out-
break-associated illnesses. Those who die are assumed to be hos-
pitalized prior to their deaths. Therefore, the total number of salmo-
nellosis patients that are hospitalized each year is 12,700 in the low
estimate and 13,230 in the high estimate.
5 The total number of campylobacteriosis cases is 1% (Tauxe
1992) of the U.S. 1993 population (U.S. Bur. of the Census) round-
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to Campylobacter in the United States of 730 per year
(ibid.).  The current study considers a range of 200 to
730 deaths from Campylobacter infections annually.
Sacks et al. (1986, p. 425) in their study on the
Campylobacter-contaminated community water sup-
ply found that 0.5 percent of cases were hospitalized
(4 out of 865 cases).  Applying this rate to the annual
number of 2.5 million Campylobacter infections, we
obtain an estimated 12,500 hospitalizations each year
for campylobacteriosis.  Assuming that the 200-730
who die from the illness are first hospitalized, an esti-
mated 12,700 to 13,230 cases of campylobacteriosis
cases are hospitalized each year.
We used Sacks et al.’s (1986, p. 425) finding that
roughly 5.4 percent visited a physician for campy-
lobacteriosis during the contaminated-water outbreak
to estimate the annual number of people in the United
States who visit a physician for Campylobacter infec-
tions.  When this rate is applied to the 2.5 million esti-
mated annual infections, this yields an estimate of
135,000 physician visits for Campylobacter infections
each year.  
The estimated number of campylobacteriosis cases
where no medical care was sought was computed as a
residual (total cases minus all hospitalizations,
including deaths, and physician visits).  The number
of cases in this category are estimated to range
between 2,352,300 and 2,351,770 cases annually.
Costs of Campylobacteriosis from All
Sources
Nolan and Harris (1984, p. 166) comment that the ill-
ness severity of campylobacteriosis mirrors that of
salmonellosis.  In our analyses of these two illnesses,
the breakdown of the severity categories is compara-
ble; the percentage that visit a physician is around 5
percent, the percentage that are hospitalized is around
1 percent, and the percentage that die is < 0.1 percent.
Given the similarity in the four severity groups for
campylobacteriosis and salmonellosis and given that
there is no parallel cost study like Cohen et al. (1978)
for campylobacteriosis, we assumed that per-patient
costs of illness for each of the four severity groups are
identical to the costs of salmonellosis.  We used
Cohen et al. (1978) estimates for all four categories of
campylobacteriosis and LS VOSL estimates for the
productivity loss from those who die prematurely.  As
previously mentioned, Cohen et al. (1978) did not
separate medical costs from productivity losses.
Therefore, one cannot divide per-patient or total costs
into medical costs and costs of lost productivity.
Table 9 presents the cost summary for annual cases of
campylobacteriosis, broken down by disease severity
category.
• No physician visited.  As with salmonellosis, esti-
mated per-patient costs for campylobacteriosis
patients who did not visit a physician are roughly
$371.38 For the estimated 2,351,770 to 2,352,300
campylobacteriosis cases in this category, estimated
annual costs total $871.7-$871.9 million.  
• Physician visit only.  As with salmonellosis, esti-
mated per-patient costs for campylobacteriosis
patients who visited a physician for their illness are
$794.39 This includes office visits, laboratory
charges, and some productivity loss.  For the esti-
mated 135,000 cases in the category, estimated
costs total $107.2 million annually.
• Hospitalized.  As with salmonellosis, estimated
per-patient costs for campylobacteriosis patients
who were hospitalized for their illness are $9,087.40
This includes the costs of emergency plus regular
room charges, hospital doctors’ fees, medication,
and operations.  For the estimated 12,500 cases
who were hospitalized and survived, estimated
costs total $113.6 million annually.  
• Deaths.  As for the estimated 200 to 730 annual
deaths from campylobacteriosis, per patient costs
are the sum of Cohen et al.’s (1978) per patient
costs of $9,087 (updated to 1993 as above) plus
38Per-case costs increase from $125 (Cohen et al. 1978) to
roughly $370.65 after adding 39 percent to account for fringe bene-
fits (U.S. Dept. of Comm., Bureau of the Census 1995, table 677)
and updating to 1993 dollars. Because Cohen et al. (1978) state
that “these costs were primarily accountable to loss of salary or
output,” we updated costs to 1993 dollars with BLS’s average week-
ly earnings for all production or nonsupervisory workers in private
nonagricultural industries in 1993 (Economic Indicators, July 1994).
39Because Cohen et al. (1978) state that the costs per case for
this category are “mainly . . . attributed to medical care,” we update
their estimate of $222 per case to $794 using BLS’s CPI for the
physician services component (U.S. Dept. of Comm., Bureau of the
Census 1993, tables 151 and 163).
40Because Cohen et al. (1978) explain that their estimate of
$1,750 per case for this category is mainly comprised of medical
costs, we updated this amount to $9,087 using BLS’s CPI for the
hospital room component (U.S. Dept. of Comm., Bureau of the
Census 1993, table 163).Economic Research Service/USDA                      Bacterial Foodborne Disease:  Medical Costs and Productivity Losses / AER-741     27
Table 9—Cost summary for U.S. campylobacteriosis cases, 1993
Cost per case Estimated cases and total costs
Severity Cohen This Low High
of illness et al. analysis Cases Costs Cases Cost
1976$ 1993$  Number Mil. Dollars Number Mil. Dollars
No physician visit1 125 371 2,352,300 871.9 2,351,770 871.7
Physician visit2 222 794 135,000 107.2 135,000 107.2
Hospitalized3 1,750 9,087 12,500 113.6 12,500 113.6
Deaths4 N/A 385,355 200 77.1 730 281.3
Total5 N/A N/A 2,500,000 1,169.8 2,500,000 1,373.8
If 55-70% are foodborne, foodborne costs are $0.6-1.0 billion annually.6
N/A = Not applicable.
Note: Some numbers have been rounded for this table.
1 Cases in this category were calculated as a residual. We use Cohen et al.’s (1978) estimate that the costs per case are $125 (1976 dollars),
after we increase this value by 39% to account for fringe benefits and update to 1993 dollars using average weekly earnings for nonagricultural
workers from the U.S. Bureau of Labor Statistics (BLS).
2 Assuming 5.4% of all cases visit a physician (Sacks et al. 1986). Cost per case is from Cohen et al.’s (1978) estimate of $222 (1976 dollars),
updated to 1993 dollars using BLS’s CPI for physician services (U.S. Dept. of Comm., Bur. of the Census).
3 This category is for those who were hospitalized and survived. Assuming 0.5% of all cases are hospitalized (Sacks et al. 1986). Cost per
case is from Cohen et al.’s (1978) estimate of $1,750 (1976 dollars), updated to 1993 dollars using BLS’s CPI for hospital rooms (U.S. Dept. of
Comm., Bur. of the Census).
4 The low estimate of 200 deaths was calculated in Tauxe (1992) using Smith and Blaser’s (1985) case fatality rate of 24/10,000 culture-con-
firmed cases. The high estimate of 730 deaths was calculated in Tauxe (1992) using his case fatality rate of 3/10,000 outbreak-associated ill-
nesses. Those who die are assumed to be hospitalized prior to their deaths. Therefore, the total number of salmonellosis patients that are hos-
pitalized each year is 12,700 for the low estimate and 13,230 for the high estimate. Costs for those who die are the sum of the cost per hospi-
talized case ($9,087) and Landefeld and Seskin’s (1982) average value of a statistical life for the age distribution ($376,268 after averaging
across gender and updating to 1993 values using the average weekly earnings.)
5 The total number of campylobacteriosis cases is 1% (Tauxe 1992) of the U.S. 1993 population (U.S. Dept. of Comm., Bur. of the Census)
rounded down to 2.5 million cases.
6 The 55% foodborne estimate is from the Seattle-King County study (1984) and the 70% foodborne estimate is from Deming et al. (1987).
LS’s VOSL.  We assumed that the age distribution
of deaths due to campylobacteriosis mirrors that of
salmonellosis.  Applying the age distribution of
deaths to Landefeld and Seskin’s VOSL estimates
by age, we obtained an average VOSL of
$376,268.  When LS VOSL costs are combined
with per patient costs ($9,087) from Cohen et al.
(1978), the per patient costs for those who died are
$385,355 (table 9).  For the 200-730 campylobac-
teriosis deaths annually, lost productivity adds up
to $77.1-$281.3 million. 
• Total.  For all patients with campylobacteriosis,
costs are estimated at $1,169.8-$1,373.8 million
annually.  The difference between the low- and the
high-cost estimates is completely due to the range
of 200-730 deaths.
Very few studies have estimated the costs of campy-
lobacteriosis (Sockett and Stanwell-Smith 1986;
Roberts 1989; Todd 1989[b]), partly because only
recently has Campylobacter been attributed to causing
substantial foodborne illnesses.  None of these studies
are detailed cost analyses for campylobacteriosis in
the United States.  While it is not an unreasonable
assumption to apply the costs per salmonellosis case
to those of campylobacteriosis, better estimates are
needed.  
Sockett and Stanwell-Smith (1986) provide the most
detailed cost study of campylobacteriosis to date.
They estimated costs incurred by health-care services
per case of campylobacteriosis in the United
Kingdom (UK) (1985, in £).  Because the structure of
health care in the UK differs considerably from that
in the United States, these costs are not directly 28 Bacterial Foodborne Disease:  Medical Costs and Productivity Losses / AER-741                      Economic Research Service/USDA
applicable to our analysis.41 However, if we assumed
that costs are similar in the United States and UK, the
average cost estimates from the current analysis are
roughly $468-$550 per case whereas the Sockett and
Stanwell-Smith (1986) estimates would suggest a
range of $339-$370 per case (in 1993 U.S. dollars).42
Their estimates were lower because they assume a
lower death rate.
Costs of Foodborne Campylobacteriosis
We assumed that 55-70 percent of all estimated
human illness cases of Campylobacter in the United
States are foodborne (1,375,000 to 1,750,000
cases)(see page 70 of text).  Estimates of those who
do not visit a physician range from 1,293,765 to
1,646,239 cases annually.  A low of 74,250 and a
high of 94,500 visit a physician.  The number of hos-
pitalized cases (including those who died) ranges
from 6,985 to 9,261.  Foodborne deaths caused by
Campylobacter range from 110 to 511 annually.
Given our assumption that 55-70 percent of all U.S.
campylobacteriosis cases are attributed to food, esti-
mated costs of foodborne campylobacteriosis range
from $0.6-$1.0 billion annually.  Due to the limita-
tions of the Cohen et al. (1978) data for salmonellosis
and the lack of current and detailed cost information
for campylobacteriosis, medical costs and the costs of
lost productivity cannot be separated.
Remarks
As previously mentioned, poultry is the most com-
mon cause of sporadic cases of campylobacteriosis in
the United States.  This is largely because poultry nat-
urally harbors Campylobacter in the crop and gut.
Mass mechanized processing can cause heavy cross-
contamination (Skirrow and Blaser 1992, p. 6).
Cleaning practices at the slaughterhouse and packing
plant may influence the Campylobacter contamination
41Regardless of differences in health care, it is interesting that a
British study by Kendall and Tanner (1982, p. 155) found that the
annual incidence of Campylobacter infections in a general practice
population in Great Britain was 1.1 percent as compared with
Tauxe’s (1992) incidence rate of 1 percent in the United States.
42The estimated $468-$550 average costs were calculated by
dividing the estimated total annual costs of $1,169.8-$1,373.8 mil-
lion by the estimated 2.5 million U.S. cases (table 9). The estimat-
ed $339-$370 average costs were calculated from the Sockett and
Stanwell-Smith (1986) estimates by using the exchange rate of £1
to U.S. $1.53 (Riggs Bank, Washington, DC, Nov. 15, 1994) and by
updating to 1993 dollars (using BLS CPI for all items).
rate; Harris et al. report a progressive increase in con-
tamination of poultry carcasses slaughtered from
Monday through Wednesday after a weekend cleanup
(1986, p. 403).  Park et al. (1991, p. 102S) recom-
mend that Campylobacter contamination of raw
chicken be reduced by improving processing proce-
dures at slaughter to minimize fecal contamination
and by reducing available water on the carcass.
Washing carcasses in a strong brine solution may be
helpful in reducing Campylobacter contamination
(Park et al. 1991, p. 102S).  Campylobacter tends to
be found more frequently on moist meat rather than
on dry meat because Campylobacter is sensitive to
drying (Park et al. 1991, p. 102S).  Perhaps, air-
chilled chicken would have fewer Campylobacter
than ice-bath-chilled chicken.
According to CDC, approximately 90 percent of C.
jejuni outbreaks would not occur with universal pas-
teurization of milk and improved drinking water treat-
ment (Tauxe 1992, p. 12).  Raw milk often harbors a
wide range of pathogens such as C. jejuni, Salmonella
serotypes, and Listeria.  For this reason it is illegal to
sell raw milk in most locations in the United States
(CAST 1994, p. 32).  
Additional gains in reducing the annual number of
cases of campylobacteriosis could be made through
improved food-handling practices at both the retail
and household levels.  Tauxe (1992, p. 16) states that
“ingestion of a small drop of raw chicken juice could
easily be the infective dose.”  That being the case,
leaky packages of chicken purchased at supermarkets
may be causing illnesses.  As previously mentioned,
Campylobacter needs moisture to survive; reducing
free water in poultry packages would seem to have
the double benefit of encouraging the die-off of exist-
ing Campylobacter and of reducing potential kitchen
contamination levels. 
At the household level, Campylobacter infections
could be reduced by greater education of consumers
on kitchen hygiene for handling and cooking poultry.
Hopkins and Scott (1983) reported that “handling raw
chicken appeared to be a strong risk factor” for get-
ting campylobacteriosis.  Deming et al. (1987, p. 532)
hypothesize that errors in food handling increase the
risk of illness from eating cooked chicken.  Tauxe et
al. (1992) state that the 1984 Seattle study found the
risk of campylobacteriosis “was inversely associated
with the frequency of using soap to clean the kitchen
cutting board.”Economic Research Service/USDA                      Bacterial Foodborne Disease:  Medical Costs and Productivity Losses / AER-741     29
Consumption patterns affect the risks of foodborne
illnesses.  Poultry consumption increased 35 percent
during the 10-year period between 1982 and 1992, as
consumers substituted chicken for other meats (Lin et
al. 1993, p. 38).  This increase is partly because of
concerns over dietary fat content, and partly because
chicken has become cheaper than other meats.  A
recent consumer survey showed that 95 percent of the
chicken bought for home consumption consisted of
fresh products, such as fresh chicken parts (Lin et al.
1993, p. 38).  The prevalence of Campylobacter jeju-
ni and Salmonella in raw poultry means that this new
consumption trend may lead to increasing numbers of
foodborne illness cases.
COI Estimates of Escherichia Coli
O157:H7 Disease
E. coli O157:H7 was first isolated by CDC in 1975
(FDA Consumer 1994, p. 9) but was not identified as
a cause of human illnesses until 1982 when two out-
breaks of gastrointestinal illness in Michigan and
Oregon were investigated and linked to consumption
of contaminated hamburgers (Riley et al. 1983)(fig.
7).  There has been worldwide detection of E. coli
O157:H7 and its associated illnesses.  Bovine isolates
or human cases of E. coli O157:H7 have been docu-
mented in over 16 countries and on 6 continents
(USDA:APHIS:VS 1994, p. 2).  Benenson (1990, p.
137) states that infections from enterohemorrhagic
strains of E. coli (mainly O157:H7) are recognized as
important health problems in Europe, southern South
America, and North America.  The following analysis
updates the 1992 COI estimates found in Roberts and
Marks (1995) to 1993 dollars.
E. coli O157:H7 and its link to an associated life-
threatening illness called hemolytic uremic syndrome
(HUS) became well known to the public as a result of
the 1993 E. coli O157:H7 disease outbreak caused by
contaminated hamburger in Washington, California,
Idaho, and Nevada.  The American Gastroenterological
Association’s (AGA) Consensus Conference Statement
on E. coli O157:H7 Infections (1995, p. 1923) indicat-
ed that this outbreak led to over 700 illness cases (pri-
marily children) and of these cases, 195 were hospital-
ized (28 percent), 4 died (0.57 percent), and 55 devel-
oped HUS (7.86 percent).  In recent years, an increas-
ing number of E. coli O157:H7 outbreaks and sporadic
cases have been documented (AGA 1995, p. 1923).
E. coli O157:H7 is a hardy organism.  Although bile
acids can help kill some microorganisms such as
Clostridium botulinum, Escherichia is resistant to
these acids (CAST 1994, p. 25).  E. coli O157:H7 can
also survive some acid environments in food such as
that found in apple cider (FDA Consumer 1994, p. 8).
E. coli O157:H7 can grow and multiply slowly at
temperatures as low as 44oF and can even survive
freezing (FDA Consumer 1994, p. 9).  E. coli
O157:H7 can also survive in water for extended peri-
ods (USDA:APHIS:VS 1994, p. 1).  However, E. coli
O157:H7 is easily killed by heat used in pasteuriza-
tion and cooking (USDA:APHIS:VS 1994, p. 1).  The
1993 outbreak of E. coli O157:H7 infections indicat-
ed that the infectious dose is less than 1,000 organ-
isms (AGA 1995, p. 1925).  The CAST report esti-
mates that the infectious illness dose is in the range of
10 to 1,000 colony-forming units (1994, p. 12).
E. coli O157:H7 is a toxicoinfective microorganism
because it causes human illnesses through the toxins
that it produces (CAST 1994, p. 19).  E. coli
O157:H7 toxins cause human illnesses by adhering to
receptors in the kidney, intestine, and central nervous
system where it prevents protein synthesis and kills
cells (CAST 1994, p. 19).  The bloody diarrhea and
abdominal cramping typically found in symptomatic
cases of E. coli O157:H7 disease are caused by the
toxins that E. coli O157:H7 produces and by the par-
tial destruction of the colon’s mucosal lining
(USDA:APHIS:VS 1994, p. 1).  In the United States,
E. coli O157:H7 is a major cause of bloody diarrhea
(AGA 1995, p. 1924). 
E. coli O157:H7 causes a wide range of illness severi-
ties in humans from mild cases of acute diarrhea to
premature death.  Acute illness from E. coli O157:H7
disease is manifested by abdominal cramps, vomiting,
diarrhea (often bloody), and sometimes fever.  Ostroff
et al. (1989, p. 355) found that 95 percent of the 93
reported sporadic cases of E. coli O157:H7 disease in
Washington State in 1987 had bloody diarrhea.
Griffin and Tauxe (1991, p. 64), in reviewing the lit-
erature, speculated that bloody diarrhea is the most
commonly reported symptom, because persons with
bloody diarrhea are more likely to seek medical care
and because physicians are more likely to culture
stools if patients report bloody stools.
The incubation period for E. coli O157:H7 in humans
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Benenson (1990, p. 137) states that the incubation
period may be as short as 12 hours but the median is
48 hours.  On average, the acute illness ends 6 to 8
days after onset (CDC April 16, 1993, p. 262).  
Although most E. coli O157:H7 infections are mild
and do not require medical care, E. coli O157:H7
infections can result in hemorrhagic colitis (bloody
inflammation of the colon).43 Symptoms of hemor-
rhagic colitis may include the sudden onset of severe
abdominal cramps, little or no fever, and watery diar-
rhea (Riley et al. 1983; Pai et al. 1984; Ostroff et al.
1989) that may become so grossly bloody that it has
been described as “all blood and no stool.”  Vomiting
occurs in roughly half of the affected individuals
(Griffin and Tauxe 1991, p. 64).  
Most cases of hemorrhagic colitis fully recover 6 to
8 days after onset (Griffin and Tauxe 1991, p. 64).
Patients with more severe symptoms are hospital-
ized.  Physicians may misdiagnose hemorrhagic coli-
tis as appendicitis, inflammatory bowel disease, or
various forms of colitis, and these misdiagnoses
could lead to unnecessary and/or inappropriate
surgery, antibiotic therapy, and therapeutic proce-
dures.  Although most patients with E. coli
O157:H7-induced hemorrhagic colitis recover with-
out developing sequelae, others develop HUS
(Griffin and Tauxe 1991, p. 65).44
Although less than 5 percent of E. coli O157:H7 dis-
ease cases develop HUS, outcomes from HUS are
severe.  HUS is a life-threatening disease characterized
by red blood cell destruction, kidney failure, and neu-
rological complications, such as seizures and strokes
(McCarthy 1993, p. 10A; AGA 1995, p. 1923).  Those
who develop chronic kidney failure may require life-
long dialysis or a kidney transplant.45 Other neurolog-
ical complications such as central nervous system
deterioration, blindness, or partial paralysis may also
result (Merck 1992).  Many HUS patients die.
44Another condition that may follow E. coli O157:H7 infection is
thrombotic thrombocytopenic purpura (TTP), which is similar to
HUS but Griffin and Tauxe suggest that TTP may have more promi-
nent abnormalities in the central nervous system and may be rela-
tively more common in E. coli O157:H7 disease patients who are
adults (1991, pp. 84-85). Remuzzi (1987, p. 294) believes “that
none of the proposed differentiating features can clearly separate
these two clinical syndromes.” The current study focused on HUS
in children because of the preponderance of E. coli O157:H7 infec-
tions among the very young.
45During dialysis such as hemodialysis, the blood is removed from
the patient, sent through a machine that balances its water and
mineral content while removing toxic waste products, and then is
returned to the patient.
43Hemorrhagic colitis can be the result of several different
diseases.
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Emergence of 0157:H7 Escherichia coli
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HUS especially strikes children under 5 years of age
and the immunocompromised elderly (Griffin et al.
1988; Griffin and Tauxe 1991; Martin et al. 1990).  E.
coli O157:H7 disease may be the leading cause of
acute kidney failure and HUS in young children and
infants.  Tarr et al. (1989, p. 585) found that E. coli
O157:H7 disease is the leading cause of HUS in the
Pacific Northwest.  Siegler et al.’s (1994) results from
a 20-year population-based study of HUS in children
in Utah were consistent with Tarr et al.
Other risk factors for E. coli O157:H7 disease include a
previous gastrectomy, recent antimicrobial use, and
occupational exposure to ground beef, cattle, or clinical
stool specimens (Griffin and Tauxe 1991, p. 65).  Spika
et al. (1986, p. 290) and Martin et al. (1990, p. 1161)
found that attendance at day care may be a risk factor.46
In 1991, a swimming-associated outbreak of hemor-
rhagic colitis and HUS was traced to E. coli O157:H7-
contaminated lake water (Keene et al. 1994, p. 579).
Over 67 percent of sporadic E. coli O157:H7 cases
have occurred between May and September, while 88
percent of all outbreak cases have occurred between
May and November (USDA:APHIS:VS 1994, p. 2).
This seasonality may be related to the summer barbe-
cue season.
A 2-year study of stool samples showed that a sig-
nificantly lower percentage of stool samples tested
positive for  E. coli O157:H7 in the South than in
the Western and Northern United States
(USDA:APHIS:VS 1994, p. 2).  Yet, there is no
strong evidence suggesting a geographical pattern for
E. coli O157:H7 disease.  The documentation of the
incidence of E. coli O157:H7 infections in humans is
hindered by the variation in State reporting require-
ments to the CDC.  As of the summer of 1993, 17
States had reporting requirements for E. coli
O157:H7, 20 States were amending their public health
regulations to require such reporting, 10 States and
the District of Columbia were seriously considering
this requirement, and the remaining three States were
not addressing the issue (Vogt 1994, p. CRS-7).
As with Salmonella and Campylobacter, E. coli
O157:H7 can live harmlessly in the gastrointestinal
tracts of farm animals and poultry and later contami-
nate meat and poultry products during slaughter.
Most outbreak cases associated with food in the
United States are linked to bovine products
(USDA:APHIS:VS 1994; Griffin and Tauxe 1991, p.
71).  Some outbreaks are suspected or have been con-
firmed as originating in the cross contamination of
other foods such as mayonnaise, apple cider, and veg-
etables by meat products or manure (USDA:
APHIS:VS 1994, p. 1).47 Other foods associated with
human E. coli O157:H7 disease outbreaks and spo-
radic cases include hot dogs, raw milk, raw potatoes,
turkey roll, and salad bar items such as ranch dress-
ing, pea salad, and cantaloupe (Griffin and Tauxe
1991; USDA:APHIS:VS 1994; AGA 1995, p. 1923).
Sporadic cases of E. coli O157:H7 disease have also
been attributed to person-to-person transmission and
to contaminated water (Griffin and Tauxe 1991, p.
73).  Outbreaks from contaminated water have also
occurred.  Swerdlow et al. (1992) examined a large
outbreak of E. coli O157:H7 infections traced to cont-
aminated water in a Missouri municipal water system.
Keene et al. (1994) investigated a 1991 swimming-
associated outbreak of hemorrhagic colitis caused by
E. coli O157:H7 contaminated water.
Bennett et al. (1987, p. 109) found that in 1985 poten-
tially 5 percent of E. coli O157:H7 infections were
attributed to attendance at day care centers.  Because
E. coli O157:H7 is not spontaneously generated, it is
possible that many of these person-to-person cases
originated with consumption of food contaminated
with E. coli O157:H7.  Several other studies also
report or suggest that E. coli O157:H7 disease can be
caused by person-to-person transmission (Ratnam et
al. 1986; Spika et al. 1986).  In the 1993 outbreak in
the Northwest, more than 50 of the 500-plus cases
were attributed to person-to-person contact, especially
taking place among infants in child care facilities
(FDA Consumer 1994, p. 8).  In addition to food,
water, and human sources of transmission of E. coli
O157:H7, Renwick et al. (1993) report transmission
from calves to a child, presumably through oral con-
tact with feces.  
Estimates of Cases
Laboratory screening for E. coli O157:H7 is relatively
straightforward (Griffin et al. 1988, p. 711) and pro-
46Belongia et al. (1993, p. 883) found that “person-to-person trans-
mission of E. coli O157:H7 is common when infected preschool
children attend day care while symptomatic.”
47Apple cider contaminated with E. coli O157:H7 is believed to
result from making cider with apples that have fallen from orchard
trees and that are contaminated with manure fertilizer or feces from
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vides the opportunity to compare the frequency of iso-
lation of this pathogen to frequencies of other
pathogens causing diarrheal illnesses in humans.
Gransden et al. (1986, p. 523) found that E. coli
O157:H7 was the second leading bacterial cause of
diarrhea (following Campylobacter) in 1,425 school
children in British Columbia who had stool cultures
taken.  MacDonald et al. (1988, p. 3567) report that out
of 6,485 stool specimens from a health maintenance
organization in Washington State, researchers isolated
E. coli O157:H7 less frequently than Salmonella or
Campylobacter, but more frequently than Shigella.48
We updated Roberts and Marks’ (1995) COI estimates
for E. coli O157:H7.  As with the other foodborne
pathogens studied here, this analysis considers four
main patient categories, those who:  do not visit a
physician, visit a physician, are hospitalized, and die.
However, the COI analysis for E. coli O157:H7 infec-
tions is more complicated than for salmonellosis and
campylobacteriosis, because hospitalized acute illness
cases and deaths are subdivided into those who have
hemorrhagic colitis and those with HUS.  The COI
analysis for E. coli O157:H7 is further complicated in
that some HUS cases develop chronic illnesses and
some of these chronic illness cases die prematurely.
For simplicity, our analysis will first discuss medical
costs, subdivided into acute and chronic cases, fol-
lowed by a discussion of the costs of lost productivity,
also subdivided into acute and chronic cases.  Table
10 presents the estimated acute and chronic E. coli
O157:H7 disease cases in the United States, broken
down by the four disease severity categories used
throughout this report.  Figure 8 presents the distribu-
tion of estimated annual cases of E. coli O157:H7 dis-
ease and disease outcomes.  Table 11 presents the
assumptions used here to estimate annual costs of E.
coli O157:H7 disease.
To simplify the analysis, all cases are assumed to be 4
years of age at death or at the onset of the illness.
This was roughly the average age (3.8 years) in
Martin et al. (1990), which is the largest U.S. study of
children with HUS.  They studied 117 children under
age 18 with HUS in Minnesota.  This is also the aver-
age age in Siegler et al.’s (1994, p. 36) 20-year popu-
lation-based study.  Several studies also identified age
less than 4 or 5 years as a risk factor for HUS from E.
coli O157:H7 disease (Pai et al. 1984, p. 590; Griffin
48Isolation rates were as follows: 7/100,000 persons for Shigella;
8/100,000 persons for E. coli O157:H7; 21/100,000 persons for
Salmonella; and 50/100,000 persons for Campylobacter.
Table 10—Estimated U.S. Escherichia coli
O157:H7 disease cases, 19931




No physician visit2 5,000 10,000
Visited physician2 3,200 6,400
Hospitalized and 
survived3 1,600 3,100
Hemorrhagic colitis  1,340 2,630
HUS 260 470
Deaths 
(during hospitalization)4 200 500
Hemorrhagic colitis deaths 100 250
HUS deaths 100 250
Total acute cases5 10,000 20,000
Chronic:
No physician visit 0 0
Visited physician 0 0
Hospitalized and survived
(all are HUS)6 11 25
Deaths (all are HUS)7 19 37
Total chronic cases 30 62
1 We assumed no chronic conditions resulted from hemorrhagic
colitis (HC) and assumed both chronic and acute conditions result-
ed from hemolytic uremic syndrome (HUS). For both acute and
chronic E. coli O157:H7 illness, we estimate there is a total of 219-
537 deaths each year (see below).
2 Of the 82% of all E. coli O157:H7 acute illness cases that are
not hospitalized, we assume that 50% of all cases do not seek any
medical attention and the remaining 32% visit a physician.
3 Griffin and Tauxe (1991) found that 18% (p. 69) of all acute ill-
ness cases are hospitalized (1,800 to 3,600 cases) and 20% (cal-
culated from Table 2 on p. 70) of the hospitalized cases (360-720)
develop HUS. After subtracting the 100-250 HUS acute illness
deaths, there were 260-470 hospitalized HUS cases who survived.
We categorize the remainder of the hospitalized cases (80%) as
those that develop HC (1,440-2,880). After subtracting the 100-250 
HC acute illness deaths, there were 1,340-2,630 hospitalized HC
cases who survived.
4 The American Gastroenterological Association’s (AGA) 1994
Consensus Conference on E. coli O157:H7 Infections estimate the
annual number of E. coli O157:H7 acute illness deaths as ranging
between 200 and 500. We assume that 50% of all E. coli O157:H7
acute illness deaths were HC patients and 50% were HUS patients.
5 The AGA’s 1994 Consensus Conference on E. coli O157:H7
Infections (p. 7) estimate the annual number of E. coli O157:H7 dis-
ease cases as ranging between 10,000 and 20,000 cases.
6 In Martin et al. (1990), 8.55 percent of HUS patients had kidney
failure and we use this percentage to represent the proportion of
acute illness HUS cases that developed chronic complications. Out
of the 360-720 HUS cases, we estimate that 30-62 developed
chronic complications.
7 Using the HCFA’s data on the rates of kidney transplantation,
survival after the operation, and survival on dialysis for pediatric
patients, life tables for the 30-62 chronic illness cases were estimat-
ed (Eggers, personal communication with Marks). We estimate that
19-37 die prematurely from chronic illness due to HUS.Economic Research Service/USDA                      Bacterial Foodborne Disease:  Medical Costs and Productivity Losses / AER-741     33Table 11—Assumptions used to estimate annual costs of illness for E. coli O157:H7 disease, 1993
Cost category & severity Costs during acute illness Costs during chronic illness 
Overview: Incremental costs Estimates of new cases annually are divided into severity level categories to  Some survivors develop chronic conditions. All lifetime
due to foodborne disease estimate costs. Acute illness costs are not discounted, except for productivity costs are discounted at 3% per year to calculate the 1993 
losses for deaths occurring during the acute illness. present value.
Medical costs
No physician visit  No medical costs estimated. (Although some may self-medicate.)  Not relevant.
Visited physician Physician visit cost calculated by dividing the updated Health Care Financing Not relevant.
Administration annual national expenditures on physician services by the National 
Center for Health Statistics annual number of physician visits. Laboratory
expenses are computed separately.
Hospitalized Hospital room cost is the American Hospital Association’s average cost per day. For known chronic conditions associated with the
An intensive care room is assumed to be double the cost of a regular room. foodborne illness, chronic costs are computed the same
Total fees for physician care, laboratory tests, and medications during as acute costs, except that they are computed for the
hospitalization are assumed to be equal to hospital room costs. Costs of dialysis are  remaining life of an individual and discounted back to 
computed separately. 1993 using a 3% discount rate. Discounted costs of 
kidney transplants and drug therapy were also included.
Productivity losses  If ill person is a child under age 16, productivity loss is calculated for one For children, the productivity loss is calculated for one
parent/caretaker. parent/caretaker’s time estimated for care of chronically ill
child until age 16. After the age of 16, the ill individual’s
productivity loss is estimated.
No physician visit Productivity loss uses the BLS average weekly earnings for all nonagricultural The average weekly earnings are multiplied by 52 weeks,
workers (pre-tax, no fringe benefits) multiplied by 39% to account for fringe adjusted by the labor force participation rate for the age of
benefits, divided by 5 to get a daily rate, and multiplied by the estimated days lost the patent, and multiplied by the percentage of productive
from work. capacity lost. Or, an estimate of the proportion of
productivity lost because of the disability is multiplied by
Visited physician Time away from work was estimated either by assuming the average duration of Landefeld and Seskin’s (1982) value of life according to
illness or by using estimates from survey data. The cost per day is estimated by the age of the patient to get the marginal lifetime
adjusting BLS average weekly earnings as above. productivity lost.
Hospitalized Time away from work is assumed to be 3 times the days in the hospital, adjusted
for weekends. The cost per day is estimated by adjusting BLS average weekly
earnings as above.
Death The present value of a statistical life lost is computed as the average of male and The value of a statistical life lost to chronic illness is
female values given by Landefeld and Seskin (1982) for each age, updated to Landefeld and Seskin (1982) value for the age of the
1993 values using the change in average weekly earnings. person in the year he/she dies, discounted back to 1993.
Other costs: education, Not estimated. Not estimated
nursing home, lost leisure,









































































































































AEconomic Research Service/USDA                      Bacterial Foodborne Disease:  Medical Costs and Productivity Losses / AER-741     35
et al. 1988, p. 706; Ostroff et al. 1989, p. 355; Pavia
et al. 1990, p. 549; Cimolai et al. 1990, p. 590).
Figure 9 presents the age-specific rates of infection
with E. coli O157:H7 for 93 surveillance cases in
Washington State in 1987.  Note that the highest
infection rate is for children less than 5 years old.
The annual estimated incidence of E. coli O157:H7
disease is between 2.1 and 8 cases per 100,000 persons
(Ostroff et al. 1989, p. 355; and MacDonald et al.
1988, p. 3567, respectively).  Participants of the AGA’s
1994 Consensus Conference on E. coli O157:H7 infec-
tions (1995, p. 1924) believed that the best estimate of
E. coli O157:H7 disease cases was between 10,000 and
20,000 cases per year (a rate of approximately 4 to 8
cases per 100,000 persons in 1993).  We use these con-
sensus estimates for this analysis.  
Using data on 12 U.S. outbreaks of E. coli O157:H7
disease between 1982 and 1990, Griffin and Tauxe
(1991, p. 69) found that 18 percent of all cases are
hospitalized and 20 percent of the hospitalized cases
develop HUS (calculated from table 2 on p. 70).49
These percentages are used in this analysis.  The
remainder of the hospitalized cases (80 percent) are
categorized as those who develop hemorrhagic colitis.
Using these percentages along with the estimated
range of 10,000-20,000 E. coli O157:H7 disease
cases, an estimated 1,800-3,600 cases are hospitalized.
This includes hospitalized patients who survive and
those who die prematurely because of acute E. coli
O157:H7 disease.  Of these 1,800 to 3,600 cases, 360
to 720 (or 20 percent) develop HUS, and 1,440 to
2,880 (or 80 percent) develop hemorrhagic colitis.  
In Martin et al.’s (1990, p. 1164) study of 117 children
who had HUS, 9 children had renal failure and sur-
vived, and one child required a kidney transplant.50
Here, we assumed that these 10 renal failure and
transplant cases (or 10/117=8.55 percent) constitute
those HUS patients who remain chronically ill with
kidney failure.  Using this percentage (8.55 percent),
we estimated that of the 360 to 720 cases who con-
tract HUS in our analysis, approximately 30 to 62
remain chronically ill.  
49This translates into 3.6 percent of all E. coli O157:H7 cases
develop HUS. Our estimate is conservative when compared with
Karmali et al. (1985, p. 778) who found that roughly 10 percent of
all E. coli O157:H7 infections develop HUS.
50Martin et al.’s (1990, p. 1164) table 3 indicates 10 cases of renal
failure, but one of these is linked to the sepsis death which would
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We assumed that all of the 30 to 62 chronic illness
cases required dialysis and some had kidney trans-
plants, and that there were premature deaths resulting
from both of these procedures.  Because kidney fail-
ure is the major chronic complication of HUS in chil-
dren, end-stage renal disease (ESRD) data were used
in the cost estimation.  We used data on the percent-
age of ESRD children receiving kidney transplants
(Eggers, personal communication with Marks (ERS)
1993) and HCFA’s Medicare data on survival rates
after kidney transplantation and survival rates on dial-
ysis for pediatric patients (HCFA 1992, tables 35-37)
to develop life tables for kidney transplant and dialy-
sis survivors, and to estimate the number of premature
deaths due to chronic illness from HUS.  Table 12
shows the breakdown of the estimated 19 to 37 pre-
mature deaths from chronic E. coli O157:H7 illness,
by age at death.  The estimated number of chronic ill-
ness deaths is the sum of the estimate of premature
deaths from complications during kidney transplanta-
tion and the estimate of premature deaths from com-
plications during dialysis.  None of these deaths
occurred during the first year of illness but were
spread out over subsequent years.51 Age at death and
number of deaths depend upon both kidney transplant
survival rates and dialysis survival rates.
Not all kidney transplants take place within the first
few years following the onset of the chronic illness.
A variety of reasons, such as the patient’s health and
the availability of a suitable kidney, may delay kidney
transplants or remove this procedure as an option for
patients.  Paul Eggers of HCFA provided data on the
cumulative percentage of children receiving trans-
plants within the first 6 months of ESRD and the per-
centage receiving transplants for each of the following
5 years after ESRD was diagnosed (personal commu-
nication between Eggers and Marks (ERS), 1993).
This cumulative rate of receiving a transplant increas-
es over time as more kidney transplants are per-
formed.  From these data, the cumulative percentage
receiving transplants for the remaining years in the
average life span of 77 years was estimated, as was
the annual percentage receiving transplants (decreas-
ing) for each of the years in this timeframe.  Using
these annual percentages, out of the 30 to 62 chronic
illness cases, an estimated 26 to 53 cases had kidney
transplants.  Table 12 also shows the breakdown of
the estimated range of 26 to 53 transplant recipients
by year.52
Survivability after a transplant depends on the type of
kidney received, with higher survival rates for transplant
recipients of a kidney from a “living-related” donor ver-
sus a kidney from a cadaver.  For the representative age
used in this study, an estimated 56 percent of the kidney
transplant patients had cadaver donors and 44 percent
had living-related donors (personal communication
between Eggers and Marks (ERS), 1993). 
Two groups of deaths from E. coli O157:H7 disease
were considered: acute illness deaths and chronic ill-
ness deaths.  In the literature, human deaths attributed
to E. coli O157:H7 disease generally refer to acute ill-
ness deaths and do not include chronic illness deaths. 
Griffin and Tauxe (1991, p. 69) found a 1.9-percent
death rate (op. cit.).  However, participants of the
Consensus Conference on E. coli O157:H7 generally
agreed that an estimated 200 to 500 deaths occur from
E. coli O157:H7 disease each year (Notes by Roberts
for this conference), which in our study translates into
a death rate of 2 to 2.5 percent.53  This death rate is
high compared with other microbial infections. 
We were unable to find published data that specified
what percentage of the estimated 200 to 500 E. coli
O157:H7 acute illness deaths were from hemorrhagic
colitis cases and what percentage were from HUS.
Therefore, we assumed that 50 percent of all acute E.
coli O157:H7 disease deaths were hemorrhagic colitis
patients and 50 percent were HUS patients.  Of the esti-
mated 1,440 to 2,880 cases of hemorrhagic colitis, an
estimated 100 to 250 cases died prematurely from the
acute illness.  The remaining 1,340 to 2,630 patients
hospitalized with hemorrhagic colitis achieved a com-
plete recovery.  And of the estimated 360 to 720 cases
that contract HUS, an estimated 100 to 250 cases died
prematurely from their acute illness.  These proportions
of the percentage of acute illness deaths from HUS and
hemorrhagic colitis reflect the greater severity of HUS.
To estimate the number of HUS deaths attributed to
chronic complications from kidney transplants, HCFA
data on cadaver-donor transplant patient survival 
51This “first year” is really only 6 months, because it was assumed
that the patients became ill in the middle of the year, on average.
52All kidney transplants were performed within the 6 full years fol-
lowing the originating illness at age 4, because, over time, the pro-
portion that received a transplant each year declines sharply.
53This range of deaths was agreed upon during the conference yet
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Table 12—Chronic illness: Deaths, dialysis recipients, and transplant survivors
Chronic deaths1 Dialysis recipients Transplant recipients Transplant survivors
Age Low High Low High Low High Low High
Numbers
4 in 1993  0 0 30 62 0 0 0 0
5 2 4 15 31 15 31 14 29
6 1 3 8 17 6 12 19 39
7 2 0 5 11 3 5 21 44
8 1 3 3 8 1 3 21 44
9 1 2 2 7 1 1 21 44
10 1 1 2 5 0 1 20 44
11 0 2 2 5 0 0 20 42
12 0 0 2 5 0 0 20 42
13 1 1 2 5 0 0 19 41
14 0 0 2 5 0 0 19 41
15 0 0 2 5 0 0 19 41
16 0 0 2 5 0 0 19 41
17 1 0 2 5 0 0 18 41
18 0 1 2 5 0 0 18 40
19 0 0 2 5 0 0 18 40
20 0 1 2 5 0 0 18 40
21 0 0 2 4 0 0 18 40
22 0 1 2 4 0 0 18 39
23 0 3 2 4 0 0 18 36
24 1 0 2 4 0 0 17 36
25 1 0 2 4 0 0 16 36
26 0 0 2 4 0 0 16 36
27 0 0 2 4 0 0 16 36
28 0 0 2 4 0 0 16 36
29 0 1 2 4 0 0 16 35
30 0 0 2 4 0 0 16 35
31 0 0 2 4 0 0 16 35
32 0 0 2 4 0 0 16 35
33 0 0 2 4 0 0 16 35
34 0 0 2 4 0 0 16 35
35 0 1 2 4 0 0 16 34
36 1 0 2 4 0 0 15 34
37 0 0 2 4 0 0 15 34
38 0 1 2 4 0 0 15 33
39 0 1 2 4 0 0 15 32
40 1 2 2 4 0 0 15 31
41 0 0 1 3 0 0 15 31
42 0 1 1 3 0 0 15 30
43 0 0 1 3 0 0 15 30
44 0 0 1 3 0 0 15 30
45 0 0 1 3 0 0 15 30
46 0 0 1 3 0 0 15 30
47 0 0 1 3 0 0 15 30
48 0 0 1 3 0 0 15 30
49 1 0 1 3 0 0 14 30
50 0 1 1 3 0 0 14 29
51 0 0 1 3 0 0 14 29
52 1 0 1 3 0 0 13 29
53 0 0 1 3 0 0 13 29
54 0 0 1 3 0 0 13 29
55 0 0 1 3 0 0 13 29
56 0 0 1 3 0 0 13 29
57 0 0 1 3 0 0 13 29
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Table 12—Chronic illness: Deaths, dialysis recipients, and transplant survivors--Continued
Chronic deaths1 Dialysis recipients Transplant recipients Transplant survivors
Age Low High Low High Low High Low High
Numbers
58 0 0 1 3 0 0 13 29
59 0 2 1 3 0 0 13 27
60 0 1 1 3 0 0 13 26
61 0 0 1 3 0 0 13 26
62 0 0 1 3 0 0 13 26
63 1 0 1 3 0 0 12 26
64 0 0 1 3 0 0 12 26
65 0 1 1 3 0 0 12 25
66 0 0 1 3 0 0 12 25
67 0 0 1 3 0 0 12 25
68 0 0 1 3 0 0 12 25
69 0 2 1 3 0 0 12 23
70 0 0 1 3 0 0 12 23
71 0 0 1 3 0 0 12 23
72 0 0 1 3 0 0 12 23
73 1 0 1 3 0 0 11 23
74 0 0 1 3 0 0 11 23
75 1 0 1 3 0 0 10 23
76 0 1 1 3 0 0 10 22
77 0 0 1 3 0 0 10 22
Total 19 37 * * 26 53 * *
*=These could not be totaled as they would overcount the numbers of recipients or survivors over time.
1 Of the estimated 19 to 37 chronic illness deaths, 3 to 6 occur from complications from dialysis and 16 to 31 occur from complications arising
from the kidney transplants.
(1992, table 36, p. 41) and HCFA data on living-relat-
ed donor transplant patient survival were used (1992,
table 37, p. 42).  For both types of kidney transplants,
these HCFA cumulative survival rates show that trans-
plant patient survival rate decreases over time as more
kidney transplant patients die.  These data on the sur-
vivability following the two types of kidney trans-
plants were available only for the first full 5 years
after the kidney transplant.  From these 5 years of
data, the survival rates were estimated as well as the
number of transplant survivors for both types of kid-
ney transplants for each year in the average life-span
of 77 years.  Table 12 provides estimates of the total
number of transplant survivors from operations using
both cadaver and living-related donor kidneys.  Given
the estimated 26 to 53 kidney transplants and the
number of transplant survivors, an estimated 16 to 31
premature deaths occur as a result of complications
from the kidney transplants.
To estimate the number of HUS deaths attributed to
complications from dialysis, HCFA data on ESRD
were used (1992, table 35, p. 40).  As with the kidney
transplant survival data, the HCFA cumulative esti-
mates of dialysis patient survival declined over time as
more patients died prematurely.  These data only pro-
vided for the first full 5 years after the initiation of dial-
ysis and were used to estimate the cumulative dialysis
survival rate for each of the remaining years in the
average life span of 77 years.  Once all cumulative dial-
ysis survival rates were determined, they were used to
develop the percentage of dialysis patients that die each
year over the 77-year life span.  These annual death
rates for dialysis patients were used to estimate that
three to six patients with chronic illness due to HUS die
prematurely from complications during dialysis.
Out of the 30 to 62 chronic illness cases, an estimated
19 to 37 died prematurely (table 12) from chronic
complications over their lifetime (3 to 6 from dialysis
and 16 to 31 from transplants).  Adding these estimat-
ed chronic illness deaths to the estimated 200 to 500
acute illness deaths provides an annual estimate of
219 to 537 deaths caused by E. coli O157:H7 disease.
Of the 82 percent of all E. coli 1057:H7 disease cases
that are not hospitalized, we assumed that 50 percent
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to 10,000 cases) and that the remaining 32 percent of all
cases visit a physician (3,200 to 6,400 cases).  This is a
higher rate of physician visits than for salmonellosis and
campylobacteriosis, but E. coli O157:H7’s bloody diar-
rhea is likely to scare people into seeing a physician.  
Costs of E. Coli O157:H7 Disease
As previously mentioned, the COI analysis for E. coli
O157:H7 disease differs from those for salmonellosis
and campylobacteriosis.  E. coli O157:H7 disease cases
were divided into acute and chronic cases, and E. coli
O157:H7 disease had two categories of illness that
required hospitalization, hemorrhagic colitis and HUS.  
Medical Costs for Acute E. Coli O157:H7 Disease
Acute illness medical costs consisted of the costs of
hemodialysis, hospital room charges, and physician
fees.  Hospital room charges include regular hospital
rooms and intensive care unit (ICU) rooms.  Several
nationwide data bases were used.  For example, the
American Hospital Association’s Hospital Statistics
provided data on daily costs of hospitalization.  The
National Hospital Discharge Survey (NHDS) imple-
mented by HCFA’s National Center for Health
Statistics was used to provide estimates for hospital
length of stay.  The study also used HCFA’s estimates
of per capita expenditures on physician services and
HCFA’s medicare reimbursement rates for the annual
costs of ESRD and the costs of kidney transplants.54
Table 13 presents the estimated annual medical costs
of acute illness from E. coli O157:H7 disease by
severity category.  
• No physician visited.  For the estimated 5,000 to
10,000 E. coli O157:H7 disease cases who do not
seek medical care, the study assumed that they
have abdominal discomfort and non-bloody diar-
rhea (often lasting several days) yet do not pur-
chase over-the-counter medications and do not miss
work because of their illnesses.  For the cases in
this category, no medical costs were computed.  
• Physician visited.  For the estimated 3,200 to 6,400
cases who visited a physician for E. coli O157:H7
disease but were not hospitalized, it was assumed
that these cases had diarrhea (often bloody and last-
ing several days) and that they visited a physician
once or twice and had one or two laboratory tests.
Prescribed medications and medication costs were
not included in the estimated costs.
The costs of physician visits was estimated at
$109.57 per visit.55 This number reflects the per-
visit cost of a doctor visit for all reasons, not
specifically for the foodborne illness, and includes
the portion paid by insurance.  Laboratory tests
were estimated at $50 per case.  Medical costs for
those E. coli O157:H7 disease cases who visited a
physician for their illness but did not require hospi-
talization are estimated at between $0.5 million and
$2.0 million annually.
• Hospitalized for Hemorrhagic Colitis.  For the esti-
mated 1,440 to 2,880 cases of hemorrhagic colitis,
we assumed that these cases were hospitalized for
their bloody diarrhea, dehydration, and severe
abdominal cramps.  The estimated length of stay
(LOS) in a hospital for patients with hemorrhagic
colitis is 6.5 days (the average from the NHDS
range of 5 to 8 days, Steahr 1993).  To compute
hospitalization costs, the average cost to communi-
ty hospitals per patient per day in 1993 dollars was
used ($887.20).56
• Fees for laboratory tests, supplies, medications, and
physician visits while hospitalized are assumed to
equal the costs of hospitalization (following Roberts
and Pinner 1990) but were updated using the physi-
cian services CPI, for a total cost of $843.74 per
54Medicare billing records provide a major source of information
on the medical costs of specific diseases. However, such informa-
tion is specific to the Medicare population and may understate the
treatment costs of diseases affecting the non-Medicare population.
55In 1990, the average number of physician and dental contacts
per person per year was 4.7 for males and 6.4 for females
(Statistical Abstract of the United States 1993: table 174), for an
average of 5.55 visits per person. The average cost of a physician
visit was estimated by dividing per capita annual natjioal expendi-
tures on physicians’ services, $542 in 1991 (Statistical Abstract of
the United States 1993: table 151), by the average number of
annual physician visit (5.55), and updating the resulting number to
1993 dollars (using the 1991 physician services CPI from the
Statistical Abstract of the United States 1993: table 163, and the
1993 physician services CPI from personal correspondence with
BLS on June 16, 1994).
56In 1991, the daily hospitalization cost per person was estimated
at $752 per patient (American Hospital Association in Statistical
Abstract of the United States 1993: table 182. This estimate was
updated to 1993 dollars using the change in the hospital room CPI
(1991 CPI from the Statistical Abstract of the United States 1993:
table 163, and the 1993 CPI from personal correspondence with
BLS in June 1994).Table 13—Estimated medical costs of acute E. coli O157:H7 disease, 1993
Unit Service/ Cost/ Cases Total costs8
Severity of illness cost8 case case8 Low High Low High
Dollars Number Dollars Number Million Dollars
No physician visit 0 0 0 5,000 10,000  0 0
Visited physician:
Physician visits2 110/visit 1-2 110-219
Laboratory tests 50/case 1-2 50-100
Subtotal 160-319 3,200 6,400 0.5 2.0
Hospitalized with hemorrhagic colitis:
Hospital room3 887/day 6.5 5,767
Physician fees, lab tests, etc.4 844/day 6.5 5,484
Subtotal 11,251 1,440 2,880 16.2 32.4
Hospitalized with HUS:1
Hospital room5 1,183/day 15 17,744 360 720 6.4 12.8
Physician fees, lab tests, etc.6 1,125/day 15 16,875 360 720 6.1 12.1
Dialysis and medication7 130/day 12 1,566 169 338 0.3 0.5
Subtotal 36,185 12.7 25.5
Total N/A N/A N/A 10,000 20,000 29.4 59.9
N/A = Not applicable.
1 Medical costs are for those who survive and those who die (after hospitalization) from the acute illness.
2 The average cost of a physician visit was estimated by dividing per capita annual national expenditures on physician services, $542 in 1991 (Statistical Abstract of the United States 1993: table
151), by the average number of annual physician visits (table 174, averaged across gender), and updating the resulting number to 1993 dollars using the physician services CPI (table 163 and
personal correspondence with BLS on June 16, 1994). We estimate these cases visit a physician one to two times for their illness.
3 In 1991, the daily hospitalization cost per person was estimated at $752 per patient (American Hospital Association in Statistical Abstract of the United States 1993: (table 182). This estimate
was updated to 1993 dollars using the change in the hospital room CPI (Table 163 and personal correspondence with BLS in June 1994). The average hospital length of stay is 6.5 days (average
from NHDS data, Steahr 1993).
4 Fees for laboratory tests, supplies, medications, and physician visits while hospitalized are assumed to equal the costs of hospitalization (following Roberts and Pinner 1990) but were updated
using the physician services CPI (as above). Medical costs exclude costs of neurological procedures and gastrointestinal procedures.
5 Martin et al. (1990) found that HUS patients stay on average 15.4 days in a hospital, which we round down to 15 days. We assume the patient stays in a regular hospital room 10 days at the
same daily room rate as above, and stays in an intensive care unit (ICU) 5 days at double the regular room rate.
6 Fees calculated in the same fashion for ICU days as for days in a regular hospital room.
7 Daily rate of medicare reimbursements for dialysis (Eggers 1994, table 48), updated to 1993 dollars using the general medical care CPI (table 163 and personal correspondence with BLS in
June 1994).
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patient per day.57 The total costs of hospitalization
and fees are estimated at $1,730.94 per patient per
day.  For the estimated 1,440 to 2,880 cases of hem-
orrhagic colitis, total costs for this medical category
ranged from $16.2 million to $32.4 million.  We
assumed that these cases recovered fully. 
• Hospitalized for acute HUS.  Of the estimated 360
to 720 E. coli O157:H7 disease cases hospitalized
for HUS (which included the 100 to 250 who died
prematurely from the acute illness), 30 to 62 of
these patients later developed chronic illnesses
(which includes 19 to 37 who die from chronic ill-
ness due to HUS).  The acute and chronic medical
costs are not mutually exclusive, because those who
develop chronic illnesses first bear the costs incurred
during HUS.  Additional medical costs incurred by
the 32 to 60 patients who develop chronic illness
due to HUS illness are discussed in the next section.
In Martin et al.’s (1990, p. 1163) study of 117 HUS
cases in Minnesota, the average hospital length of stay
for HUS patients was 15.4 days.  Following Martin et
al., we assumed an average patient stay of 15 days
(after rounding) in the hospital.  We also assumed that 5
of these days would be spent in an ICU.  We used an
estimate for ICU room costs of $1,774/ICU day, or
twice the normal hospital room charge of $887/day.
Thus the average cost equals $1,183 per day for the
duration of hospitalization.  Total annual costs of the
regular and ICU hospital rooms for the 360 to 720 acute
HUS cases range from $6.4 million to $12.8 million.
We also assumed that the physician fees, laboratory
tests, and other charges during hospitalization would
be similar to the hospital room and ICU room fees,
but were updated using the physician services CPI
(updated as described under physician visits) to get an
average cost of $1,125 per day.  Estimated total annu-
al costs of physician fees, laboratory tests, etc. for the
360 to 720 acute HUS cases range from $6.1 million
to $12.1 million.
Martin et al.’s (1990, p. 1163) found that 47 percent
of HUS cases required dialysis for an average of 12
days.  For the current analysis, this translates into 169
to 338 acute HUS cases requiring dialysis.  The annu-
al medicare reimbursement rate for kidney dialysis for
children in 1993 dollars was $130.50 per day.58 For
the estimated 169 to 338 children who required dialy-
sis, estimated total annual costs of dialysis ranged
from $0.3-$0.5 million. 
Estimated medical costs for the 360 to 720 hospital-
ized acute HUS cases ranged from $12.7-$25.5 mil-
lion annually.  This includes the costs of hospitaliza-
tion, dialysis, physician fees, laboratory tests, and
other charges during hospitalization.
• Deaths.  We assumed that the estimated 200 to 500
patients who died prematurely from acute E. coli
O157:H7 disease incurred hospitalization costs
prior to their deaths.  As previously mentioned,
these deaths were divided among those hospitalized
for hemorrhagic colitis (50 percent of deaths) and
those hospitalized for HUS (50 percent of
deaths).59 The acute illness medical costs associat-
ed with these deaths are included in the two hospi-
talization categories above.
• Subtotal.  Acute illness medical costs for the four
disease severity categories were estimated to total
between $29.4 million and $59.9 million annually.
Medical Costs for Chronic Illness Due to HUS
As previously mentioned, HUS may lead to chronic
kidney failure, requiring lifelong dialysis or a kidney
transplant.  We estimated costs for chronic kidney-
related disease, but did not estimate costs for the
chronic neurological complications or intestinal oper-
ations (laparotomies or colostomies).  
57As before, we use the 1991 hospital cost of $752 per day, but
we updated this cost with the physician services CPI (1991 CPI
from Statistical Abstract of the United States 1993: table 163 and
the 1993 CPI from personal communication with BLS in June
1994).
58In 1990, the average Medicare End Stage Renal Disease
Program expenditures per dialysis patient were $38,502 per year
(Eggers 1993, table 48). This cost estimate was updated to 1993
dollars using the general medical care CPI (1990 CPI from
Statistical Abstract of the United States 1993: table 163; 1993 CPI
from personal communication with BLS in June 1994) to get 1993
annual costs of $47,630.85 per patient or $130.50 per patient per
day.
Peritoneal dialysis such as Continuous Ambulatory Peritoneal
Dialysis (CAPD) and Continuous Cyclic Peritoneal Dialysis (CCPD)
results in one infection every 9 months, on average. Consequently,
the infection may be treated with antibiotics in the hospital for 2
days or at home, depending on the severity of the infection. In
addition, the children must visit a physician once a month for a
checkup. We assumed that the HCFA costs of dialysis for pediatric
patients include some, if not all, of these costs.
59Patricia Griffin, personal communication July 1993, estimates
that 5 percent of deaths occur in nonhospitalized cases which
would mean that our assumptions used here overestimated hospi-
talization costs by 5 percent.42 Bacterial Foodborne Disease:  Medical Costs and Productivity Losses / AER-741                      Economic Research Service/USDA
Estimated annual medical costs for chronic illness due
to HUS were calculated by adding the costs of three
separate medical services for these cases: dialysis,
kidney transplants, and drug therapy.  For each of
these three categories, costs for each year of service
were determined by multiplying the average cost per
service by the number of patients receiving that ser-
vice.  A total cost for each type of service was then
computed by summing annual costs of the service.
After the total costs for each of these three subcate-
gories were estimated and combined, total medical
costs for chronic illness due to HUS cases were dis-
counted at a rate of 3 percent.
Once chronic kidney failure occurred, our representa-
tive 4-year-old patient either continued hemodialysis
at the hospital on an outpatient basis, received a trans-
plant, or switched to peritoneal dialysis (performed
within the abdominal cavity).  In practice, the child
has the option to continue hemodialysis at the hospital
as an outpatient, yet most receive a kidney transplant
or eventually switch to some form of peritoneal dialy-
sis because it can be carried on a person while going
about normal activities.  If there is no medical reason
for choosing one form over another, the decision is
generally left up to the parents.  Some patients with
skin infections or perforations in their peritoneum (i.e.,
from an operation or other medical condition) have no
choice but to continue hemodialysis.  HCFA’s statistics
(1986-89) for children under 15 years old with ESRD
show that by the end of year one, 24 percent were
undergoing outpatient hemodialysis, 23 percent were
undergoing peritoneal dialysis at home, 6 percent died,
and 47 percent received a kidney transplant (HCFA
1992, table 7 on p. 11).  
In general, for each year, we computed total costs of
dialysis for patients with chronic illness due to HUS
by multiplying the average annual cost of dialysis by
the estimated number of chronic E. coli O157:H7 dis-
ease cases who required dialysis.  We then summed
these annual dialysis costs over the 77 years in the
average life span to estimate the total costs of dialysis.
Because the costs of in-facility hemodialysis are reim-
bursed at the same rate as that of at-home peritoneal
dialysis, the costs for pediatric dialysis patients reflect
the same costs for both types of dialysis (as previously
mentioned, $130.50 per patient per day or roughly
$47,631 per year in 1993 dollars).60
Assuming that the onset of illness occurs halfway through
the initial year and that no chronic patients receive a
transplant during the acute phase (Eggers personal com-
munication with Marks (ERS) 1993), chronic patients
require 6 months of dialysis in the initial year (minus 12
days that were accounted for in the acute phase), for a
total cost of $22,249/case.  The annual costs of dialysis
per case for subsequent years is estimated at $47,631.  
All patients who had chronic illness due to HUS
received dialysis in the first year.  A declining number
received dialysis in subsequent years as more kidney
transplants were performed and as the number of pre-
mature deaths from complications from dialysis and
kidney transplants increased over time.61 Table 14 
shows the low and high estimates of the number of
dialysis recipients each year after onset of HUS illness
at 4 years old.  The estimated total costs of dialysis
for the 30 to 62 cases with chronic illness due to
HUS range from $7.0 million to $16.6 million.  We
later combined these estimated dialysis costs with the
estimated costs of kidney transplants and drug thera-
py to calculate the total chronic medical costs, which
were then discounted using a 3-percent rate.
The total cost of the kidney transplants for the cases
with chronic illness due to HUS is the product of the
number of transplant recipients and the average cost
per transplant.  Table 15 provides the breakdown of
the 26 to 53 kidney transplants by year of operation
(as previously described).62 All transplants were esti-
mated to occur within the 6 years following the E.
coli O157:H7 infection.  The average cost of a kidney
transplant was from medicare reimbursement data and
was updated to 1993 dollars to get an average of 
$110,844.23 per transplant.63 The total costs for the
26 to 53 cases that had kidney transplants ranged from
$2.9 million to $5.9 million.  As previously men-
tioned, we combined these estimated costs with the
estimated costs of dialysis and drug therapy, and then
discounted them using a 3-percent rate.
60For simplicity, most of this manuscript uses the generic word
“Dialysis” to represent the many kinds of dialysis.
61We assumed that dialysis is no longer needed after kidney
transplants.
62Often, a second or third transplant or a return to dialysis is nec-
essary. Our analysis does not include the additional medical
expenses due to additional transplants.
63Eggers (1993, table 49) provides an estimate of $89,600 per
kidney transplant in 1991. This number was updated to 1993 dol-
lars using the general medical care CPI (1991 CPI from U.S.
Statistical Abstract of the United States 1993: table 163; 1993 CPI
from personal communication with BLS in June 1994). Eggers
does distinguish between the costs of a transplant using a cadaver
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Table 14—Estimated dialysis costs for chronic illness from E. coli O157:H7 disease, 19931
Dialysis Dialysis Total costs of dialysis
Year Age Low High costs/case2 Low2 High2
- - - - - - - - - - - -Number - - - - - - - - - - - -  - - -- - - - - - - - - - - - Dollars - - - - - - - - - - - - - - -
0 4 30 62 22,249 667,484 1,379,468
1 5 15 31 47,631 714,463 1,476,556
2 6 8 17 47,631 381,047 809,724
3 7 5 11 47,631 238,154 523,939
4 8 3 8 47,631 142,893 381,047
5 9 2 7 47,631 95,262 333,416
6 10 2 5 47,631 95,262 238,154
7 11 2 5 47,631 95,262 238,154
8 12 2 5 47,631 95,262 238,154
9 13 2 5 47,631 95,262 238,154
10 14 2 5 47,631 95,262 238,154
11 15 2 5 47,631 95,262 238,154
12 16 2 5 47,631 95,262 238,154
13 17 2 5 47,631 95,262 238,154
14 18 2 5 47,631 95,262 238,154
15 19 2 5 47,631 95,262 238,154
16 20 2 5 47,631 95,262 238,154
17 21 2 4 47,631 95,262 190,523
18 22 2 4 47,631 95,262 190,523
19 23 2 4 47,631 95,262 190,523
20 24 2 4 47,631 95,262 190,523
21 25 2 4 47,631 95,262 190,523
22 26 2 4 47,631 95,262 190,523
23 27 2 4 47,631 95,262 190,523
24 28 2 4 47,631 95,262 190,523
25 29 2 4 47,631 95,262 190,523
26 30 2 4 47,631 95,262 190,523
27 31 2 4 47,631 95,262 190,523
28 32 2 4 47,631 95,262 190,523
29 33 2 4 47,631 95,262 190,523
30 34 2 4 47,631 95,262 190,523
31 35 2 4 47,631 95,262 190,523
32 36 2 4 47,631 95,262 190,523
33 37 2 4 47,631 95,262 190,523
34 38 2 4 47,631 95,262 190,523
35 39 2 4 47,631 95,262 190,523
36 40 2 4 47,631 95,262 190,523
37 41 1 3 47,631 47,631 142,893
38 42 1 3 47,631 47,631 142,893
39 43 1 3 47,631 47,631 142,893
40 44 1 3 47,631 47,631 142,893
41 45 1 3 47,631 47,631 142,893
42 46 1 3 47,631 47,631 142,893
43 47 1 3 47,631 47,631 142,893
44 48 1 3 47,631 47,631 142,893
45 49 1 3 47,631 47,631 142,893
46 50 1 3 47,631 47,631 142,893
47 51 1 3 47,631 47,631 142,893
48 52 1 3 47,631 47,631 142,893
49 53 1 3 47,631 47,631 142,893
50 54 1 3 47,631 47,631 142,893
51 55 1 3 47,631 47,631 142,893
52 56 1 3 47,631 47,631 142,893
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Table 14—Estimated dialysis costs for chronic illness from E. coli O157:H7 disease, 19931--Continued
Dialysis Dialysis Total costs of dialysis
Year Age Low High costs/case2 Low2 High2
- - - - - - - - - - - -Number - - - - - - - - - - - -  - - -- - - - - - - - - - - - Dollars - - - - - - - - - - - - - - -
53 57 1 3 47,631 47,631 142,893
54 58 1 3 47,631 47,631 142,893
55 59 1 3 47,631 47,631 142,893
56 60 1 3 47,631 47,631 142,893
57 61 1 3 47,631 47,631 142,893
58 62 1 3 47,631 47,631 142,893
59 63 1 3 47,631 47,631 142,893
60 64 1 3 47,631 47,631 142,893
61 65 1 3 47,631 47,631 142,893
62 66 1 3 47,631 47,631 142,893
63 67 1 3 47,631 47,631 142,893
64 68 1 3 47,631 47,631 142,893
65 69 1 3 47,631 47,631 142,893
66 70 1 3 47,631 47,631 142,893
67 71 1 3 47,631 47,631 142,893
68 72 1 3 47,631 47,631 142,893
69 73 1 3 47,631 47,631 142,893
70 74 1 3 47,631 47,631 142,893
71 75 1 3 47,631 47,631 142,893
72 76 1 3 47,631 47,631 142,893
73 77 1 3 47,631 47,631 142,893
Total N/A N/A N/A N/A 6,954,757 16,621,341
N/A = Not applicable.
1 At this stage, costs have not been discounted.
2 Costs were rounded for this table.
Table 15—Estimated kidney transplant costs for chronic illness from E. coli O157:H7 disease, 1993
Transplant recipients Transplant Total cost of transplants
Year Low1 High1 cost/case2 Low3 High3
- - - - - -Number- - - - - - - - - - - - - - - - - - - Dollars - - - - - - - - - - - - -
0 0 0 110,844 0 0
1 15 31 110,844 1,622,663 3,436,171
2 6 12 110,844 665,065 1,330,131
3 3 5 110,844 332,533 554,221
4 1 3 110,844 110,844 332,533
5 1 1 110,844 110,844 110,844
6 0 1 110,844 0 110,844
Total 26 53 110,844 2,881,950 5,874,744
1 Given an estimated 30 to 62 cases of chronic illness due to HUS, transplant recipients were determined using HCFA data on end stage renal
disease in children (Eggers, personal communication with Marks, 1993).
2 Eggers (1993, table 49) provides an estimate of $89,600 per kidney transplant in 1991. This number was updated to 1993 dollars using the
general medical care CPI (1991 CPI from U.S. Statistical Abstract of the United States 1993: table 163: 1993 CPI from personal communication
with BLS in June 1994).
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Transplant recipients require immunosuppressant drug
therapy for the remainder of their lives to prevent the
body from attacking the foreign kidney cells.  While
advances in this type of drug therapy have occurred
over recent years, the possibility of rejection of the
new kidney still exists.  Drug therapy for survivors
costs $4,237.77 per year in 1993 dollars.64 The total
costs of drug therapy for the 30 to 62 cases of chronic
illness due to HUS is $4.7 million to $10.0 million
(not discounted at this stage) (table 16).
• Subtotal.  Estimated total medical costs for kidney
transplants, dialysis, and drug therapy for the 30 to
62 cases of chronic kidney failure caused by E. coli
O157:H7 disease were discounted at a rate of 3
percent to total $9.0-$19.5 million (table 17).
Productivity Losses for Acute E. Coli O157:H7
Disease
For those who do not die, the value of time lost is
derived by estimating the amount of time lost from
regular activities and multiplying it by the rate of
daily earnings.  Time spent by parents caring for sick
children, as well as payment to paid caretakers, is
included in the productivity loss estimates.  For cases
that required hospitalization, days of lost productivity
during recuperation were also considered.
Productivity losses because workers stayed home with
their sick children were approximated by the average
weekly earnings for production or nonsupervisory
workers in private nonagricultural jobs published by
BLS, plus estimated fringe benefits.65 Pre-tax wages
and fringe benefits are used because they approximate
the worker’s full marginal product.  We assumed
fringe benefits of 39 percent to cover health plans,
vacations, and retirement benefits.66 The average age
of the parent or paid caretaker was assumed to be 25-
44 years of age.  The value of an hour of time was
assumed to be the same for everyone, regardless of
gender or race.  Assuming a civilian labor force par-
ticipation rate of 84 percent for a typical labor force
aged 25 to 44 years (personal conversation between
U.S. BLS and Buzby, June 1994), the average daily
loss of productivity is $87.58.  Table 18 presents the
costs of lost productivity during acute illness caused
by E. coli O157:H7 by severity category.
• No physician visited.  For each of the estimated
5,000 to 10,000 children who had a mild illness and
did not visit a physician or a hospital, we assumed
that a parent or paid caretaker stayed home to take
care of the child and missed 2 days of work.  
Griffin and Tauxe (1991, p. 64) estimate that on
average, hemorrhagic colitis caused by E. coli
O157:H7 lasts from 6 to 8 days.  Because those
cases that did not seek medical care are even
milder than hemorrhagic colitis, we assumed that
these mild cases experienced 4 days of illness.
Evaluated at the average private sector wage rate of
roughly $88 per day, this productivity loss totals
$0.9-$1.8 million annually.
• Physician visit only.  For those 3,200 to 6,400 chil-
dren who visited a physician but were not hospital-
ized, we assumed 4 work days would be missed by
a parent or caretaker to take care of the sick child.
Evaluated at the average private sector wage rate of
$88 per day, the productivity loss totals between
$1.1 million and $2.2 million annually.
• Hospitalized for hemorrhagic colitis.  We assumed
that time spent at home recovering from hemorrhag-
ic colitis was twice as long as the number of days of
hospitalization.  Therefore, children with hemorrhag-
ic colitis were ill for a total of 19.5 days (6.5 days in
the hospital as previously mentioned, 13 days at
home).  We assumed parent or paid caretaker to be
with the child in the hospital and home with the
child until the child is well.  Adjusting for weekends,
the average time lost from work would be 14 days
which was evaluated at the average wage.  For the
estimated 1,340 to 2,630 cases with hemorrhagic
colitis who did not die, total productivity losses
ranged from $1.6 million to $3.2 million.67
67Out of the low estimate of 1,440 patients with hemorrhagic colitis,
100 died and 1,340 patients recovered. Similarly, out of the high
estimate of 2,880 patients with hemorrhagic colitis, 250 died and
2,630 recovered. Productivity losses for those who died are dis-
cussed in the deaths section.
64Cost estimate of $4,000 in 1990 is from conversation with
Eggers (and Marks, 1993), but was updated to 1993 dollars using
the general medical care CPI (1990 CPI from Statistical Abstract of
the United States 1993: table 163; 1993 CPI from personal com-
munication with BLS in June 1994).
65BLS reports that average weekly earnings in 1993 were $373.64
(BLS, Economic Indicators, July 1994). This translates into roughly
$74.73 per day.
66The Statistical Abstract of the United States 1993 (table 677)
provides employer costs for employee compensation per hour
worked and divides this total compensation into wage/salary (71.8
percent) and total benefit (28.2 percent) components. Fringe bene-
fits equal to 39 percent of wages were calculated by dividing the
proportion attributed to total benefits by the proportion attributed to
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Table 16—Estimated drug therapy costs for kidney transplant survivors, 19931
Transplant survivors Drug therapy Total costs, drug therapy
Year Age Low2 High2 costs/year3 Low High
Years  - - - - - -Number- - - - - - - - - - - - - - - - - - - -Dollars- - - - - - - - - - - - - -
0 4 0 0 0 0 0
1 5 14 29 4,238 59,329 122,895
2 6 19 39 4,238 80,518 165,273
3 7 21 44 4,238 88,983 186,462
4 8 21 44 4,238 88,983 186,462
5 9 21 44 4,238 88,983 186,462
6 10 20 44 4,238 84,755 186,462
7 11 20 42 4,238 84,755 177,986
8 12 20 42 4,238 84,755 177,986
9 13 19 41 4,238 80,518 173,749
10 14 19 41 4,238 80,518 173,749
11 15 19 41 4,238 80,518 173,749
12 16 19 41 4,238 80,518 173,749
13 17 18 41 4,238 76,280 173,749
14 18 18 40 4,238 76,280 169,511
15 19 18 40 4,238 76,280 169,511
16 20 18 40 4,238 76,280 169,511
17 21 18 40 4,238 76,280 169,511
18 22 18 39 4,238 76,280 165,273
19 23 18 36 4,238 76,280 152,560
20 24 17 36 4,238 72,042 152,560
21 25 16 36 4,238 67,804 152,560
22 26 16 36 4,238 67,804 152,560
23 27 16 36 4,238 67,804 152,560
24 28 16 36 4,238 67,804 152,560
25 29 16 35 4,238 67,804 148,322
26 30 16 35 4,238 67,804 148,322
27 31 16 35 4,238 67,804 148,322
28 32 16 35 4,238 67,804 148,322
29 33 16 35 4,238 67,804 148,322
30 34 16 35 4,238 67,804 148,322
31 35 16 34 4,238 67,804 144,084
32 36 15 34 4,238 63,567 144,084
33 37 15 34 4,238 63,567 144,084
34 38 15 33 4,238 63,567 139,846
35 39 15 32 4,238 63,567 135,609
36 40 15 31 4,238 63,567 131,371
37 41 15 31 4,238 63,567 131,371
38 42 15 30 4,238 63,567 127,133
39 43 15 30 4,238 63,567 127,133
40 44 15 30 4,238 63,567 127,133
41 45 15 30 4,238 63,567 127,133
42 46 15 30 4,238 63,567 127,133
43 47 15 30 4,238 63,567 127,133
44 48 15 30 4,238 63,567 127,133
45 49 14 30 4,238 59,329 127,133
46 50 14 29 4,238 59,329 122,895
47 51 14 29 4,238 59,329 122,895
48 52 13 29 4,238 55,091 122,895
49 53 13 29 4,238 55,091 122,895
50 54 13 29 4,238 55,091 122,895
51 55 13 29 4,238 55,091 122,895
52 56 13 29 4,238 55,091 122,895
53 57 13 29 4,238 55,091 122,895
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Table 16—Estimated drug therapy costs for kidney transplant survivors, 19931--Continued
Transplant survivors Drug therapy Total costs, drug therapy
Year Age Low2 High2 costs/year3 Low High
Years  - - - - - -Number- - - - - - - - - - - - - - - - - - - -Dollars- - - - - - - - - - - - - -
54 58 13 29 4,238 55,091 122,895
55 59 13 27 4,238 55,091 114,420
56 60 13 26 4,238 55,091 110,182
57 61 13 26 4,238 55,091 110,182
58 62 13 26 4,238 55,091 110,182
59 63 12 26 4,238 50,853 110,182
60 64 12 26 4,238 50,853 110,182
61 65 12 25 4,238 50,853 105,944
62 66 12 25 4,238 50,853 105,944
63 67 12 25 4,238 50,853 105,944
64 68 12 25 4,238 50,853 105,944
65 69 12 23 4,238 50,853 97,469
66 70 12 23 4,238 50,853 97,469
67 71 12 23 4,238 50,853 97,469
68 72 12 23 4,238 50,853 97,469
69 73 11 23 4,238 46,615 97,469
70 74 11 23 4,238 46,615 97,469
71 75 10 23 4,238 42,378 97,469
72 76 10 22 4,238 42,378 93,231 
73 77 10 22 4,238 42,378 93,231
Total N/A N/A N/A N/A 4,674,260 9,958,759 
N/A = Not applicable.
1At this stage, costs have not been discounted. Note that no transplants occurred in year 0.
2Transplant survivors in this table is the sum of those surviving with cadaver donor kidneys and living-related donor kidneys. Given the number
of transplants in the previous table, we use HCFA data on living-related donor transplant patient survival (1992, table 37, p. 42) and on cadaver
donor transplant patient survival (1992, table 36, p. 41), we assumed 56% of transplants used cadaver donors and 44% had living-related
donors (personal communication; Eggers and Marks, 1993).
3Cost estimate of $4,000 in 1990 is from conversation with Eggers and Marks, (1993), but was updated to 1993 using the general medical care
CPI (Statistical Abstract of the United States 1993: table 163 for 1990 CPI; personal communication with BLS in June 1994 for 1993 CPI).
• Hospitalized cases with acute HUS.  Of the estimated
260-470 children with acute HUS who were hospital-
ized but did not die, 230 to 408 recovered and 30 to 62
developed chronic illness due to HUS.  Productivity
losses for the chronic cases are discussed in the next
section.  Productivity losses for the acute HUS cases
were estimated in a parallel fashion to those hospital-
ized for hemorrhagic colitis where recuperation at
home is estimated to be twice the time spent in the hos-
pital (15 days in the hospital as previously mentioned,
30 days at home).  Adjusting for weekends, parents and
paid caretakers missed an estimated 32 days per case.
The total acute illness productivity losses for the 260 to
470 acute HUS cases who did not die were estimated
to range from $0.7 million to $1.3 million.
• Deaths.  For each of the 200 to 500 persons estimated
to die prematurely from acute E. coli O157:H7 disease
each year, the value of life was estimated at approxi-
mately $1.2 million in 1993 dollars, an average of the
values given for male and female children 4 years old,
according to Landefeld and Seskin’s adjusted human
capital/willingness-to-pay method.68 The total produc-
tivity loss associated with deaths from acute E. coli
O157:H7 disease cases was estimated to range from
$241.7 million to $604.2 million annually.
• Subtotal.  Productivity losses for the four disease
severity categories of acute E. coli O157:H7 dis-
ease were estimated to total between $246.1 mil-
lion and $612.8 million annually.
68Updated as previously described.48 Bacterial Foodborne Disease:  Medical Costs and Productivity Losses / AER-741                      Economic Research Service/USDA
Table 17—Estimated medical costs of chronic E. coli O157:H7 disease, 1993
Undiscounted medical costs   Discounted medical costs  
Year Age Low1 High1 Low2 High2
Years Dollars
0 4 667,484 1,379,488 667,484 1,379,468
1 5 2,436,455 5,035,623 2,365,490 4,888,954
2 6 1,126,630 2,305,128 1,061,957 2,172,804
3 7 659,680 1,264,622 603,701 1,157,309
4 8 342,730 900,041 304,511 799,675
5 9 295,099 630,722 254,555 544,066
6 10 180,017 535,460 150,761 448,440
7 11 180,017 416,141 146,370 338,360
8 12 180,017 416,141 142,107 328,505
9 13 175,779 411,903 134,720 315,689
10 14 175,779 411,903 130,796 306,494
11 15 175,779 411,903 126,987 297,567 
12 16 175,779 411,903 123,288 288,900
13 17 171,542 411,903 116,811 280,486
14 18 171,542 407,665 113,409 269,515
15 19 171,542 407,665 110,106 261,665
16 20 171,542 407,665 106,689 254,043
17 21 171,542 360,034 103,785 217,827
18 22 171,542 355,796 100,763 208,993
19 23 171,542 343,083 97,828 195,656
20 24 167,304 343,083 92,632 189,957
21 25 163,066 343,083 87,656 184,424
22 26 163,066 343,083 85,103 179,053
23 27 163,066 343,083 82,624 173,837
24 28 163,066 343,083 80,218 168,774
25 29 163,066 338,845 77,881 161,834
26 30 163,066 338,845 75,613 157,121
27 31 163,066 338,845 73,411 152,544
28 32 163,066 338,845 71,272 148,101
29 33 163,066 338,845 69,196 143,788
30 34 163,066 338,845 67,181 139,600
31 35 163,066 334,608 65,224 133,839
32 36 158,828 334,608 61,679 129,941
33 37 158,828 334,608 59,882 126,156
34 38 158,828 330,370 58,138 120,930
35 39 158,828 326,132 56,445 115,902
36 40 158,828 321,894 54,801 111,064
37 41 111,197 274,263 32,249 91,872
38 42 111,197 270,026 36,164 87,819
39 43 111,197 270,026 35,111 85,262
40 44 111,197 270,026 34,088 82,778
41 45 111,197 270,026 33,095 80,367
42 46 111,197 270,026 31,132 78,026
43 47 111,197 270,026 31,196 75,754
44 48 111,197 270,026 30,287 73,547
45 49 106,960 270,026 28,284 71,405
46 50 106,960 265,788 27,460 68,237
47 51 106,960 265,788 26,661 66,250
48 52 102,722 265,788 24,859 64,320
49 53 102,722 265,788 24,135 62,447
50 54 102,722 265,788 23,432 60,628
51 55 102,722 265,788 22,749 58,862
52 56 102,722 265,788 22,087 57,148
53 57 102,722 265,788 21,443 55,483
54 58 102,722 265,788 20,819 53,867
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Table 17—Estimated medical costs of chronic E. coli O157:H7 disease, 1993--Continued
Undiscounted medical costs   Discounted medical costs  
Year Age Low1 High1 Low2 High2
Years Dollars
55 59 102,722 257,312 20,212 50,631
56 60 102,722 253,075 19,624 48,346
57 61 102,722 253,075 19,052 46,938
58 62 102,722 253,075 18,497 45,571
59 63 98,484 253,075 17,217 44,244
60 64 98,484 253,075 16,716 42,955
61 65 98,484 248,837 16,229 41,006
62 66 98,484 248,837 15,756 39,811
63 67 98,484 248,837 15,298 38,652
64 68 98,484 248,837 14,852 37,526
65 69 98,484 240,361 14,419 35,192
66 70 98,484 240,361 13,999 34,167
67 71 98,484 240,361 13,592 33,172
68 72 98,484 240,361 13,196 32,206
69 73 94,246 240,361 12,260 31,268
70 74 94,246 240,361 11,903 30,357
71 75 90,009 240,361 11,037 29,473
72 76 90,009 236,123 10,715 28,110 
73 77 90,009 236,123 10,403 27,291
Total 14,501,967 32,454,843 8,977,515 19,482,273 
1 These costs have not been discounted and they are the sum of the costs of dialysis, kidney transplants, and drug therapy for chronic E. coli
O157:H7 disease patients, by year.
2 Discounted at 3 percent.
Table 18—Estimated productivity losses of acute E. coli 0157:H7 disease, 19931
Daily Work  Rate/ Cases Total costs2
Severity of illness wage rate2 missed case2 Low  High Low High
Dollars Days Dollars Number Million dollars
No physician visit3 88   2   175 5,000  10,000 0.9 1.8
Visited physician3 88   4   350 3,200  6,400 1.1 2.2
Hospitalized (and survived)4
Hemorrhagic colitis 88   14   1,220 1,340  2,630 1.6 3.2
HUS 88   32   2,815 260  470 0.7 1.3
Death during acute5 1,208,488 all   1,208,488 200  500 241.7 604.2
illness (present value)
Total N/A N/A N/A 10,000  20,000 246.1 612.8
N/A = Not applicable.
1 For those cases who do not die, lost productivity is derived by multiplying the amount of time lost from regular activities and by the rate of
daily earnings. We adjust BLS’s average weekly earnings for all private, nonagricultural jobs (BLS, Economic Indicators, July 1994) for fringe
benefits of 39% (of earnings, Statistical Abstract of the United States 1993: table 677) to cover health plans, vacations, and retirement benefits,
the civilian labor force participation rate of 84% for a typical work force aged 25-44 years (personal conversation with BLS and Buzby, June
1994), and five work days per week to get the average daily loss of productivity is $87.58.
2 Figures were rounded for this table.
3 Average duration of illness 6-8 days; (Griffin and Tauxe). We assume that parents and caretakers miss 2 days of work for those cases with
no physician visit and 4 days for cases with physician visit.
4 Assume work missed for 3 times the number of days hospitalized adjusted for weekends by multiplying by 5/7.
5 Landefeld and Seskin’s (1982) adjusted willingness to pay per human capital estimate for 4-year-olds, updated to 1993 prices using the
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Productivity Losses for Chronic Illness Due
to HUS
The annual productivity loss due to chronic illness
from HUS is the sum of the value of those who died
prematurely because of chronic illness due to HUS
and the survivors’ lost productivity (until the age of
16, the parents or caretakers’ time is valued for stay-
ing home to take care of the sick child and to take the
child to medical treatments).
• HUS survivors.  This category consists of two com-
ponents; productivity losses of caretakers of children
under 16 with HUS and productivity losses of HUS
patients over 16 years of age.  A parent or paid care-
taker is assumed to spend 18 hours out of a 40-hour
work week with their child’s hemodialysis treatment
as a hospital out-patient, or a loss of 45 percent of
work time during the initial year of illness.69 In the
second year, all children who did not yet receive a
transplant are assumed to have switched to peritoneal
dialysis, resulting in a 1-percent decline in productiv-
ity until the child is age 16 (Conversation with Mary
O’Shay, nurse in the pediatric ESRD unit in a hospi-
tal in Buffalo, New York, and Marks of ERS).70
Assuming the parent was in the 25 to 29-year-old
age group when the child was born (the modal age
group for first birth—Statistical Abstract of the
United States 1993: table 93), an average age of 31
is assumed when the child reaches the age of 4.
The value of annual productivity lost is computed
as the 45-percent (first year) and 1-percent (subse-
quent years) productivity loss times BLS’ average
weekly earnings times 52 for a 31-year-old in year
1 (for a 32-year-old in year 2, and so on) multiplied
by BLS’ labor force participation rate by age group
(personal conversation, BLS and Buzby, June 14,
1994) until year 12 when the child is 16.  The
reduced stream of earnings is converted into pre-
sent values.
At age 16 and after, productivity losses were comput-
ed by adjusting the patient’s annual earnings by age.
Transplant recipients 16 to 40 years of age have a 23-
percent productivity loss from what they would have
earned without any illness, 40-64 year olds a 39-per-
cent loss, and 65 plus a 13-percent loss (Garner 1984).
Dialysis patients aged 16 to 40 encounter a 37-percent
69Productivity losses for a parent or caretaker of a sick child (less
than 16 years of age) are based on the time necessary to obtain
treatment. Because over 80 percent of the chronically ill children
receive transplants by the fourth year after acute illness, these
productivity losses mostly involve taking the child to the hospital
for hemodialysis or caring for a child on peritoneal dialysis until
the transplant operation. Hemodialysis involves 4-hour treatments
three times per week at a hospital. Allowing a half hour before
and after each treatment for scheduling variability, 15 hours per
week are required for hemodialysis. In addition, there is travel
time to and from the hospital (estimated at 1 hour for each trip)
and time missed from school (3 half days per week). Most facili-
ties have Monday through Saturday hours, so conceivably treat-
ments can be scheduled after school or on Saturdays to avoid
missing school. (However, the 4-hour duration of treatments and
the limited number of dialysis machines limits the possibility of
after-school time). Some facilities do not have flexible scheduling.
Others offer tutoring to compensate for time missed from school.
Moreover, since children must go to hospital facilities and not to
free-standing facilities as adults can, travel time may be increased
to get to a limited number of facilities. Assuming 1 hour per trip
and no loss of school time, the minimum amount of time required
for children on hemodialysis is 18 hours per week. Since children
are encouraged to switch to peritoneal dialysis and then trans-
plantation as soon as possible, all of the patients’ parents/caretak-
ers require this time commitment for the half year of dialysis in the
acute phase and 24 percent require this time commitment by the
end of year 1, with the remainder assumed to be on peritoneal
dialysis by end of year 2. For a hemodialysis patient’s
parents/caretakers, 18 hours out of a 40-hour productive week
results in a 45 percent productivity loss.
70Among the two major types of peritoneal dialysis, Continuous
Ambulatory Peritoneal Dialysis (CAPD) and Continuous Cyclic
Peritoneal Dialysis (CCPD), CCPD is preferred for younger patients
and CAPD for older patients. CCPD requires a machine which fills
and drains solution into the child’s peritoneum while she/he sleeps (10
to 12 hours per night every night). This requires the help of a
parent/caretaker to connect the catheter to the child at night and dis-
connect it in the morning. While parents and the child can sleep dur-
ing the treatment, the child must be monitored (blood pressure,
weight, check for infections) during the day. Most, if not all, parents
can relegate these responsibilities, possibly to a school nurse, so that
they can still work full time. In rare instances, the parent may decide
to pull the child from school and oversee her/his care. This may hap-
pen in 1 to 2 percent of cases. We assume a 1 percent productivity
loss for a parent/caretaker of a child on CCPD peritoneal dialysis until
age 16. CAPD does not require a machine and, as such, provides
greater freedom. Instead, the solution required for dialysis is emptied
into a bag attached to the catheter leading to the peritoneum. The
solution is left in the abdomen for 4 hours and then emptied into a bag.
This draining process is done five times per day for children (4 times
per day for adults) and takes 30 to 40 minutes each time (totaling about
3 hours per day or 21 hours per week). Generally, a child needs help
by a parent/caretaker (possibly by the school nurse) with this process
until she/he is mature enough to do it by her/himself. Although the age
of maturity depends on the child, estimates are that between ages 11
and 16 the child can perform the exchange by her/himself. We assume
that by age 16, children will have switched from CCPD to CAPD peri-
toneal dialysis and that there will be no productivity loss for a
parent/caretaker since the child will be performing the procedure by
her/himself. While the child must also be monitored (blood pressure,
etc.) with CAPD, we assume parents will be able to work full-time
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loss, 40-64 have a 46-percent loss, and 65 plus a 5-
percent loss.  At and after time period 12, when the
patients are age 16 and over, 88 percent of all sur-
vivors have received transplants, while 12 percent
remain on dialysis.  The disability loss per year was
computed as the appropriate percentage productivity
loss times the average weekly earnings times 52
weeks multiplied by the labor force participation rate
by age group.  Given that the average life span in the
United States is 77 years, over this life span produc-
tivity lost for survivors of chronic illness due to HUS,
discounted at 3 percent annually, ranged from $2.7
million to $5.9 million.
Table 19 shows the present value of lost productivity
of survivors of chronic illness from E. coli O157:H7
disease for a typical year in 1993 dollars (undiscount-
ed and discounted at 3 percent).
• Chronic illness deaths.  As previously mentioned,
of the 30 to 62 cases with chronic illness due to
HUS (i.e., kidney failure), 19 to 37 died premature-
ly of complications during dialysis or a kidney
transplant operation (and an estimated 10 to 17 of
these children died before the age of 16)(HCFA
Medicare data, personal communication with
Eggers and Marks (ERS), 1991).  For those who
die prematurely from chronic illness due to HUS,
LS’s VOSL was used to represent the cost of lost
productivity.71 Table 20 shows the present value of
lost lives due to chronic illness from E. coli
O157:H7 disease for a typical year in 1993 dollars.
After discounting by 3 percent, the present value of
the productivity loss for the 19 to 37 premature
deaths from chronic illness due to HUS was esti-
mated at $14.5-$27.9 million.
• Subtotal.  The total productivity loss due to chronic
illness deaths and lost productive output ranged
from $17.3-$33.9 million annually.
Total Costs of E. Coli O157:H7 Disease from
All Sources
Total annual costs of E. coli O157:H7 disease in the
United States were estimated to range between $301.8
million and $726.0 million (table 21).  Estimated
medical costs total $38.4-$79.4 million and are small
relative to the estimated productivity losses which
total $263.3-$646.6 million.  Of the estimated medical
costs, costs for acute illness account for $29.4-$59.9
million annually and chronic costs range from $9.0-
$19.5 million.  Of the estimated productivity losses,
costs for acute illness account for $246.1-$612.8 mil-
lion, while chronic illness productivity losses total
between $17.3 million and $33.9 million (discounted
at a rate of 3 percent).  Deaths during the acute phase
of the illness are the largest cost component account-
ing for roughly 81 percent of all costs.
Note that these cost estimates vary from those found
in Roberts and Marks (1995) largely because we: (1)
used improved incidence estimates, (2) divided acute
illness deaths differently, and (3) reported estimates in
1993 dollars as opposed to 1992 dollars.
Medical costs are only 12 percent of total estimated
costs, roughly 9 percent during the acute illness and 3
percent during chronic illness due to HUS (i.e., kid-
ney failure).  Productivity losses account for 88 per-
cent of estimated costs: 81 percent for persons who
die during the acute phase of the illness, 2 percent for
persons who survive the acute illness, 4 percent for
persons who die during the chronic illness, and 1 per-
cent for survivors with reduced productivity because
of chronic illness due to HUS.72
Costs of Foodborne E. Coli O157:H7 Disease
If we assume that 80 percent of the estimated human
illnesses due to E. coli O157:H7 are attributed to
food, the estimated total costs of foodborne E. coli
O157:H7 disease ranges from $0.2-$0.6 billion annu-
ally.  The assumption that 80 percent of all E. coli
O157:H7 cases are from food (CDC unpublished out-
break data) appears reasonable in light of the relative-
ly low number of cases from contaminated water and
Martin et al.’s (1990) estimate that an upper bound of
16 percent of cases are from person-to-person transmis-
sion in day care centers.
Remarks
Some HUS cases have more than one transplant
operation but only one was included in the costs.  A
few HUS cases have multiple complications, includ-
ing blindness, cardiac involvement, respiratory com-
71LS’s VOSL updated to 1993 dollars and averaged across gender,
as previously described.
72These are approximations of the ranges used in the analysis.Table 19—Present value of lost productivity of survivors due to chronic illness from E. coli O157:H7 disease, 1993
Dialysis Transplant Productivity loss
Total survivors Recipient Dis. loss/ Disability loss Survivors Dis. loss/ Disability loss Undiscounted Discounted
Year Age Low High Low High recipient Low High Low High case Low High Low1 High1 Low2 High2
- - - - - - - - - - - - - Number - - - - - - - - - - - - - - -         - - - - - - Dollars - - - - -                    - - Number - -        - - - - - - - - - - - - - - - - - - - - - - - Dollars - - - - - - - - - - - - - - - - - - - - -
0 4 30 62 30 62 5,906 177,175 366,162 177,175 366,162 177,175 366,162
1 5 28 58 15 31 5,879 88,183 182,245 14 29 281 3,933 8,148 92,116 190,393 89,433 184,847
2 6 27 55 8 17 281 2,248 4,776 19 39 281 5,338 10,957 7,586 15,734 7,150 14,830
3 7 25 55 5 11 281 1,405 3,091 21 44 281 5,900 12,362 7,305 15,453 6,685 14,141
4 8 24 52 3 8 341 1,023 2,728 21 44 341 7,162 15,007 8,185 17,735 7,273 15,757
5 9 23 50 2 7 341 682 2,387 21 44 341 7,162 15,007 7,844 17,394 6,767 15,004
6 10 22 49 2 5 341 682 1,705 20 44 341 6,821 15,007 7,503 16,712 6,284 13,996
7 11 22 47 2 5 341 682 1,705 20 42 341 6,821 14,324 7,503 16,030 6,101 13,034
8 12 22 47 2 5 341 682 1,705 20 42 341 6,821 14,324 7,503 16,030 5,923 12,654
9 13 21 46 2 5 341 682 1,705 19 41 341 6,480 13,983 7,162 15,689 5,489 12,024
10 14 21 46 2 5 341 682 1,705 19 41 341 6,480 13,983 7,162 15,689 5,329 11,674
11 15 21 46 2 5 341 682 1,705 19 41 341 6,480 13,983 7,162 15,689 5,174 11,334
12 16 21 46 2 5 1,455 2,910 7,275 19 41 1,455 27,644 59,653 30,554 66,928 21,430 46,942
13 17 20 46 2 5 1,455 2,910 7,275 18 41 1,455 26,189 59,653 29,099 66,928 19,815 45,574
14 18 20 45 2 5 2,247 4,494 11,235 18 40 2,247 40,445 89,877 44,939 101,112 29,710 66,847
15 19 20 45 2 5 2,247 4,494 11,235 18 40 2,247 40,445 89,877 44,939 101,112 28,844 64,900
16 20 20 44 2 5 5,708 11,417 28,542 18 40 5,708 102,750 228,333 114,166 256,874 71,145 160,076
17 21 20 44 2 4 5,708 11,417 22,833 18 40 5,708 102,750 228,333 114,166 251,166 69,073 151,960
18 22 20 43 2 4 5,708 11,417 22,833 18 39 5,708 102,750 222,624 114,166 245,458 67,061 144,181
19 23 20 40 2 4 5,708 11,417 22,833 18 36 5,708 102,750 205,499 114,166 228,333 65,107 130,215
20 24 19 40 2 4 5,708 11,417 22,833 17 36 5,708 97,041 205,499 108,458 228,333 60,051 126,422
21 25 18 40 2 4 10,397 20,794 41,587 16 36 10,397 166,349 374,284 187,142 415,871 100,598 223,551
22 26 18 40 2 4 10,397 20,794 41,587 16 36 10,397 166,349 374,284 187,142 415,871 97,668 217,040
23 27 18 40 2 4 10,397 20,794 41,587 16 36 10,397 166,349 374,284 187,142 415,871 94,823 210,719
24 28 18 40 2 4 10,397 20,794 41,587 16 36 10,397 166,349 374,284 187,142 415,871 92,061 204,581
25 29 18 39 2 4 10,397 20,794 41,587 16 35 6,580 105,285 230,312 126,079 271,899 60,216 129,860
26 30 18 39 2 4 10,397 20,794 41,587 16 35 6,580 105,285 230,312 126,079 271,899 58,462 126,078
27 31 18 39 2 4 10,397 20,794 41,587 16 35 6,580 105,285 230,312 126,079 271,899 56,759 122,406
28 32 18 39 2 4 10,397 20,794 41,587 16 35 6,580 105,285 230,312 126,079 271,899 55,106 118,841
29 33 18 39 2 4 10,397 20,794 41,587 16 35 6,580 105,285 230,312 126,079 271,899 53,501 115,379
30 34 18 39 2 4 10,397 20,794 41,587 16 35 6,580 105,285 230,312 126,079 271,899 51,943 112,019
31 35 18 38 2 4 12,621 25,242 50,483 16 34 7,988 127,808 271,591 153,049 322,074 61,218 128,826
32 36 17 38 2 4 12,621 25,242 50,483 15 34 7,988 119,820 271,591 145,061 322,074 56,333 125,073
33 37 17 38 2 4 12,621 25,242 50,483 15 34 7,988 119,820 271,591 145,061 322,074 54,692 121,431
34 38 17 37 2 4 12,621 25,242 50,483 15 33 7,988 119,820 263,603 145,061 314,086 53,099 114,970
35 39 17 36 2 4 12,621 25,242 50,483 15 32 7,988 119,820 255,615 145,061 306,099 51,552 108,782
36 40 16 34 2 4 12,621 25,242 50,483 15 31 7,988 119,820 247,627 145,061 298,111 50,051 102,858
37 41 16 34 1 3 12,621 12,621 37,862 15 31 7,988 119,820 247,627 132,440 285,490 44,365 95,634
38 42 16 33 1 3 12,621 12,621 37,862 15 30 7,988 119,820 239,639 132,440 277,502 43,073 90,251
39 43 16 33 1 3 12,621 12,621 37,862 15 30 7,988 119,820 239,639 132,440 277,502 41,819 87,622
40 44 16 33 1 3 12,621 12,621 37,862 15 30 7,988 119,820 239,639 132,440 277,502 40,601 85,070
41 45 16 33 1 3 15,984 15,984 47,953 15 30 13,464 201,958 403,916 217,942 451,869 64,866 134,489
42 46 16 33 1 3 15,984 15,984 47,953 15 30 13,464 201,958 403,916 217,942 451,869 62,976 130,572
43 47 16 33 1 3 15,984 15,984 47,953 15 30 13,464 201,958 403,916 217,942 451,869 61,142 126,769







































































































































ATable 19—Present value of lost productivity of survivors due to chronic illness from E. coli O157:H7 disease, 1993--Continued
Dialysis Transplant Productivity loss
Total survivors Recipient Dis. loss/ Disability loss Survivors Dis. loss/ Disability loss Undiscounted Discounted
Year  Age Low High Low High recipient Low High Low High case Low High Low1 High1 Low2 High2
- - - - - - - - - - - - - Number - - - - - - - - - - - - - - -         - - - - - - Dollars - - - - -                    - - Number - -        - - - - - - - - - - - - - - - - - - - - - - - Dollars - - - - - - - - - - - - - - - - - - - - -
44 48 16 33 1 3 15,984 15,984 47,953 15 30 13,464 201,958  403,916 217,942 451,869 59,361 123,076
45 49 15 33 1 3 15,984 15,984 47,953 14 30 13,464 188,494  403,916 204,478 451,869 54,072 119,492
46 50 15 32 1 3 15,984 15,984 47,953 14 29 13,464 188,494  390,452 204,478 438,405 52,497 112,555
47 51 15 32 1 3 15,984 15,984 47,953 14 29 13,464 188,494  390,452 204,478 438,405 50,968 109,276
48 52 14 32 1 3 15,984 15,984 47,953 13 29 13,464 175,030  390,452 191,015 438,405 46,225 106,093
49 53 14 32 1 3 15,984 15,984 47,953 13 29 13,464 175,030  390,452 191,015 438,405 44,879 103,003
50 54 14 32 1 3 15,984 15,984 47,953 13 29 13,464 175,030  390,452 191,015 438,405 43,572 100,003
51 55 14 32 1 3 9,667 9,667 29,002 13 29 8,143 105,858  236,145 115,525 265,147 25,585 58,720
52 56 14 32 1 3 9,667 9,667 29,002 13 29 8,143 105,858  236,145 115,525 265,147 24,839 57,010
53 57 14 32 1 3 9,667 9,667 29,002 13 29 8,143 105,858  236,145 115,525 265,147 24,116 55,350
54 58 14 32 1 3 9,667 9,667 29,002 13 29 8,143 105,858  236,145 115,525 265,147 23,414 53,737
55 59 14 30 1 3 9,667 9,667 29,002 13 27 8,143 105,858  219,859 115,525 248,861 22,732 48,968
56 60 14 29 1 3 9,667 9,667 29,002 13 26 8,143 105,858  211,716 115,525 240,718 22,070 45,986
57 61 14 29 1 3 9,667 9,667 29,002 13 26 8,143 105,858  211,716 115,525 240,718 21,427 44,646
58 62 14 29 1 3 9,667 9,667 29,002 13 26 8,143 105,858  211,716 115,525 240,718 20,803 43,346
59 63 13 29 1 3 9,667 9,667 29,002 12 26 8,143 97,715  211,716 107,383 240,718 18,773 42,084
60 64 13 29 1 3 9,667 9,667 29,002 12 26 8,143 97,715  211,716 107,383 240,718 18,226 40,858
61 65 13 28 1 3 129 129 387 12 25 317 3,799  7,915 3,928 8,302 647 1,368
62 66 13 28 1 3 129 129 387 12 25 317 3,799  7,915 3,928 8,302 628 1,328
63 67 13 28 1 3 129 129 387 12 25 317 3,799  7,915 3,928 8,302 610 1,290
64 68 13 28 1 3 129 129 387 12 25 317 3,799  7,915 3,928 8,302 592 1,252
65 69 13 26 1 3 129 129 387 12 23 317 3,799  7,282 3,928 7,669 575 1,123
66 70 13 26 1 3 129 129 387 12 23 317 3,799  7,282 3,928 7,669 558 1,090
67 71 13 26 1 3 129 129 387 12 23 317 3,799  7,282 3,928 7,669 542 1,058
68 72 13 26 1 3 129 129 387 12 23 317 3,799  7,282 3,928 7,669 526 1,028
69 73 12 26 1 3 129 129 387 11 23 317 3,483  7,282 3,612 7,669 470 998
70 74 12 26 1 3 129 129 387 11 23 317 3,483  7,282 3,612 7,669 456 969
71 75 11 26 1 3 129 129 387 10 23 317 3,166  7,282 3,295 7,669 404 940
72 76 11 25 1 3 129 129 387 10 22 317 3,166  6,965 3,295 7,352 392 875
73 77 11 25 1 3 129 129 387 10 22 317 3,166  6,965 3,295 7,352 381 850
Total in millions N/A N/A N/A N/A 1.0 2.4 N/A N/A N/A N/A 6.2  13.3 7.2 15.6 2.7 5.9
N/A = Not applicable.
1 These costs have not been discounted.
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Total deaths earnings earnings Productivity loss due to deaths  
Year Age Low High in 1993 $ in 1993 $1 Low High
- - - - - - - Number - - - - - - -     - - - - - - - - - - - - - - - - - - - - - Dollars - - - - - - - - - - - - - - - - - - - - - - - -
1 5 2 4 1,232,869 1,196,960 2,393,920 4,787,840
2 6 1 3 1,257,249 1,185,078 1,185,078 3,555,234
3 7 2 0 1,281,630 1,172,873 2,345,745 0
4 8 1 3 1,308,213 1,162,330 1,162,330 3,486,991
5 9 1 2 1,334,796 1,151,407 1,151,407 2,302,814
6 10 1 1 1,361,379 1,140,134 1,140,134 1,140,134
7 11 0 2 1,387,962 1,128,541 0 2,257,081
8 12 0 0 1,414,546 1,116,655 0 0
9 13 1 1 1,438,530 1,102,513 1,102,513 1,102,513
10 14 0 0 1,462,514 1,088,247 0 0
11 15 0 0 1,486,497 1,073,877 0 0
12 16 0 0 1,510,481 1,059,421 0 0
13 17 1 0 1,534,465 1,044,896 1,044,896 0
14 18 0 1 1,544,493 1,021,092 0 1,021,092
15 19 0 0 1,554,521 997,788 0 0
16 20 0 1 1,564,549 974,975 0 974,975
17 21 0 0 1,574,577 952,645 0 0
18 22 0 1 1,584,605 930,789 0 930,789
19 23 0 3 1,574,730 898,047 0 2,694,140
20 24 1 0 1,564,855 866,422 866,422 0
21 25 1 0 1,554,980 835,878 835,878 0
22 26 0 0 1,545,105 806,379 0 0
23 27 0 0 1,535,229 777,888 0 0
24 28 0 0 1,506,486 741,091 0 0
25 29 0 1 1,477,742 705,778 0 705,778
26 30 0 0 1,448,998 671,893 0 0
27 31 0 0 1,420,254 639,383 0 0
28 32 0 0 1,391,510 608,197 0 0
29 33 0 0 1,361,425 577,716 0 0
30 34 0 0 1,331,340 548,495 0 0
31 35 0 1 1,301,255 520,485 0 520,485
32 36 1 0 1,271,170 493,642 493,642 0
33 37 0 0 1,241,085 467,922 0 0
34 38 0 1 1,205,340 441,208 0 441,208
35 39 0 1 1,169,594 415,654 0 415,654
36 40 1 2 1,133,849 391,215 391,215 782,429
37 41 0 0 1,098,104 367,846 0 0
38 42 0 1 1,062,358 345,507 0 345,507
39 43 0 0 1,018,773 321,681 0 0
40 44 0 0 975,188 298,950 0 0
41 45 0 0 931,602 277,271 0 0
42 46 0 0 888,017 256,601 0 0
43 47 0 0 844,431 236,899 0 0
44 48 0 0 803,427 218,831 0 0
45 49 1 0 762,423 201,614 201,614 0
See footnotes at end of table. –ContinuedEconomic Research Service/USDA                      Bacterial Foodborne Disease:  Medical Costs and Productivity Losses / AER-741     55
plications, neurological damage, pancreatic destruc-
tion, and intestinal surgery such as colostomy.  One
mother wrote that her surviving child’s medical bills
during his intensive care were $300,000 (Heersink
1994).
The January 1993 E. coli O157:H7 outbreak in the
Northwest demonstrates the difficulty of identifying
the incidence of foodborne diseases and the need for
new data collection systems.  CDC reported:
“Despite the magnitude of this outbreak (with 500
culture-confirmed cases and 4 deaths in four States),
the problem may not have been recognized in three
States if the epidemiological link had not been estab-
lished in Washington” (CDC April 16, 1993, p.
262).73 CDC claims that reports of subsequent E.
coli O157:H7 outbreaks are increasing, largely
because of increased public awareness (FDA
Consumer 1994, p. 1923).




Total deaths earnings earnings Productivity loss due to deaths  
Year Age Low High in 1993 $ in 1993 $1 Low High
- - - - - - - Number - - - - - - -   - - - - - - - - - - - - - - - - - - - - - Dollars - - - - - - - - - - - - - - - - -- - - - - -
46 50 0 1 721,418 185,214 0 185,214
47 51 0 0 680,414 169,599 0 0
48 52 1 0 639,410 154,736 154,736 0
49 53 0 0 598,929 140,719 0 0
50 54 0 0 558,449 127,386 0 0
51 55 0 0 517,969 114,711 0 0
52 56 0 0 477,489 102,666 0 0
53 57 0 0 437,009 91,226 0 0
54 58 0 0 401,484 81,369 0 0
55 59 0 2 365,960 72,009 0 144,018
56 60 0 1 330,436 63,125 0 63,125
57 61 0 0 294,911 54,698 0 0
58 62 0 0 259,387 46,708 0 0
59 63 1 0 237,002 41,434 41,434 0
60 64 0 0 214,617 36,428 0 0
61 65 0 1 192,232 31,678 0 31,678
62 66 0 0 169,847 27,174 0 0
63 67 0 0 147,462 22,905 0 0
64 68 0 0 136,672 20,611 0 0
65 69 0 2 125,881 18,431 0 36,861
66 70 0 0 115,090 16,360 0 0
67 71 0 0 104,300 14,394 0 0
68 72 0 0 93,509 12,529 0 0
69 73 1 0 86,870 11,301 11,301 0
70 74 0 0 80,231 10,133 0 0
71 75 1 0 73,592 9,024 9,024 0
72 76 0 1 66,953 7,971 0 7,971
73 77 0 0 60,314 6,971 0 0
Total N/A 19 37 N/A N/A 14,531,290 27,933,531
N/A = Not applicable.
1 Discounted at 3%.
73As previously mentioned, the 1994 AGA Consensus Conference
(1995, p. 1923) estimates that this outbreak caused over 700
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Table 21—Cost summary for U.S. E. coli O157:H7 disease cases, 19931
Estimated cost
Cost category Table Low High
Million dollars
Medical costs:2
Acute illness medical costs—
No physician visit 0.0 0.0
Physician visit 0.5 2.0
Hospitalized-hemorrhagic colitis 16.2 32.4
Hospitalized-HUS 12.7 25.5
Subtotal 13 29.4 59.9
Chronic illness medical costs
Chronic cases (present value) 17 9.0 19.5
Total medical costs 38.4 79.4
Productivity losses:3
Acute illness productivity losses—
No physician visit 0.9 1.8
Visited physician 1.1 2.2
Hospitalized-hemorrhagic colitis 1.6 3.2
Hospitalized-HUS 0.7 1.3
Deaths (present value) 241.7 604.2
Subtotal  18 246.1 612.8
Chronic illness productivity losses—
Survivors (present value) 19 2.7 5.9
Deaths (present value) 20 14.5 27.9
Subtotal  17.3 33.9
Total productivity losses 263.3 646.6
Total       301.8 726.0
If 80% are foodborne, foodborne costs are $0.2-0.6 billion annually.
1Numbers may not total due to rounding.
2Medical costs were estimated using data from the American Hospital Association’s Hospital Statistics and the U.S. Health Care Financing
Administration.
3Productivity losses were estimated using data from the U.S. Bureau of Labor Statistics and Landefeld and Seskin’s (1982) estimated values
of statistical life. The 219-537 premature deaths include 200-500 deaths from the acute illness and 19-37 deaths from chronic complications.Economic Research Service/USDA                      Bacterial Foodborne Disease:  Medical Costs and Productivity Losses / AER-741     57
COI Estimates of Listeriosis
Listeriosis is the disease caused by the infectious bac-
terium, Listeria monocytogenes.  Listeriosis may have
a bimodal distribution of severity with most cases
being either mild or severe (CAST 1994, p. 51).
Milder cases of listeriosis are characterized by a sud-
den onset of fever, severe headache, vomiting, and
other influenza-type symptoms.  Reported cases of lis-
teriosis are often manifested as septicemia and/or
meningoencephalitis and may also involve delirium
and coma (Benenson 1990, p. 250).  Listeriosis may
cause premature death in fetuses, newborns, and some
adults or cause developmental complications for fetus-
es and newborns.
Listeria can grow at refrigeration temperatures (CAST
1994, p. 32; Pinner et al. 1992, p. 2049).  There is no
consensus as to the infectious dose of Listeria, though
research has shown that humans can be exposed to
high doses by consuming some common contaminat-
ed foods.  For example, Listeria can grow to extreme-
ly high cell count levels in hot dogs, soft cheeses, and
pâté (Pinner et al. 1992, p. 2049).
The incubation period for listeriosis is 4 days to sever-
al weeks.  The duration of illness may last a few days
or several weeks (CAST 1994, p. 12).  The United
States has a regulatory policy of zero tolerance of
Listeria monocytogenes in all ready-to-eat foods
(CAST 1994, p. 65).  At any given time, a large per-
centage of all people will have Listeria organisms in
their bodies without becoming ill.  In addition to a
bimodal distribution of severity, there appears to be a
bimodal age distribution as well with the majority of
cases occurring in the very young or in those older
than 40 years old.  Benenson (1990, p. 251) states that
30 percent of clinical cases of listeriosis occur in indi-
viduals younger than 3 weeks old and that most adults
with listeriosis are older than 40 years of age.  This
age distribution is largely because Listeria is more
likely to cause severe illnesses and death in persons
with compromised immune systems (i.e., people with
AIDS, cancer, diabetes, heart disease, or renal dis-
ease) or in those with immature immune systems
(e.g., fetuses) (Schwartz et al. 1988 in CAST 1994, p.
52).  
Listeriosis may appear mild in healthy adults and
more severe in the elderly and the immunocompro-
mised.  Illnesses identified by CDC’s hospital surveil-
lance shows three well-defined risk groups:  pregnant
women, newborn/fetal cases, and other adults (i.e.,
adults who are not pregnant women)(Roberts and
Pinner 1990).  Listeriosis in pregnant women is usual-
ly relatively mild and may be manifested as a flu-like
syndrome or placental infection.  They are hospital-
ized for observation.  Because of data limitations, the
less severe cases are not considered here.
Infected pregnant women can transmit the disease to
their newborns/fetuses either before or during deliv-
ery.  Infected newborns/fetuses may be stillborn,
develop meningitis (inflammation of the tissue sur-
rounding the brain and/or spinal cord) in the neonatal
period, or are born with septicemia (syndrome of
decreased blood pressure and capillary leakage)
(Benenson 1990, p. 250).74 Septicemia and meningi-
tis can both be serious and life-threatening.  A portion
of babies with meningitis will go on to develop chron-
ic neurological complications.  
Other adults with listeriosis typically develop sepsis
or meningitis syndromes.  Almost 90 percent of these
adults were estimated to have one or more underlying
diseases, including cancer, diabetes, renal disease,
heart disease, and AIDS (Schwartz et al. 1988).
Occasionally, milder disease syndromes, such as
abscesses or other local infections will occur but these
may remain undetected by CDC’s active surveillance,
which counts specimens taken from normally sterile
locations, namely blood and cerebrospinal fluid.  
Of all listeriosis cases, roughly 85-95 percent are
attributed to food (Schuchat 1994).  Listeria has been
isolated on foods such as raw milk products, vegeta-
bles, seafood, poultry, red meat, and liquid whole egg
(CAST 1994, p. 32).  Consuming non-reheated hot
dogs and undercooked poultry were implicated as risk
factors for listeriosis in a 1988 CDC study (Tappero et
al. 1995, p. 1119).  In samples of uncooked meat and
poultry from seven countries, up to 70 percent had
detectable levels of Listeria (Farber 1993 and Shelef
1989 in CAST 1994, p. 32).  Schuchat et al. (1992, p.
2041) found that 32 percent of the 165 culture-con-
firmed listeriosis cases could be attributed to eating
food purchased from store delicatessen counters or
soft cheeses.  In Pinner et al.’s (1992, p. 2047) micro-
biologic survey of refrigerated foods specimens
obtained from households with listeriosis patients, 36
percent of the beef samples and 31 percent of the
poultry samples were contaminated with Listeria.
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Estimates of Cases
We update Roberts and Pinner’s (1990) COI analysis
to estimate the annual costs of listeriosis.  We do not
have estimates for mild cases, only hospitalized cases.
The estimate of 1,860 listeriosis cases occurring annu-
ally in the United States originates from an extrapola-
tion to the U.S. population of incidence data from a
CDC-conducted surveillance study of hospitals in six
geographic regions in 1986 and 1987 (Gellin et al.
1987).75 This is the largest population-based listerio-
sis study in the United States.  The case estimate of
1,860 includes 65 fetal cases (stillbirths or sponta-
neous abortions).  If fetal cases were excluded, the
estimated number of cases would decline to 1,795.
We considered an estimated range of 1,795-1,860
cases annually.76
The CDC study also estimated incidence rates by dis-
ease syndrome, age group, and outcome (whether the
patient lived or died).  This information was used to
define the three risk groups.  In this analysis, maternal
cases and all other adult cases are classified as acute
cases and do not develop chronic complications.  All
newborn/fetal cases are initially considered acute and
some develop chronic complications.  All acute and
chronic listeriosis cases are assumed to require hospi-
talization.  This is a reasonable assumption because
all the observed cases were diagnosed by hospitals.
Roberts and Pinner (1990) applied the CDC estimates
to the U.S. population to get national estimates for
each risk group.  Their estimates were used in this
analysis.  The annual number of pregnant women who
have listeriosis is estimated at 252.  The estimated
annual number of newborn/fetal cases ranges between
295 and 360.77 An estimated 1,248 other adults have
listeriosis per year.  Table 22 presents the annual cases
of acute and chronic listeriosis, divided into disease
severity categories (no physician visit, visited a physi-
cian, hospitalized, and died).  Figure 10 presents liste-
riosis cases and disease outcomes.
Of the estimated 252 pregnant women with listeriosis
each year, all cases are acute and expected to survive
their illness.  Of the estimated 295 to 360
newborn/fetal acute illness cases each year, 14 to 79
die prematurely because of the acute illness and 281
survive.  Of the 281 newborn/fetal cases who survive
the acute illness, 43 develop chronic complications
that leave them with some level of permanent disabili-
75These areas included the States of Missouri, New Jersey,
Oklahoma, Tennessee, and Washington, as well as Los Angeles
County.
76 Tappero et al. (1995) found that the incidence of listeriosis had
decreased since the 1960’s and that projections from surveillance
data suggest that there were 1,092 listeriosis cases and 248
deaths in 1993. Tappero et al. was published after this analysis
was concluded.
77The number of newborn/fetal cases is larger than the number of
maternal cases, because the mother is often asymptomatic
although she transmits the disease to her infant.
Table 22—Estimated U.S. listeriosis cases, 19931
Severity Cases
of illness Low High
Number
Acute:
No physician visit 0 0








Other adult 431 431
Total acute cases 1,795 1,860
Chronic:
No physician visit 0 0








Other adult 0 0
Total chronic cases 43 43
1 Following Roberts and Pinner (1990) Ch. 22 in (Foodborne
Listeriosis), we assume that each year, there are 252 maternal lis-
teriosis cases, 295 to 360 newborn/fetal cases, and 1,248 other
adult cases. Cases that do not require hospitalization are not
included because of data limitations.
2 Total hospitalized and survived are shown in this section. Those
who died were also hospitalized and when combined with this sec-
tion, there are 1,795-1,860 hospitalized cases.
3 Total deaths range from 445 to 510. High estimate for new
born/fetal cases includes 65 fetal deaths. Hospitalization costs for
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ty.  Of the estimated 1,248 other adults with acute lis-
teriosis, 817 survive the illness and 431 die each year.
This death rate of 34.5 percent for other adults is
close to the 33-percent death rate given by Benenson
for non-pregnant adults with listeriosis (1990, p.
250).
Costs of Listeriosis
As in the COI for E. coli O157:H7 disease, listerio-
sis cases are divided into acute and chronic disease
categories.  Again, several nationwide databases
were used in this analysis, such as the American
Hospital Association’s Hospital Statistics, which
provided data on daily costs of hospitalization.
Table 23 presents the assumptions used for the COI
analysis for listeriosis.  
Medical Costs for Acute Listeriosis
Acute illness medical costs include the costs of regu-
lar hospital rooms, ICU rooms, physician services,
and other fees associated with both types of hospital
rooms.  Table 24 presents the estimated medical costs
of acute listeriosis by severity category.
• No physician visited.  No estimate was made for
milder illnesses.
• Physician visit only.  No estimate was made for
milder illnesses.
• Hospitalized.  CDC case estimates are based on
finding Listeria in spinal and brain fluid in hospital-
ized patients.  As previously mentioned, the three
demographic groups of listeriosis patients identified
are maternal cases, newborn/fetal cases, and other
adults.  As in the COI analysis on E. coli O157:H7
disease, we used the average cost to community
hospitals per patient per day in 1993 dollars
($887).78 As in Roberts and Pinner (1990), fees for
laboratory tests, supplies, medications, and physi-
cian visits while hospitalized are assumed to equal
the costs of hospitalization but were updated using
78In 1991, the daily hospitalization cost per person was estimated
at $752 per patient (American Hospital Association in Statistical
Abstract of the United States 1993 (table 182). This estimate was
updated to 1993 dollars using the change in the hospital room CPI
(1991 CPI from the Statistical Abstract of the United States 1993:
table 163, and the 1993 CPI from personal correspondence with
BLS in June 1994).Table 23—Assumptions used to estimate annual costs of illness for listeriosis, 1993
Cost category & severity Costs during acute illness Costs during chronic illness 
Overview: Incremental costs Estimates of new cases annually are divided into severity level categories to  Some survivors develop chronic conditions. All lifetime
due to foodborne disease estimate costs. Acute illness costs are not discounted, except for productivity costs are discounted at 3 percent per year to calculate the 
losses for deaths occurring during the acute illness. 1993 present value.
Medical costs
No physician visit  No cases or medical costs estimated. Not estimated.
Visited physician No cases or medical costs estimated. Not estimated.
Hospitalized Hospital room cost is the American Hospital Association’s average cost per day. For known chronic conditions associated with the
An intensive care room is assumed to be double the cost of a regular room. foodborne illness, chronic costs are computed the same
Total fees for physician care, laboratory tests, and medications during as acute costs, except that they are computed for the
hospitalization are assumed to be equal to hospital room costs. remaining life of an individual and discounted back to 
1993 using a 3 percent discount rate.
Productivity losses 
No physician visit No cases or productivity losses estimated. Not estimated.
Visited physician No cases or productivity losses estimated. Not estimated.
Hospitalized Time away from work is assumed to be three times the days in the hospital,  The average weekly earnings are multiplied by 52 weeks,
adjusted for weekends. The cost per day is estimated by adjusting BLS average adjusted by the labor force participation rate for the age of
weekly earnings as above. the patient, and multiplied by the percentage of productive
capacity lost. Or, an estimate of the proportion of
productivity lost because of the disability is multiplied by
Landefeld and Seskin’s (1982) value of life according to the
age of the patient to get the marginal lifetime productivity
lost.
Death The present value of a statistical life lost is computed as the average of male and The value of a statistical life lost to chronic illness is
female values given by Landefeld and Seskin (1982) for each age, updated to Landefeld and Seskin (1982) value for the age of the
1993 values using the change in average weekly earnings. person in the year he/she dies, discounted back to 1993.
Other costs: education, Not estimated. Not estimated
nursing home, lost leisure,
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Table 24—Estimated medical costs from acute listeriosis, 19931
Severity Unit Days/ Cost/ Cases Total costs
of illness cost case case Low High  Low High
Dollars Days Dollars - - - - -Number- - - - - - - - -Mil. dollars- - - -
No physician visit 0 0 0 0 0  0 0
Visited physician 0 0 0 0 0  0 0
Hospitalized
Maternal
Regular hospital room2 887 7 6210 252 252  1.6 1.6
Physician fees etc.3 844 7 5906 252 252  1.5 1.5
Subtotal 1,731 N/A 12,117 252 252  3.1 3.1
Newborn/fetal4
Regular hospital room2 887 14 12,421 295 360  3.6 4.4
Regular room physician fees3 844 14 11,812 295 360  3.6 4.4
ICU hospital room5 1,774 7 12,421 295 360  3.6 4.4
ICU room physician fees5 1,687 7 11,812 295 360  3.5 4.2
Subtotal N/A N/A 48,466 295 360  14.3 17.4
Other adult
Moderate  
Regular hospital room2 887 7 6,210 42 42  .26 .26
Regular room physician fees3 844 7 5,906 42 42  .25 .25
Severe6
Regular hospital room2 887 7 6,210 1,206 1,206  7.5 7.5
Regular room physician fees3 884 7 5,906 1,206 1,206  7.1 7.1
ICU hospital room5 1,774 7 12,421 1,206 1,206  15.0 15.0
ICU room physician fees5 1,687 7 11,812 1,206 1,206  14.2 14.2
Subtotal (other adult) N/A N/A N/A 1,248 1,248  44.3 44.3
Total N/A N/A N/A 1,795 1,860 61.7  64.8
N/A = Not applicable.
1 Subtotals and totals here may not total because of rounding. Unit costs and costs per case have been rounded for this table. Includes those
who survive and those who die during the acute illness.
2 Costs of regular hospital room in 1991, updated to 1993 using the CPI for hospital rooms from BLS.
3 Assumes physician fees, lab tests, etc. are comparable to the hospital room charge but were updated to 1993 using the CPI for physician ser-
vices from BLS.
4 Assumes regular hospital room two-thirds of time, intensive care one-third of time. The 295-360 newborn/fetal cases include the 14-79
cases where the newborn or infant died prematurely because of the illness. Hospitalization costs for the newborn/fetal deaths are for the
mother.
5 The costs of the ICU hospital room and ICU room-related fees are assumed to be double the costs of regular hospital rooms and regular
hospital room-related fees.
6 The 1,206 other adult cases with severe listeriosis include the 431 who die prematurely because of their illness.62 Bacterial Foodborne Disease:  Medical Costs and Productivity Losses / AER-741                      Economic Research Service/USDA
the physician services CPI, for a total cost of $844
per patient per day.79 Estimated total costs of hos-
pitalization in a regular hospital room, including
physician services and other fees, are $1,731 per
patient per day.
One component of medical expenses for the 252
maternal cases of listeriosis is 7 days of hospitaliza-
tion for observation of the pregnant mother and her
fetus (in addition to hospitalization for the delivery)
at a rate of roughly $887 per day or $6,210 per case.
The cost of $844 per day for physician fees, medica-
tion, and treatments for each day spent in the hospi-
tal, translates into $5,906 per maternal listeriosis
patient.  Combining these two components results in
a total of $12,117 per case.  Estimated medical
expenses for the 252 maternal cases total $3.1 million
annually. 
Acute medical expenses for all 295 to 360
newborn/fetal cases include the costs of 7 days in
intensive care at twice the rate of a regular room
($1,774 per day) and 14 days in the hospital at a regu-
lar room rate ($887 per day).80 Daily fees associated
with a regular hospital room are $844 and daily fees
associated with an ICU room are $1,687.  The total
medical cost per newborn/fetal case with listeriosis is
$48,466.  Estimated medical costs for the newborn/
fetal cases range between $14.3 million and $17.4
million annually.
Following Roberts and Pinner (1990), prior to calcu-
lating costs, we divided the 1,248 other adult acute ill-
ness cases (non-maternal, non-newborn) into two
severity levels:  (1) severe cases of meningitis or sep-
sis (1,206 cases), and (2) more moderate cases (42
cases).  All 42 moderate cases survived and of the
1,206 severe cases, 431 died prematurely and 775 sur-
vived.  Those who died were assumed to incur med-
ical costs for listeriosis before dying.
Moderate cases incur the costs of 7 days in a regular
hospital room (Roberts and Pinner 1990), plus a simi-
lar daily amount for physician’s fees, as previously
described.  The average medical cost for these milder
cases is roughly $12,117 per case, which sums to $0.5
million annually for all 42 cases.  
The severe cases require 7 days in intensive care at
$1,774 per day and 7 days in a regular hospital room
($887 per day), which totals to roughly $36,350 per
case, including physician fees as previously described.
The total medical costs for the 1,206 severe cases is
$43.8 million annually.  Estimated medical expenses
for both severe and moderate cases total $44.3 million
annually.
• Deaths.  All listeriosis patients who died from the
acute illness were assumed to incur medical costs
prior to death.  Medical costs for acute listeriosis
patients who died were accounted for in the hospi-
talization item above.
• Subtotal.  Medical costs for acute listeriosis were
estimated to range from $61.7 million to $64.8
million.
Medical/Special Education Costs for Chronic
Illness from Listeriosis
Of the three categories of listeriosis patients consid-
ered here, only among the newborn/fetal cases did
some patients develop chronic complications.
Following the advice of Dr. Robert Pinner, then an
M.D. in CDC’s Special Pathogens Branch, and as
reported in Roberts and Pinner (1990), we assumed
that the incidence and severity of listeriosis in the
newborn/fetal cases is parallel to the estimates for
neonatal group B streptococcal patients in the Institute
of Medicine (IOM) study (1985).  This means that 43
of the newborn/fetal cases develop chronic sequelae.
An Institute of Medicine (IOM, 1985) study of neona-
tal group B streptococcal patients found that chronic
sequelae, such as seizure disorders, visual or hearing
impairment, developmental retardation, or spasticity,
occurred following meningitis.
The 43 newborn/fetal cases with chronic illness are
divided into three categories:  (1) 9 mild chronic dis-
ability cases (20 percent, Cochi et al. 1985), (2) 26
moderate to severe chronic disability cases (60 per-
79As before, we used the 1991 hospital cost of $752 per day to
represent the cost of physician services, but we updated this cost
with the physician services CPI (1991 CPI from Statistical Abstract
of the United States 1993: table 163; 1993 CPI from personal com-
munication with BLS in June 1994).
80Hospitalization costs for the newborn/fetal deaths are for the
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cent, IOM Study 1985), and (3) 8 total impairment 
cases (the remaining 20 percent).81 Table 25 presents
the estimated medical costs of chronic listeriosis by
severity category.  Note that these medical costs
include the costs of special education, because they
cannot be separated with the data used here.
Nine listeriosis patients were assumed to have a mild
chronic disability from their illness.  Persons in this cat-
egory might have a seizure disorder that required regu-
lar medication and physician visits or a hearing impair-
ment that required medical care or special attention in
school.  The present value of the sum of these costs is
$43,237 per case ($2,000 per year in 1988 dollars for
20 years from Cochi et al. (1985), updated to 1993 dol-
lars and discounted at 3 percent) for a total of $0.4 mil-
lion each year for the nine mild disability cases.  
Twenty-six listeriosis patients were assumed to have a
moderate to severe chronic disability from their ill-
ness.  Persons in this category might have a signifi-
cant learning problem requiring special education.  On
average, the cost of special education for this category
is estimated at $108,092 per case ($5,000 per year in
1988 dollars for 20 years from IOM (1985), updated
to 1993 dollars and discounted at 3 percent).  For the
26 moderate to severe chronic cases who survive, the
present value of the special education costs total $2.8
million annually.  
Eight listeriosis patients were assumed to have a total
impairment (physical or mental) from their illness.
Persons in this category require institutional or con-
tinual total care at a cost of $506,062 ($20,000 per
year in 1988 dollars for 25 years from Cochi et al.
(1985), updated to 1993 dollars and discounted at 3
percent).  For the eight total impairment cases, this
amounts to a present value of $4.0 million annually.
• Subtotal.  Estimated medical and special education
costs for chronic listeriosis total $7.2 million annually.  
Productivity Losses for Acute Listeriosis
Table 26 presents the productivity losses for acute lis-
teriosis by disease severity category (no physician
Table 25—Estimated medical costs and special education costs from chronic listeriosis, 19931
Severity Cost/ Cases Total costs
of illness case Low High Low High
Dollars - - - - -Number- - - - -  - - - - -Million dollars- - - - -
No physician visit1 0 0 0  0 0
Visited physician 0 0 0  0 0
Hospitalized
Maternal 0 0 0  0 0
Newborn/fetal2
Mild disability 43,237 9 9  0.4 0.4
Moderate to severe disability 108,092 26 26  2.8 2.8
Total impairment 506,062 8 8  4.0 4.0
Subtotal N/A 43 43  7.2 7.2
Other adult 0 0 0  0 0
Total N/A 43 43  7.2 7.2
N/A means not applicable.
1 Subtotals and total may not add because of rounding. Medical costs and the costs of special education are combined in this table, because
they cannot be separated with the data used here.
2 The breakdown of the 43 newborn/fetal cases into disability sub-categories follows Roberts and Pinner (1990). Cost per case is extrapolated
from Cochi et al. (1985) and the Institute of Medicine Study (1985).
81The 8 cases were rounded down from 8.6 so that there were a
total of 43 cases. This category was rounded down, instead of the
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visit, visited a physician, hospitalized, and died) and
by patient category for those hospitalized (maternal,
newborn/fetal, other-adult).
• No physician visited.  No estimate was made for
milder cases.
• Physician visit only.  No estimate was made for
milder cases.
• Hospitalized.  As with the medical costs, productivi-
ty losses for listeriosis were divided into three cate-
gories of patients:  (1) pregnant women, (2) new-
borns/fetal cases, and (3) other adults.  As previous-
ly mentioned, pregnant women and other adults face
only acute illness from Listeria, whereas all new-
born/fetal cases have acute illness and some develop
chronic complications.  There were no productivity
losses for acute listeriosis cases of newborns/fetus-
es, because they are not part of the labor force.
The per-person productivity loss for pregnant women
with listeriosis was estimated by multiplying the num-
ber of work days missed times the appropriate daily
wage for each age category that was provided by sur-
veillance data (Gellin et al. 1987).82 As previously
mentioned, pregnant women with listeriosis were
assumed to stay in the hospital for 7 days until they
and their fetus recovered from the infection.  As with
Table 26—Estimated productivity losses from acute listeriosis, 19931
Base Work days Rate/ Cases Total costs
Severity of illness  rate2 missed case Low High Low  High
Dollars Number Dollars - - - - -Number- - - - - - - Million dollars- - 
No physician visit 0 0 0 0 0 0  0
Visited physician 0 0 0 0 0 0  0
Hospitalized (and survived)
Maternal2 N/A 15 1,166 252 252 0.3  0.3
Newborn/fetal3 0 0 0 0 0 0  0
Other adult4
Moderate N/A 15 N/A 42 42
Severe N/A 30 N/A 754 754
Subtotal N/A N/A N/A 817 817 1.2  1.2
Deaths:5
Maternal 0 0 0 0 0 0 0
Newborn/fetal 1,097,792 N/A 1,097,792 5.6 31.6 6.1  34.7
Other adult N/A N/A N/A 431 431 118.2  118.2
Subtotal N/A N/A N/A 437 463 124.3  152.9
Total N/A N/A N/A 1,506 1,532 125.8  154.4
1 Subtotals and totals may not add due to rounding.
2 Average daily earnings for production or non-supervisory workers in private non-agricultural jobs were reported by the U.S. Bureau of Labor
Statistics (BLS) by age group were increased by 39 percent to add benefits, and then multiplied by the number of pregnant women having liste-
riosis in each age group (Gellin et al. 1987) and by the BLS labor force participation rate (74.7 percent) for females aged 25-34 (personal con-
versation with BLS and Buzby, June 1994).
3 There were no productivity losses for acute listeriosis cases of newborns/fetuses in this category, because they are not part of the workforce.
4 Demographic information is from CDC’s active surveillance, and labor market information is from average daily earnings for production or
non-supervisory workers in private non-agricultural jobs were reported by the BLS and from personal communication between BLS and Buzby
(June 1994). Base rate per day and rate per case are not included here because it depends on the age category. The remaining 21 other adult
cases were younger than 20 years old and we assumed no lost productivity for these cases.
5 Demographic information is from CDC’s active surveillance and cost information is from Landefeld and Seskin’s (1982) adjusted willingness-
to-pay/human capital estimates updated to 1993 prices using the change in average weekly earnings (BLS). Base rate per day and rate/case
are not included here because they depend on the age category. Forty percent (Bjerkedal and Erickson 1983) of 14-79 infants are not replaced
by another birth. Landefeld and Seskin’s (1982) estimate for an infant, updated to 1993 prices using the change in average weekly earnings
(BLS) is equal to roughly $1,097,792.
82The surveillance reports that 14 percent are less than 21 years
old, 63 percent are between 21 and 30 years old, and 23 percent
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the other studies in this report, it was assumed that
twice as many days were spent at home recuperating
(14 days) as the number of days spent in the hospital
(7 days).  After adjusting for weekends, maternal lis-
teriosis patients missed 15 work days on average.  As
in the COI on E. coli O157:H7, lost productivity for
those who missed work and later returned to work
was calculated using average daily earnings for pro-
duction or nonsupervisory workers in private nonagri-
cultural jobs reported by the BLS (by age group),
adjusted by 39 percent to include fringe benefits (to
cover health plans, vacations, and retirement
benefits),83 and by the BLS labor force participation
rate (74.7 percent) for females aged 25-34 (personal
conversation between U.S. BLS and Buzby, June
1994).  Estimated productivity losses for pregnant
women with listeriosis were $1,166 per case, or a total
of $0.3 million annually for the 252 cases.
Productivity losses for the 817 other adult acute cases
(non-maternal, non-newborn/fetal) who survive (65
percent of the 1,248 cases) include the value of time
spent in the hospital plus the time spent at home recu-
perating.  Demographic information is from CDC’s
active surveillance.
Acute productivity costs were calculated after divid-
ing the 817 other adult cases who survived into two
sub-categories: 42 moderate cases and 754 severe
cases (meningitis and sepsis cases).  Productivity loss-
es for the 21 patients younger than 21 years of age
were assumed to be zero, because it was assumed that
they are not yet in the labor force.  Each of the 733
(754 minus 21 cases) severe cases younger than 21
years of age was assumed to lose 6 work weeks of
productivity, while the 42 moderate cases lose only 3
work weeks each.84 This time is valued by summing
the product of the average weekly earnings by the per-
centage of each age group in the labor force, and by
the number of weeks out of work for each age group
(personal conversation with U.S. BLS and Buzby,
June 1994).  Productivity losses amount to $1.2 mil-
lion for the other adults who had acute listeriosis and
survived.  
• Deaths.  Norwegian data (Bjerkedal and Erickson
1983) have been evaluated for the likelihood that a
stillbirth or infant death will be replaced by another
pregnancy.  Although the likelihood varies by
maternal age, a replacement child is conceived 60
percent of the time.  We assume that families in the
United States respond similarly.  Thus, for fetal or
infant deaths, we assume that 60 percent of the
deaths will by replaced by siblings who fully com-
pensate for the earlier loss and that 40 percent will
not be replaced.  In other words, for the fetal or
infant death category, roughly 6 to 32 (of the 14 to
79) cases are not replaced by another birth and we
estimate the productivity loss for these cases.
Emotional costs of losing a fetus or baby (Peppers
and Knapp 1980; Tomsyck 1988) and the costs of a
delay in having a replacement child are all omitted
from the estimates.  We used the LS estimate for
the VOSL of an infant, which was $1,097,792 after
averaging across gender and updating to 1993 dol-
lars.  We estimated the productivity loss for the
fetal/newborn deaths (not replaced by another
birth) at $6.1-$34.7 million annually.
For the 431 other adult listeriosis patients who die
(about 35 percent of 1,248 cases), valuation of the
lives at the age of death was determined by using
Landefeld and Seskin’s estimates and the age distribu-
tion of other adult listeriosis patients from CDC’s
active surveillance.  Productivity losses for those who
died totaled $118.2 million.  
• Subtotal.  Productivity losses for all acute listeriosis
cases are estimated to cost $125.8-$154.4 million
annually.  This includes $0.3 million for the maternal
cases, $119.4 million for acute other adult cases
(including those who survived and those who died),
and $6.1-$34.7 million for the newborn/fetal cases.
Productivity Losses for Chronic Illness from
Listeriosis
As previously mentioned, costs of lost productivity
from chronic complications were calculated for only
some of the cases in the newborn/fetal category.
Table 27 presents the productivity losses for chronic
listeriosis by severity category.  
83The Statistical Abstract of the United States 1993 (table 677)
provides employer costs for employee compensation per hour
worked and divides this total compensation into wage/salary (71.8
percent) and total benefit (28.2 percent) components. Fringe bene-
fits of 39 percent were calculated by dividing the proportion attrib-
uted to total benefits by the proportion attributed to wage/salary
(28.2/71.8 = 39.3 percent).
84This analysis differs from Roberts and Pinner (1990) in that, as
for the other COI studies in this document, we assumed 2 days
spent recuperating at home for each day spent in the hospital.
Roberts and Pinner (1990, p. 143) assumed 1 day of home rest for
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• No physician visited.  No estimate was made for
milder cases.
• Physician visit only.  No estimate was made for
milder cases.
• Hospitalized.  Chronic productivity losses for three
severity levels of the 43 newborn/fetal listeriosis
cases are estimated as the sum of the value of lives
lost.  As above, we used the LS estimate for the
VOSL of an infant ($1,097,792).
In an exhaustive study (Conley 1973) of costs of
mental retardation in the United States in 1973,
mildly retarded adults (IQ, 50 to 70) were able to
find jobs at wages close to the average income of the
general population.  Moderately retarded persons
(IQ, 40 to 49) frequently found jobs, but their wages
were only 19 percent of the average.  Few retardates
with IQ below 40 were employed.  Combining the
income loss as a result of lower wages and the loss
as a result of greater unemployment, Roberts and
Frenkel (1990) calculated the total income loss for
mildly retarded men at 18 percent, for mildly retard-
ed women at 36 percent, for moderately retarded
men at 91 percent, for moderately retarded women at
95 percent, and for the severely retarded of both gen-
ders at 100 percent.  We averaged these data and cal-
culations across gender to estimate that 27 percent is
the earnings loss for someone with mild mental retar-
dation and 93 percent is the earnings loss for someone
with moderate to severe mental retardation.  
Of the 43 newborn/fetal cases, we assumed the 9
cases who had chronic illness classified as a mild dis-
ability lost 27 percent of their lifelong productivity.
Given the LS estimate for the VOSL of an infant, the
productivity loss for each of these nine cases is
$296,404.  This translates into an estimated total of
$2.7 million annually for all nine cases.  
Of the 43 newborn/fetal cases, the 26 chronic illness
cases classified as a moderate to severe disability
were assumed to lose 93 percent of their lifelong
productivity.  Each of these 26 cases cost $1,020,946
for an estimated total of $26.5 million each year.  
The remaining 8 newborn/fetal cases with chronic ill-
ness classified as totally impaired were assumed to
lose 100 percent of their lifelong productivity or
$1,097,792 each for an estimated total of $8.8 million
annually.  For the three categories of newborn/fetuses
Table 27—Estimated productivity losses from chronic listeriosis, 1993
Severity  Percent Base Cases           Total costs       
of Illness prod. lost  rate/case Low High Low  High
Percent Dollars - - - - - -Number- - - - - - - - -Million dollars- - - 
No physician visit  0 0 0 0 0  0
Visited physician 0 0 0 0 0  0
Hospitalized:
Maternal 0 0 0 0 0 0
Newborn/fetal1
Mild disability 27 296,404 9 9 2.7  2.7
Moderate to severe
disability 93 1,020,946 26 26 26.5  26.5
Total impairment 100 1,097,792 8 8 8.8  8.8
Subtotal N/A N/A 43 43 38.0 38.0
Other adult 0 0 0 0 0 0
Deaths 0 0 0 0 0 0
Total N/A N/A 43 43 38.0  38.0
N/A= Not applicable.
1 Landefeld and Seskin’s (1982) adjusted willingness to pay/human capital estimate for an infant, updated to 1993 prices using the change in
average weekly earnings (BLS) is equal to $1,097,792. Mild disability cases are assumed to lose 27% of their lifelong productivity and moder-
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with chronic illness due to listeriosis, including the
deaths, estimated total productivity losses are $38.0
million each year.  
• Deaths.  No estimate was made for premature
deaths from chronic listeriosis.  
• Subtotal.  Productivity losses for the chronic liste-
riosis cases are estimated at $38.0 million.  
Total Costs of Listeriosis from All Sources
Estimates of total costs for the 1,795 to 1,860 cases of
listeriosis range from $232.7 million to $264.4 million
annually.  This includes acute illness medical costs of
$61.7-$64.8 million, chronic illness medical costs/spe-
cial education and residence costs of $7.2 million,
acute illness productivity losses of $125.8-$154.4 mil-
lion, and chronic illness productivity losses of $38.0
million annually.  Table 28 presents the cost summary
for listeriosis.
The above cost estimates vary from Roberts and
Pinner (1990) in that:  1993 dollars (versus 1988
dollars) were used, psychic losses were not included,
and we used 2 days of recovery at home for each day
hospitalized (instead of 1 day at home for each day
hospitalized).  
When comparing the costs of listeriosis with the costs
of other foodborne bacterial diseases estimated in this
analysis, listeriosis has a relatively high per-case cost.
Listeriosis has a relatively high percentage of estimat-
ed premature deaths (i.e., for the newborn/fetal cases
and the other adult cases) and these deaths led to large
COI estimates.
Costs of Foodborne Listeriosis
For the current study, we assumed 85 to 95 percent of
U.S. listeriosis cases were attributed to food (see page
70 in text).  This results in an estimated range of
1,526 to 1,767 cases of which 378 to 485 die prema-
turely because of their illness.  Estimated total annual
costs of foodborne listeriosis ranged from $0.2-$0.3
billion.
Table 28—Cost summary for U.S. listeriosis cases,
19931
Estimated costs





Newborn/fetal  14.3 17.4
Other adult 44.3 44.3
Subtotal 24 61.7 64.8
Chronic3
Maternal 0 0
Newborn/fetal  7.2 7.2
Other adult 0 0
Subtotal 25 7.2 7.2
Productivity losses4
Acute
Maternal  0.3 0.3




Subtotal 26 125.8 154.4
Chronic
Maternal  0 0
Newborn/fetal 
Mild disability 2.7 2.7
Moderate
disability2 6.5 26.5
Total impaired 8.8 8.8
Other adults  0 0
Subtotal 27 38.0 38.0
Total 232.7 264.4
If 85-95% are foodborne, foodborne costs are $0.2-0.3 bil-
lion annually.5
N/A = Not applicable.
1 Subtotals and totals are subject to rounding errors. Main source
is Roberts and Pinner (1990).
2 Medical costs were estimated using data from the American
Hospital Association’s Hospital Statistics and the U.S. Health Care
Financing Administration.
3 Includes some special education and residential care expenses
for children with neurological damage.
4 Productivity losses were estimated using data from Landefeld
and Seskin’s (1982) estimated values of statistical life and average
weekly earnings for production or nonsupervisory workers in private
nonagricultural jobs (BLS).
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COI Estimates of Staphylococcus
Aureus Intoxications
Staphylococci are common in the air, milk, sewage,
and water, although main reservoirs are animals and
humans (Bergdoll 1989, p. 464).  Staphylococci cause
a wide range of human infections leading to disease.
They also cause staphylococcal food poisoning or
intoxication, which is of interest in this analysis.85
“Staphylococcal food poisoning is the only staphylo-
coccal disease not associated with staphylococci
growing in or on the human body” (Bergdoll 1989, p.
465).  Rather, food poisoning occurs when
Staphylococcus multiplies in food and produces
enterotoxin, which, when consumed in sufficient
quantity, causes human illness.86 Ingestion of rela-
tively small amounts of the enterotoxin causes human
illness (Bergdoll 1989, p. 506).  Staphylococcus
aureus (S. aureus) is the species most implicated in
causing foodborne illness, though 50-70 percent of the
other strains may also be enterotoxigenic (Bergdoll
1989, pp. 465 and 512).  
Onset of illness following consumption of S. aureus
enterotoxin is usually within 1-6 hours (Bergdoll
1989, p. 492; CAST 1994, p. 19), which is far less
than the incubation period for microbial pathogens
that are consumed and cause human illnesses.  Onset
of symptoms may occur as quickly as 30 minutes after
consumption of the S. aureus enterotoxins (Benenson
1990, p. 172).  Intoxication by S. aureus enterotoxin
is characterized by severe nausea, vomiting, cramps,
and diarrhea (Benenson 1990, p. 171).  Although the
illness generally does not last longer than 1 or 2 days,
the severity of the illness may indicate the need for
hospitalization and possibly for surgical exploration
(Benenson 1990, p. 171).
Most staphylococcal food poisoning outbreaks are
caused by human carriers contaminating food during
processing, preparation, and packaging (Bergdoll 1989,
p. 498).  S. aureus is commonly found in the nose,
throat, and mouth of humans and transmission to foods
may occur via purulent discharges such as from an
infected finger or even from apparently normal skin
(Benenson 1990, pp. 172 and 339).  At any given time,
30-50 percent of all healthy people harbor the organism,
while 15-35 percent are persistent carriers (Bergdoll
1989, p. 498).  Reported deaths from S. aureus food
poisoning typically have occurred in children and older
immunocompromised people (Bergdoll 1989, p. 494).
Foods most likely to be contaminated with S. aureus
and its enterotoxin are high-protein foods that come in
contact with workers’ hands and then are served or
are served after improper heating or improper refriger-
ation (Benenson 1990, p. 172; CAST 1994, p. 13).
Examples are milk, custard- or cream-filled baked
goods, sliced meats, potato and meat salads, sand-
wiches, and pastries (Benenson 1990, p. 172; CAST
1994, p. 13).  S. aureus also tolerates a high salt con-
tent such as that found in ham (CAST 1994, p. 13).
Bergdoll states that staphylococci in food are poor
competitors against other organisms “unless they out-
number the other organisms present, such as in milk
from a mastitic cow” (1989, p. 474).
Unlike most microbial pathogens including S. aureus,
enterotoxin from S. aureus can survive temperatures
as high as 250oF (CAST 1994, p. 36).  Also, pasteur-
ization does not inactivate S. aureus enterotoxin
(Bergdoll 1989, p. 495).
Estimates of Cases and Costs
Staphylococcus aureus in food was estimated by
Bennett et al. (1987, pgs. 104 and 109) to cause
approximately 1,513,000 cases of illness and 1,210
deaths annually.87 This study followed Roberts
(1989) in estimating the annual costs of
Staphylococcus aureus.  Roberts calculated an approx-
imation of average costs of S. aureus, Clostridium per-
fringens, and other bacterial pathogens by extrapolat-
ing the cost estimates for salmonellosis and listeriosis
from the death rate.  Roberts estimated that the aver-
age cost for S. aureus in 1987 dollars was $600.  This
value was updated to 1993 dollars using the CPI for all
items (annual average) from BLS to obtain an estimate
of $763 per case.  Therefore, annual human illness
costs from Staphylococcus aureus infections 
87As previously mentioned, Staphylococci cause both human infec-
tions and food poisoning or intoxication. Bennett et al. (1987, p.
104) estimate that each year there are 8,900,000 cases of illness
from these two categories. They also estimate that 17 percent (p.
109) of these 8,900,000 cases (or 1,513,000 cases) are attributed to
food sources. These 1,513,000 cases are interpreted here as food
poisoning or intoxication cases. Whether the death rate varies by
type of case is not available and a constant death rate is assumed.
85Staphylococcal disease or infection causes syndromes ranging
from pustules to septicemia and premature death (Benenson 1990,
p. 402).
86 Ingestion of S. aureus is not required to cause human illness
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and intoxications are estimated at $6.8 billion from all
sources and $1.2 billion from foodborne sources
only.88
COI Estimates of Clostridium
Perfringens Intoxications 
Clostridium perfringens (C. perfringens) is a toxicoin-
fective microorganism, because it causes human ill-
ness by producing toxins as it grows in the intestinal
tract (CAST 1994, p. 19).  Almost all food poisoning
outbreaks are caused by the Type A strains (C.
Welchii) (Labbe 1989, p. 193), while Type C strains
are associated with necrotizing enteritis (Benenson
1990, p. 174).
C. perfringens is a hardy organism in that it forms
spores that allow it to survive adverse conditions and
food preservation treatments (CAST 1994, p. 16).
These spores in food are not killed by normal cooking
temperatures, and resume normal vegetative cell germi-
nation and multiplication later under inadequate tem-
perature control during cooling, storage, and reheating
(Benenson 1990, p. 174; Labbe 1989, p. 198).  
In fact, C. perfringens spores “will often germinate
optimally only if they are mildly heated” and the opti-
mal sporulation temperature ranges between 35 and
40oC (Labbe 1989, pp. 199 and 203) which, not coin-
cidentally, frame the average temperature of the human
body.  Labbe (1989, p. 207) states that “the incidence
of C. perfringens food poisoning due to preformed
enterotoxin is rare” and that the ingested cells must
sporulate in the human intestines for enterotoxin to
reach levels capable of causing human illness (p. 199).
In one study reported by Labbe, a mixture of C. per-
fringens strains had an average generation time of 13
minutes in ground beef held at 40oC (1989, p. 196).  C.
perfringens is one of the fastest multiplying bacteria. 
The incubation period of C. perfringens ranges from 8
to 24 hours after ingestion of food bearing large vege-
tative cell counts (Labbe 1989, p. 206).89 The illness
in humans is typically mild, lasting only about a day
(CAST 1994, p. 11).  Symptoms are generally diar-
rhea, abdominal pain, and sometimes nausea, while
vomiting and fever are uncommon (Labbe 1989, p.
207; Benenson 1990, p. 174).  Deaths have occurred
in institutionalized or debilitated people, particularly
the elderly (Labbe 1989, p. 207).  
Estimates of Cases and Costs
C. perfringens in food was estimated by Bennett et al.
(1987, p. 104) to cause approximately 10,000 cases of
human illness and 100 deaths annually.  Following
Bennett et al. (p. 109) all C. perfringens illnesses in
humans are assumed to be foodborne.  Although C.
perfringens is commonly found on raw animal and
plant products (CAST 1994, p. 31), Canadian and
U.S. outbreak data suggest that 100 percent of food-
borne C. perfringens infections are caused by mishan-
dling in food service establishments, homes, etc.
(CAST 1994, p. 58).  Most outbreaks are linked to
inadequately cooked or reheated meats, gravies, and
meat products (Benenson 1990, p. 174).
As with the COI analysis for S. aureus, we followed
Roberts (1989) in estimating the annual costs of
Clostridium perfringens.  Assuming costs are a func-
tion of the death rate, Roberts estimated that the aver-
age cost per case for C. perfringens in 1987 dollars
was $5,100.  After updating to 1993 dollars using the
CPI for all items, annual average, from BLS, the esti-
mated cost per case is $6,487.  Estimated annual costs
of illness from C. perfringens infections, all food-
borne, are $64.9 million.90
Summary of the COI Estimates
Table 29 presents a cost summary of the medical costs
and productivity losses for the selected bacterial
pathogens and presents the costs attributable to food-
borne sources.
We estimated the annual cost-of-illness for the six
bacterial foodborne illnesses at $2.9 billion to $6.7
billion (in 1993 dollars).  Salmonellosis is the most
costly.  The acute foodborne costs are estimated to
range from $0.6 billion to $3.5 billion annually. 88This is comparable to Todd’s estimate in CAST (1994, p. 58) of
1,155,000 S. aureus cases in the United States from foodborne
sources and total foodborne costs of $1.5 billion.
89Isolated cases indicate that symptoms may appear within two
hours (Labbe 1989, p. 207).
90This compares with Todd’s (1989) estimates of 652,000 C. per-
fringens cases in the United States from foodborne sources and
total foodborne costs of $87 million.Table 29—Cost summary for selected bacterial pathogens in the United States, 19931
Total Total Total Percent Foodborne Foodborne Foodborne
Pathogen cases deaths costs foodborne cases deaths costs
- - - - - - -Number- - - - - - - - Bil. $ Percent - - - - -Number- - - - - Bil. $
Campylobacter jejuni or coli 2,500,000 200-730 1.2-1.4 55-70 1,375,000 - 1,750,000 110-511 0.6-1.0
Clostridium perfringens 10,000 100 0.1 100 10,000 100 0.1
Escherichia coli O157:H72 10,000-20,000 200-500 0.3-0.7 80 8,000 - 16,000 160-400 0.2-0.6
Listeria monocytogenes3 1,795-1,860 445-510 0.2-0.3 85-95 1,526-1,767 378-485 0.2-0.3
Salmonella (non-typhoid) 800,000-4,000,000 800-4,000 0.7-3.6 87-96 696,000 - 3,840,000 696-3,840 0.6-3.5
Staphylococcus aureus 8,900,000 7,120 6.8 17 1,513,000 1,210 1.2
Total 12,221,795-15,431,860 8,865-12,960 9.3-12.9 N/A 3,603,526 - 7,130,767 2,654-6,546 2.9-6.7
1Totals are subject to rounding.
2E. coli O157:H7 deaths are for acute illness only and do not include chronic illness deaths.
3 Cases that do not require hospitalization are not included because of data limitations.
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Foodborne disease from Staphylococcus aureus is
next, roughly estimated at $1.2 billion annually.  The
acute illness costs of foodborne campylobacteriosis
are estimated at $0.6-$1 billion annually.  Next in eco-
nomic importance is foodborne disease, acute and
chronic, caused by E. coli O157:H7 at $0.2-$0.6 bil-
lion annually.  Foodborne listeriosis is estimated at
$0.2-$0.3 billion annually; while foodborne disease
caused by Clostridium perfringens is estimated at $0.1
billion annually in 1993 dollars.
Extension to Other Bacterial Diseases
The estimates of the annual costs of foodborne illness-
es to society would increase considerably if all food-
borne pathogens were included in the analysis and if
all chronic illnesses triggered by foodborne diseases
were considered.  Bennett et al. (1987) mention other
major bacterial diseases for which costs have not yet
been estimated (in order of high to low incidence in
the United States):  Streptococcus Group A, Shigella,
Yersinia, Bacillus cereus, Salmonella typhi, Brucella,
and Clostridium botulinum.91 B. cereus has been
determined to be entirely foodborne in origin, while
the rest only have a component confirmed to be
caused by food.  With over 10 million cases annually
and 3,000 deaths (of which 5 percent are estimated to
be foodborne)(Bennett et al. 1987, pp. 104 and 109),
Streptococcus Group A may be another costly disease.
In addition, the CAST report (1994, pp. 11-14) lists
other bacteria that cause human foodborne illness:
Aeromonas hydrophila, Coxiella burnetii, other types
of E. coli besides E. coli O157:H7, Mycobacterium
bovis, avium, and tuberculosis, Vibrio parahaemolyti-
cus, and Vibrio vulnificus.
Discussion
Although technological and informational advances in
food manufacturing and marketing (i.e., refrigerating,
pasteurizing, labeling) continue to expand our ability
to control foodborne pathogens, the annual number of
foodborne illnesses could increase in the United
States.  First, the number of people in the United
States who are highly susceptible to microbial food-
borne illnesses is growing.  In general, the U.S. popu-
lation is increasing at a little over 1 percent each year
(Putnam and Allshouse 1994, p. 4) and part of this
growth is attributed to a greater number of children
and elderly people, two categories most affected by
many foodborne illnesses.  Advances in medicine
have extended the average lifespan, which in turn
increases the number of years an individual may
become ill from foodborne diseases.  Live births in
the early 1990’s are at the highest levels since 1964
(Putnam and Allshouse 1994, p. 4).  This implies that
there is also a greater number of pregnant women and
their offspring, two other categories of people who
face higher health risks from some foodborne diseases
such as listeriosis and toxoplasmosis.  Also, the
spread of chronic illnesses (e.g., AIDS) that suppress
immune systems increases the pool of people who are
highly susceptible to foodborne diseases (Roberts and
Unnevehr 1994). 
Second, new pathogen tests and improved epidemio-
logical methods allow us to recognize and report more
human illnesses with foodborne sources.  Future
advances in science can be expected to discover new
links between microbial pathogens and chronic human
illnesses.  For example, in 1982 E. coli O157:H7 was
identified as causing acute human illness and in 1985,
E. coli O157:H7 was identified as causing chronic
kidney failure. 
Third, the short lifespan of the pathogens encourages
improved virulence through quick adaptation to
changes in their environment (e.g., temperature, and
oxygen and water levels).92 For example, researchers
are concerned about a new and particularly virulent E.
coli O157:H7 strain associated with a recent outbreak
from dry salami.  This new strain appears to be more
acid-tolerant and can survive at higher temperatures
than some other previously studied E. coli strains.
Also, the annual number of foodborne illnesses in the
91Several hundred thousand Americans died from Cholera-01 dur-
ing the 1800’s and early 1900’s, but now cases and outbreaks are
seldom reported in the United States (Jones 1992, p. 130). While
no longer a problem in the United States, Vibrio cholerae (cholera)
is one of the most important and deadly bacterial diseases interna-
tionally. Cholera is responsible for thousands of deaths in Asian
countries each year and killed 3,000 people in South and Central
America in 1991 (Jones 1992, p. 131). As such, it is costly to many
developing countries in terms of lost productivity. The death rate
may be greater than 50 percent and death can occur within hours
(Benenson 1990, p. 90). Areas plagued by poverty are the most
likely to be affected by cholera, because in these areas many peo-
ple cannot afford to buy equipment and fuel to adequately heat
water and food (Jones 1992, p. 131). Cholera, indirectly linked to
food through water, occurs in seafood produced in sewage-contam-
inated areas (Benenson 1990, p. 89). Without precautionary mea-
sures, importing seafood and produce from these areas could
cause cholera in the United States (Jones 1992, p. 131).
92Under favorable conditions, some bacteria reproduce every 15-
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United States might increase if importing food from
other countries introduces new pathogen strains.  
Fourth, the trend toward consumption of convenience
foods and meals and snacks outside the home poses
increased food safety risks.  Microwave heating of
foods may be uneven, potentially allowing some bac-
teria to survive (Heddleson and Doores 1994).  Eating
food away from home (e.g., restaurants, fast-food out-
lets, nursing homes, and schools) means that con-
sumers have less control over how food is stored, han-
dled, and cooked.  This is important because con-
sumers (especially the immunocompromised) will not
know when they are placing themselves at risk.93 The
counter argument could also be advanced that com-
mercial establishments are more knowledgeable and
produce safer food than do food preparers at home.
On a more positive note, food safety controls can
occur at many points along the food chain from the
farm to the consumer.  Progress has been made in
reducing some foodborne illnesses.  For example,
CDC researchers estimate that listeriosis cases have
fallen by 44 percent in the last decade due to educa-
tional, industry, and regulatory efforts to reduce
Listeria contamination of foods and subsequent ill-
nesses (Tappero et al. 1995, p. 1118).
New regulations are addressing food safety issues.
For example, safe handling labels are now required on
all raw meat and poultry sold at retail or handled by
the food service industry.  Florida, California, and
Louisiana require restaurants selling raw shellfish to
display warnings to customers about potential risks of
consuming raw shellfish.  As previously mentioned,
other new food safety regulations have been promul-
gated such as the FSIS’s Hazard Analysis Critical
Control Point (HACCP) rule (Federal Register July
25, 1996) for meat and poultry and an FDA seafood
HACCP rule (Federal Register Dec. 18, 1994).  
The COI estimates reported here can be used in three
main ways.  First, the COI estimates can be used to
evaluate the economic impact of foodborne diseases
on the United States.  This study estimated that annual
costs of human illness for 6 of 40 known microbial
pathogens that cause foodborne illnesses range
between $9.3 billion and $12.9 billion, in terms of ill-
ness from all sources.  Of these costs, between $2.9
billion and $6.7 billion are attributed to foodborne
causes each year.  These estimates have helped high-
light the importance of bacterial health hazards and
the need for private and public actions to control
foodborne pathogens.
Second, the COI estimates can be used to target
pathogen reduction efforts toward the most costly dis-
eases.  For example, the relatively high costs of sal-
monellosis may indicate that this pathogen should be
among the first targeted for risk reduction.
Third, the COI estimates can be used to compare bene-
fits and costs of control efforts, such as irradiation and
HACCP, to determine the most cost-effective interven-
tions.94 The $606 million annual budget for the
USDA meat and poultry inspection program annually
(GAO 1996) is considerably below the total estimated
costs for just these six pathogens.  Greater expendi-
tures on food inspection may reduce the number of
annual cases of foodborne disease and, in turn, reduce
the annual costs of foodborne illness to society.95
When using the COI estimates presented here, one
should bear in mind that they underestimate the true
economic value of bacterial foodborne illnesses to
society because they exclude costs such as:  (1) pain,
suffering, and lost leisure time of the victim and
her/his family, (2) lost business and costs and liabili-
ties of lawsuits affecting agriculture and the food
industry, (3) the value of self-protective behaviors
undertaken by industry and consumers, and (4)
resources spent by Federal, State, and local govern-
ments to investigate the source and epidemiology of
the outbreak.  The missing parts listed earlier, when
available, can be added to the present analysis to pro-
vide a more complete picture of the costs of bacterial
foodborne illnesses.
93 Workers in the food industry may also be unaware of when they
are placing themselves at risk from foodborne illness. For example,
E. coli O157:H7 may be found in all types of meat products. Over
12 million people work in the food industry and are potentially
involved in the handling and preparation of meat products (AGA
Consensus Conference 1995, p. 1928), and as such, may be at
higher risk of exposure to E. coli O157:H7.
94 Better identification of which pathogens are the most costly
would pinpoint which pathogens should be targeted for benefit/cost
analyses for control onfarm, during processing, during marketing, at
food service establishments, and at home.
95 It may cost $8 million per year or more to build an adequate
foodborne disease surveillance database to identify new pathogens
and estimate annual foodborne disease incidence rates (Roberts
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This study used Landefeld and Seskin’s VOSL esti-
mates.  Had alternative methods of valuing lost lives
been used, the COI estimates would be substantially
higher.  Viscusi (1993) summarizes the results from
24 principal labor market studies and found that the
majority of the VOSL estimates lie between $3 mil-
lion and $7 million per life in 1990 dollars.  Fisher et
al.’s survey of the wage-risk-premium literature on the
willingness to pay to prevent death concluded that
reasonably consistent estimates of the value of a sta-
tistical-life range from $1.6 million to $8.5 million
(1986 dollars) (Fisher et al. 1989).  Updated to 1993
dollars using the change in average weekly earnings
(GPO 1994), Fisher et al.’s range becomes $2.0 mil-
lion to $10.4 million for each statistical-life lost and
Viscusi’s range becomes $3.2 million to $7.6 million.
Viscusi and the Fisher et al.’s estimates are greater
than the highest LS VOSL estimate of $1,584,605 in
1993 dollars (table 5, see estimate for a 22-year-old).
ERS’s COI analyses performed to date could be
improved with better data and the scope could be
expanded to new foodborne diseases or to associated
chronic complications.  These improvements should
give more credibility to the estimated costs.  For
example, the current COI estimates could be enhanced
by obtaining and using better data on incidence,
including measures of nonwage income, and revising
age and gender differences.96 Also, as knowledge
about the connection between acute bacterial illnesses
and chronic disease expands, the costs of these chron-
ic diseases need to be added to the estimates.  
The incidence estimates can be improved by more
training of physicians and lab technicians to recognize
bacterial foodborne diseases and by requiring manda-
tory reporting of illnesses to the CDC for the most
common diseases.  FSIS, FDA, and the CDC are col-
laborating on a 6-month pilot project to improve esti-
mates of which pathogens are responsible for diar-
rheal diseases and to identify which foods are the
sources of Salmonella and E. coli O157:H7 (FDA,
FSIS, CDC joint release 1995).  Other pathogens will
be included as the project gets underway.  Improved
surveillance systems can enable researchers to have a
better understanding of the frequency and extent of
foodborne illness outbreaks and perhaps can aid in
preventing similar outbreaks from occurring or alter-
natively remove contaminated foods from the market
to limit the number of cases in an outbreak.
Up-to-date detailed cost per case estimates would also
vastly improve the current COI estimates.  Better
identification of who is at high risk of foodborne dis-
eases would help develop more suitable disease-sever-
ity categories for our COI analyses and would also
enable the degree of food safety (i.e., development of
niche markets) and the target of food safety education
campaigns to be tailored to these high-risk groups.  It
may be possible to define severity levels for each dis-
ease and then compile and apply a database of com-
mon costs across illnesses.  
Prior to allocating increased public and private
resources toward foodborne disease reduction, evalua-
tion is needed as to the degree to which individuals
would prefer to control these hazards themselves (i.e.,
through their consumption choices, through improved
food-handling techniques at home to reduce cross-
contamination, or by thoroughly cooking meat to kill
all pathogens) rather than have the Federal
Government mandate stricter regulations to reduce
levels of microbial pathogens in the food chain.97
FDA researchers estimate that 30 percent of all food-
borne-illness cases in the United States are attributed
to unsafe food-handling practices in the home
(Layden 1992, p. 56).
In the United States, a mix of regulatory and self-pro-
tective actions are likely to be preferred: First, the
U.S. Congress delegated authority for inspecting food
to the Federal Government at the turn of the century
(Meat Inspection Acts of August 30, 1890, April 1,
1891, March 2, 1895, and June 30, 1906; 1906 Food
and Drugs Act).  State and city governments were del-
egated roles even earlier (Hutt and Hutt 1984).  This
delegation implies that U.S. consumers do not want to
be burdened with evaluating the scientific evidence on
food safety.  Second, not all microbial pathogens can
be prevented by the consumer.  Thorough cooking
does not eliminate heat-stable toxins produced by
such pathogens as Staphylococcus aureus and Bacillus
cereus. 
Third, Shogren and Hayes and other Iowa State
University colleagues, in a series of elegant studies,
96Averaging the LS VOSL values for males and females by age
will overestimate productivity for males and underestimate produc-
tivity for females, based on market output.
97Better identification of high-risk foods would also enable con-
sumers to make informed decisions about their food-handling and
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have estimated that consumers are willing to pay
$0.70 per meal to upgrade to a safer meal in experi-
mental auction markets (Shogren 1993, Hayes et al.
1995).  Moreover, consumers are not homogeneous;
increasingly, special populations such as people with
HIV/AIDS, the immunocompromised elderly, and
pregnant women face higher risk of acquiring food-
borne diseases than others.  These groups may be
willing to pay even more than $0.70 for a safer meal.
The costs to society of foodborne diseases as comput-
ed by the COI method may comprise only a portion of
society’s willingness to pay to reduce such diseases.
However, government agencies can act pragmatically
to estimate the individual cost components of food-
borne diseases while continuing to develop new theo-
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